THE ONLY BARRIER TO A CURE IS ACCESS TO CARE.
A YEAR IN REVIEW

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saving Sight Across the Globe</td>
<td>2</td>
</tr>
<tr>
<td>Institute News</td>
<td>5</td>
</tr>
<tr>
<td>Faculty Honors</td>
<td>6</td>
</tr>
<tr>
<td>New Faculty Appointments</td>
<td>7</td>
</tr>
<tr>
<td>In Memoriam</td>
<td>8</td>
</tr>
<tr>
<td>Research</td>
<td>10</td>
</tr>
<tr>
<td>Education</td>
<td>12</td>
</tr>
<tr>
<td>Community Outreach</td>
<td>15</td>
</tr>
<tr>
<td>Alumni</td>
<td>16</td>
</tr>
<tr>
<td>JSEI Affiliates</td>
<td>17</td>
</tr>
<tr>
<td>Philanthropy</td>
<td>18</td>
</tr>
<tr>
<td>Thank You</td>
<td>19</td>
</tr>
<tr>
<td>Jules and Doris Stein</td>
<td>25</td>
</tr>
<tr>
<td>Board of Trustees and Executive Committee</td>
<td>27</td>
</tr>
</tbody>
</table>

FACULTY

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Care Services</td>
<td>94</td>
</tr>
<tr>
<td>Research and Treatment Centers</td>
<td>97</td>
</tr>
<tr>
<td>Clinical Laboratories</td>
<td>102</td>
</tr>
<tr>
<td>Training Programs</td>
<td>104</td>
</tr>
</tbody>
</table>

PROGRAMS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volunteer and Consulting Faculty</td>
<td>110</td>
</tr>
<tr>
<td>Residents and Fellows</td>
<td>112</td>
</tr>
<tr>
<td>Research Contracts and Grants</td>
<td>114</td>
</tr>
<tr>
<td>Clinical Research Studies</td>
<td>127</td>
</tr>
<tr>
<td>Publications of the Full-Time Faculty</td>
<td>135</td>
</tr>
<tr>
<td>Giving Opportunities</td>
<td>146</td>
</tr>
</tbody>
</table>
DEAR FRIENDS

Dr. Jules Stein envisioned a world where everyone can see, and the UCLA Stein Eye Institute was borne upon the promise of eradicating eye disease and preventing avoidable blindness. Our commitment to fulfill Dr. Stein’s dream extends throughout the United States and across all borders.

Together with our affiliation partner, the Doheny Eye Institute, we are advancing vision-science research and setting a global standard for patient care. At any given time, UCLA Department of Ophthalmology doctors, residents, fellows, and alumni are delivering medical care in countries throughout the world, serving children and adults in regions with great need.

I thank our physicians and researchers who are dedicated to achieving Dr. Stein’s vision. Through their tireless work, they are giving sight to countless individuals who thought their lives would be lived in darkness.

I thank you, our donors and friends. Because of your partnership in our mission, there is hope that future generations will no longer need fear being blinded by eye disease. The impact of our collective investment in blindness prevention, both here at home and abroad, is incalculable.

Please enjoy these highlights of our 2017–2018 academic year, which reflect our efforts to ensure that people the world over have the gift of sight.

Sincerely,

Bartly J. Mondino, MD
Bradley R. Straatsma, MD, Endowed Chair in Ophthalmology
Director, Stein Eye Institute
Chairman, UCLA Department of Ophthalmology
Affiliation Chairman, Doheny Eye Institute
# UCLA Department of Ophthalmology

## ACADEMIC DIVISIONS

### CATARACT AND REFRACTIVE SURGERY
- John Bartlett, MD
- Kenneth Lu, MD
- Kevin Miller, MD, Chief
- Mitra Nejad, MD

### Optometrists
- Carolyn Duong, OD
- Linda Hwang, OD
- Mark Landig, OD
- Amanda Powers, OD

### COMPREHENSIVE OPHTHALMOLOGY
- Gavin Bahadur, MD
- Rachel Feit-Leichman, MD
- Tania Oncinlx, MD
- Susan Ransome, MD
- Meryl Shapiro-Tuchin, MD
- Ronald Smith, MD

### Optometrists
- Michael Baker, OD
- Vivian Shibayama, OD

### CORNEA AND UVEITIS
- Anthony Aldave, MD, Chief SEI
- Saba Al-Hashimi, MD
- Benjamin Bert, MD
- Richard Casey, MD
- Sophie Deng, MD, PhD
- Gary Holland, MD
- Hugo Hsu, MD, Chief DEI
- John Irvine, MD
- Batool Jafri, MD
- Olivia Lee, MD
- Ralph Levinson, MD
- Bartly Mondino, MD, Chairman

### GLAUCOMA
- Joseph Caprioli, MD, Chief SEI
- Vikas Chopra, MD
- Anne Coleman, MD, PhD
- Brian Francis, MD, Chief DEI
- JoAnn Giaconi, MD
- Alex Huang, MD, PhD
- Simon Law, MD, PharmD
- Kouros Nouri-Mahdavi, MD
- Natik Piri, PhD
- James Tan, MD, PhD

### NEURO-OPHTHALMOLOGY
- Anthony Arnold, MD, Chief SEI
- Laura Bonelli, MD
- Lynn Gordon, MD, PhD
- Stacy Pineles, MD
- Peter Quiros, MD
- Alfredo Sadun, MD, PhD, Chief DEI

### OPHTHALMIC PATHOLOGY
- Ben Glasgow, MD

### ORBITAL AND OPHTHALMIC PLASTIC SURGERY
- Robert Goldberg, MD, Chief
- Daniel Rootman, MD

### PEDIATRIC OPHTHALMOLOGY AND STRABISMUS
- Joseph Demer, MD, PhD, Chief
- Simon Fung, MD
- Sherwin Isenberg, MD
- Monica Khitri, MD
- Stacy Pineles, MD
- Federico Velez, MD

### Optometrist
- Laura Robbins, OD

### RETINA
- Gad Heilweil, MD
- Jean-Pierre Hubschman, MD
- Hamid Hosseini, MD
- Michael Ip, MD, Chief DEI
- Ali Khan, MD
- Allan Kreiger, MD
- Tara McCannel, MD, PhD
- Pradeep Prasad, MD
- Steven Schwartz, MD, Chief SEI
- Irena Tsui, MD

### Optometrists
- Melissa Chun, OD
- Jennie Kageyama, OD

### RETINAL DISEASES AND OPHTHALMIC GENETICS
- Michael Gorin, MD, PhD, Chief
- Phillip Le, MD, PhD
- Colin McCannel, MD
- Steven Nusinowitz, PhD
- SriniVas Sadda, MD
- David Sarraf, MD

### VISION SCIENCE
- Suraj Bhat, PhD
- Gordon Fain, PhD
- Debora Farber, PhD, DPhhc
- Joseph Horwitz, PhD
- Wayne Hubbell, PhD
- Steven Nusinowitz, PhD
- Natik Piri, PhD
- Roxana Radu, MD
- Alapakkam Sampath, PhD, Chief
- Deming Sun, MD
- Hui Sun, PhD
- Gabriel Travis, MD
- David Williams, PhD
- Xian-Jie Yang, PhD
- Jie Zheng, PhD

---

Find out more about UCLA Department of Ophthalmology Academic Divisions and our faculty at: [www.uclahealth.org/eye/academic-divisions](http://www.uclahealth.org/eye/academic-divisions).
A YEAR IN REVIEW

JULY 1, 2017–JUNE 30, 2018

“...our work has no borders,” says Bartly J. Mondino, MD, director of the Stein Eye Institute and chairman of the UCLA Department of Ophthalmology. “We are dedicated to preserving and restoring sight both here at home and abroad.”

The World Health Organization reports that an estimated 39 million people are blind—yet up to 80% of these cases could be easily prevented or treated if individuals had access to vision care. Taking this call to action, Stein Eye ophthalmologists bring their specialized skills to underserved regions where avoidable blindness is most prevalent.

“More than 230 international fellows from throughout the world have trained at Stein Eye. They then bring this subspecialty clinical and research expertise back to their home country, advancing eye care in their region,” says Dr. Mondino. “In addition to our fellows, Stein Eye faculty, staff, and alumni have shown incredible leadership in their outreach efforts.”
Changing the Quality of Life in Sub-Saharan Africa

Bradley R. Straatsma, MD, JD, founding director of the Stein Eye Institute and founding chairman of the UCLA Department of Ophthalmology, is a shining example of how one person can make a difference in the lives of so many.

Dr. Straatsma led UCLA into becoming one of the world’s premier centers for vision research, education, and patient care, and he was recently instrumental in the development of the first subspecialty and training eye hospital in the Central Africa region: the Magrabi ICO Cameroon Eye Institute (MICEI) in Yaoundé, Cameroon.

“Blindness is closely linked with extreme poverty and significantly shorter life spans, especially in poorer countries. Independent of a patient’s ability to pay, MICEI offers services for cataract, cornea, glaucoma, neuro-ophthalmology, orbit and oculoplastic surgery, pediatric ophthalmology, refractive surgery, in addition to retina and vitreous surgery,” says Dr. Straatsma. The not-for-profit eye center officially opened in 2017 and provided vision care for 20,000 patients its inaugural year.

Teaching sight-saving procedures to eye health providers is a critical tool for advancing vision care. Jean-Pierre Hubschman, MD, Stein Eye associate professor of ophthalmology, was MICEI’s first Visiting Professor and conducted the hospital’s first vitreo-retinal surgery with Henry Nkumbe, MD, MICEI’s medical director.

“By providing subspecialty services and advanced training,” says Dr. Straatsma, “MICEI is enhancing vision and the quality of life for individuals, families, and ultimately all of society in Sub-Saharan Africa.”

Volunteer Organizations Making a Global Difference

Ending corneal blindness is the inspired mission of Visionaries International, a non-profit volunteer organization founded by Stein Eye faculty member Anthony J. Aldave, MD, Walton Li Chair in Cornea and Uveitis.

“The consequences are especially serious in the developing world, where 90 percent of all corneal blind live,” says Dr. Aldave, chief of the Institute’s Cornea and Uveitis Division. “Lack of transplantable corneas and inadequate numbers of trained transplant surgeons are the main barriers to treatment.” To combat these obstacles, Dr. Aldave and dedicated volunteers “train the trainers” in performing newer forms of corneal transplantation to treat corneal blindness.

Stein Eye alumnus Harry S. Brown, MD, FACS, established Surgical Eye Expeditions (SEE) International in 1974 to prevent blindness and restore vision to disadvantaged individuals worldwide by providing sustainable medical, surgical, and educational services.

The alumnus organization has grown to more than 650 volunteers from over 75 different countries. To date, SEE has conducted 500,000 surgeries and provided free vision screenings to 3.8 million individuals in over 80 countries.
Protecting Children’s Vision Across the World

Corneal infections from bacteria are the world’s leading cause of preventable blindness in children. Leonard Apt, MD, the late founding chief of the Division of Pediatric Ophthalmology, and Sherwin J. Isenberg, MD, Laraine and David Gerber Chair in Ophthalmology, were key participants in one of the most significant breakthroughs in pediatric vision care: they identified povidone-iodine (betadine) as a practical, low-cost solution for preventing neonatal eye infections.

“In low-resource countries,” explains Dr. Isenberg, “antibiotics are unaffordable so infections would go untreated, and babies would go blind. Povidone-iodine changed that, as it costs pennies. The treatment is now used globally.”

Institute doctors also work with physicians and institutions overseas to give children a brighter future. As an example, Irena Tsui, MD, assistant professor of ophthalmology, and her international colleagues, are exploring the effects of Zika virus on infants in Brazil. Their study results indicate that all infants born during Zika virus epidemics should undergo screening eye examinations, as eye abnormalities can be the only initial finding in congenital Zika virus infection.

Making a Difference Here at Home

“The vast majority of vision problems in underserved populations are treatable,” says Anne L. Coleman, MD, PhD, The Fran and Ray Stark Foundation Chair in Ophthalmology. As Director of the Stein Eye Institute Centers for Community Outreach and Policy, Dr. Coleman oversees the UCLA Mobile Eye Clinic, which has provided free care to more than 300,000 underserved children and adults in Los Angeles County since it began operations in 1975.

“The importance Stein Eye places on caring for our most vulnerable populations cannot be overstated,” says Dr. Coleman. “The only barrier to a cure is access to care.”
Doheny Eye Institute Marks 70 Years of Care

The Doheny Eye Institute began in 1947, with the launch of its forerunner, the Estelle Doheny Eye Foundation, which was founded by Mrs. Carrie Estelle Doheny in the desire to make a positive difference in people’s lives by saving sight.

“In its 70-year history, Doheny Eye Institute ophthalmologists and vision-scientists have made major clinical and research advances,” says Bartly J. Mondino, MD, chairman of the UCLA Department of Ophthalmology and affiliation chairman of the Doheny Eye Institute. “Under the leadership of Executive Director Marissa Goldberg, and President and Chief Scientific Officer Srinivas R. Sadda, MD, they are poised for a future filled with new innovations and discoveries.”

New Leadership Roles

As the first Vice-Chairman for Education, Anthony C. Arnold, MD, is the primary supervisor for UCLA weekly grand rounds, the annual seminar, and the UCLA neuroscience seminar. He is an advisor to the residency program director, and he assists in departmental continuing medical education activities. In addition, he provides oversight for affiliated training sites, fellowship programs, and undergraduate and graduate medical education. Dr. Arnold is also newly appointed to the Executive Committee of the Stein Eye Institute and UCLA Department of Ophthalmology.

Previously serving as associate residency director for the UCLA Department of Ophthalmology, Stacy L. Pineles, MD, has been named the program’s director, taking over the position previously held by Dr. Arnold.

As Associate Director of the Vision Science Division, Alapakkam P. Sampath, PhD, provides operational oversight of the Division and its laboratory research. Gabriel H. Travis, MD, stepping down as a co-director, will serve as a special advisor to the Executive Committee.

Fifty Years of Vision

The original dream for ophthalmology at UCLA has evolved into the Institute’s bold transformation to a vision-science campus.

2017 AAO Annual Meeting
UCLA Department of Ophthalmology faculty, staff, and alumni were honored at the November 11–14, 2017, American Academy of Ophthalmology Annual Meeting in New Orleans, Louisiana.

Life Achievement Honor Award
Baruch D. Kuppermann, MD
Paul P. Lee, MD, JD
Kevin M. Miller, MD
Jay Stuart Pepose, MD, PhD
Alfredo A. Sadun, MD, PhD

Senior Achievement Award
Joseph L. Demer, MD, PhD
Christina Joy Flaxel, MD
JoAnn A. Giaconi, MD
David Sarraf, MD
Neda Shamie, MD
Paul A. Sidoti, MD

Achievement Award
Mina M. Chung, MD
Troy R. Elander, MD
Troy M. Tanji, MD
Kristina Tarczy-Hornoch, MD
Stephen H. Tsang, MD, PhD
Fei Yu, PhD

Secretariat Award
Gary N. Holland, MD

Faculty Honors

Anthony J. Aldave, MD, Walton Li Chair in Cornea and Uveitis, was invited to give the David Easty Lecture by the Bowman Club, the UK Corneal Society. The lecture was given in Newcastle upon Tyne, United Kingdom, on March 23, 2018.

In addition, Dr. Aldave gave a plenary lecture at the 6th Biennial Asia Cornea Society meeting in Qingdao, China, on May 17, 2018.

Anthony C. Arnold, MD, professor of clinical ophthalmology, has been appointed Mary Oakley Foundation Chair in Neurodegenerative Disease.

Anne L. Coleman, MD, PhD, The Fran and Ray Stark Foundation Chair in Ophthalmology, was the keynote speaker at the 16th Annual Downeast Ophthalmology Symposium, September 16, 2017, in Bar Harbor, Maine.

Dr. Coleman also presented the keynote address at the Australian and New Zealand Glaucoma Symposium during the Royal Australian and New Zealand College of Ophthalmologists Scientific Congress, November 1, 2017, in Perth, Australia.

Joseph L. Demer, MD, PhD, Arthur L. Rosenbaum, MD, Chair in Pediatric Ophthalmology, delivered the keynote address to the Japanese Neuro-Ophthalmology Society on November 10, 2017, in Yokohama, Japan.

Dr. Demer was also honored with a Lifetime Achievement Award from the American Association for Pediatric Ophthalmology and Strabismus on March 18, 2018, in Washington, D.C.


Michael S. Ip, MD, professor of ophthalmology, presented the Alex E. Krill Memorial Lecture at the Chicago Ophthalmological Society meeting on December 4, 2017, in Chicago, Illinois.

In addition, Dr. Ip was the keynote speaker at the Milwaukee Ophthalmological Society meeting on April 24, 2018, in Milwaukee, Wisconsin.


Stacy L. Pineles, MD, Associate Professor of Ophthalmology, has been named the Jerome and Joan Snyder Chair in Ophthalmology.

Peter A. Quiros, MD, health sciences associate clinical professor, was elected to a two-year term as president of the Latin American Neuro-Ophthalmology Club.

SriniVas R. Sadda, MD, professor of ophthalmology, received the Presidents’ Young Investigator Award from the American Society of Retina Specialists (ASRS) on August 14, 2017, at the ASRS annual meeting in Boston, Massachusetts.
David Sarraf, MD, health sciences clinical professor of ophthalmology, received the LuEsther T. Mertz Lecture-ship Award from The Macula Foundation, on April 10, 2018, in New York, New York. Dr. Sarraf also presented the Mark J. Daily, MD, Retina Lecture at the 29th Loyola Ophthalmology Resident Alumni Day held at Loyola University on June 8, 2018, in Chicago, Illinois.

In addition, The Retinal Atlas, 2nd Edition, by Dr. Sarraf and co-authors, received highly commended honors at the 2017 British Medical Association Medical Book Awards on September 18, 2017, in London, United Kingdom.

David S. Williams, PhD, professor of neurobiology, received a $2.3 million grant for research on RPE cell biology, aging, and disease from the National Eye Institute, National Institutes of Health on September 1, 2017.

Dr. Williams also received two awards from the Foundation Fighting Blindness on October 16, 2017: a New Foundation Fighting Blindness Individual Investigator Award of $300,000 for studies on gene editing to treat Usher syndrome, and a New Foundation Fighting Blindness Program Project Award of $2.5 million for collaborative research on understanding Usher syndrome and choroideremia.

Best in the West
UCLA Health is consistently ranked among the best hospitals in the country by U.S. News & World Report, and UCLA Stein Eye and Doheny Eye Institutes are ranked among the top five in the nation in ophthalmology.

New Faculty Appointments
Specializing in infections of the cornea, Saba Al-Hashimi, MD, health sciences assistant clinical professor, joined the UCLA Department of Ophthalmology faculty on July 10, 2017.

Benjamin B. Bert, MD, health sciences assistant clinical professor, became a UCLA Department of Ophthalmology faculty member on July 1, 2017. He specializes in cornea-external ocular disease and refractive surgery.

Simon Fung, MD, a specialist in adult and pediatric cornea and anterior segment, began his faculty appointment as an assistant professor of ophthalmology on January 11, 2018.

Hamid Hosseini, MD, assistant professor of ophthalmology, specializes in retinal and macular conditions. He was promoted to his current position on August 1, 2017.
David R. Fett, MD, associate clinical professor of ophthalmology, passed away from a heart attack on August 3, 2017.

Following his undergraduate education at the Massachusetts Institute of Technology, Dr. Fett graduated from the Geisel School of Medicine at Dartmouth. He conducted his residency training at the UCLA Stein Eye Institute (1981–1984) and then completed a fellowship in ophthalmic plastic surgery at the University of Illinois in Chicago. Upon his return to Los Angeles, Dr. Fett began a successful private practice in oculoplastic surgery, performing approximately 40,000 surgeries by the time he retired in 2016.

Passionate about education and helping others, Dr. Fett spoke publicly about the importance of giving back. A leader in the community, Dr. Fett was an active member of the Leo Baeck Temple, supported his alma maters, and served on advisory boards. As a volunteer clinical faculty member at the UCLA Stein Eye Institute, he furthered the education of residents and fellows. Among his philanthropic gifts, he supported the training of fellows with the establishment of the David and Randi Fett Orbital and Ophthalmic Plastic Surgery Fellowship Endowment.

“Dr. Fett was a great friend, colleague, and supporter of UCLA,” says Bartly J. Mondino, MD, director of the Stein Eye Institute. “Through his academic contributions and his generous philanthropy, he has advanced the education of generations of Stein Eye residents and fellows.”
Henry I. Baylis, MD

Henry I. Baylis, MD, founding chief of the UCLA Stein Eye Institute Orbital and Ophthalmic Plastic Surgery Division, died September 19, 2017.

Dr. Baylis was born in Pontiac, Michigan, in 1935 and attended medical school at the University of Michigan. He conducted his residency at the University of California San Francisco and trained in ophthalmic plastic surgery in New York.

Soon after arriving in Los Angeles to open his medical practice, Dr. Baylis joined the clinical faculty of the UCLA Stein Eye Institute. Combining a passion for the discipline with an innovative approach to teaching and surgery, Dr. Baylis created an innovative and academically robust Division—formally established in 1981—with the vision and support of Institute Founding Director, Bradley R. Straatsma, MD, JD.

Dr. Baylis regularly presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS), and the annual Baylis Lecture at the ASOPRS meeting honors Dr. Baylis’s leadership in aesthetic oculofacial surgery. In addition to writing respected academic articles and running a busy clinic, he founded the premier subspecialty publication, Journal of Ophthalmic Plastic and Reconstructive Surgery. To further education in the field, Dr. Baylis started the ASOPRS Fellowship at UCLA in 1975, which has since trained 60 fellows.

“Hank’s career was characterized by imagination and bold innovation. His numerous articles on surgical technique introduced ideas that have become cornerstones of our specialty,” says Robert Alan Goldberg, MD, chief of the Orbital and Ophthalmic Plastic Surgery Division.

Through his foresight and leadership, Dr. Baylis saw his field transform to a robust discipline with an accredited subspecialty curriculum, academic divisions in almost every university ophthalmology program, and wide respect from colleagues in related specialties.

Dr. Baylis is survived by his three children, two grandchildren, and his wife, Barbara Baylis.

Honoring the Life Work of Dr. Henry Baylis

To recognize Dr. Baylis’s remarkable contributions to both academic medicine and ophthalmology, the Stein Eye Institute established the Henry I. Baylis, M.D. Fund in Orbital and Ophthalmic Surgery to support the research activities of the Orbital and Ophthalmic Plastic Surgery Division.

Due to initial generous support from alumni and colleagues, the fund was converted to an endowment. The aim is to raise $2 million, so an administrative chair may be established.

“Dr. Baylis was a true pathfinder, and we endeavor to fully honor his legacy,” says Bartly J. Mondino, MD, director of the Stein Eye Institute and chairman of the UCLA Department of Ophthalmology. “We thank our alumni and friends for their continued commitment to outstanding members of the UCLA family.”

For information on how you can support the chair campaign in honor of Dr. Baylis, contact Director of Development, M. Gail Summers, at: mgsummers@mednet.ucla.edu or 310-206-9701.
Stein Eye researchers are investigating a new concept with major implications for the second-leading cause of blindness worldwide: the possibility that many cases of glaucoma can be attributed in part to repetitive strain injury to the optic nerve caused by everyday eye movements. “If this turns out to be the case, it could be a major breakthrough,” says Joseph L. Demer, MD, PhD, Arthur L. Rosenbaum, MD, Chair in Pediatric Ophthalmology, chief of the Pediatric Ophthalmology and Strabismus Division, and director of the Ocular Motility Clinical and Basic Science Laboratory.

Computer simulation, by finite element analysis, of mechanical strain in the optic nerve head and adjacent eye wall caused by tethering of the optic nerve sheath during adduction eye movement. This simulation incorporates a combination of biomechanical properties—all measured in tissues donated to eyebanks—that are predicted to result in glaucomatous optic nerve damage over a lifetime of eye movements. (Credit: simulation and graphic by Joseph Park, MS, using data collected by Andrew Shin, Joseph Park, and Joseph L. Demer.)
Stein Eye researchers are investigating a new concept with major implications: the possibility that many cases of glaucoma can be attributed in part to repetitive strain injury to the optic nerve caused by everyday eye movements.

“Currently, intraocular pressure is the only significant modifiable risk for glaucoma, but most cases of glaucoma occur at normal, not elevated, pressure.”

During his research using magnetic resonance imaging (MRI) to learn about eye muscle function, Dr. Demer began to hypothesize that the types of eye movements people make tens of thousands of times a day might contribute to some cases of glaucoma. “We would have our volunteers make large eye movements as they were undergoing scanning, and we noticed there are certain gaze positions where the optic nerve isn’t quite long enough to allow the eye to rotate freely without it tightening,” he says. The most notable of these positions is adduction, in which the eye rotates inwardly toward the nose. “In almost everyone, that causes the optic nerve to use up all of its available slack and become tight, pulling on the back of the eye,” Dr. Demer explains. “But as some people get older, the optic nerve sheath thickens and stiffens, much like the sclerosis that occurs in the arteries. “We are finding that when the optic nerve pulls up tight in younger people, it harmlessly stretches without applying excessive force to the back of the eye,” Dr. Demer explains. “But as some people get older and the sheath becomes less elastic, the eye gets pulled back into the socket, and the optic nerve head is deformed.”

Dr. Demer and his collaborators are continuing to test their hypothesis. They have established a biomechanics laboratory, and using eye bank tissue provided by donors with and without glaucoma, they are measuring the elasticity and viscosity of various parts of the human eye. They are combining that work with microscopic analysis of the connected tissues in the same eyes in an effort to correlate the microscopic appearance and chemical composition of the tissues with their mechanical behavior. They are also testing the clinical implications in larger groups of patients.

The researchers are studying also the potential connection between the tethering of the optic nerve and the elongation of the eye that is characteristic of myopia (nearsightedness). “The glaucomatous condition of the optic nerve seems to be more prevalent and important in myopia,” Dr. Caprioli says. “This might explain the extra glaucoma risk conferred by myopia.”

Overall, Dr. Caprioli notes, “this work, if confirmed, would add an important risk factor for glaucoma that could lend itself to treatment.”
Club LatinoAmericano de Neuro-oftalmología

The Club LatinoAmericano de Neuro-oftalmología (CLAN) held their XXIX reunion at the UCLA Stein Eye Institute on October 6–7, 2017. Spanish-speaking professionals and invited experts who specialize in neuro-ophthalmology came together at CLAN to discuss complex issues and clinical cases. The event was co-coordinated by Peter A. Quiros, MD.

Invited Speaker, Joseph L. Demer, MD, PhD, spoke about the contributions of orbital connective tissues and extraocular muscle compartmentalization to ocular motility and strabismus. UCLA Department of Ophthalmology faculty Drs. Anthony C. Arnold, Laura Bonelli, Lynn K. Gordon, Stacy L. Pineles, and Alfredo A. Sadun contributed to the two-day program, as did volunteer faculty member Dr. Howard R. Krauss and neuro-ophthalmology clinical fellow alumnus Dr. Melinda Chang.

Basic and Advanced Training in Cataract Surgery

Dr. Kevin M. Miller, chief of the Cataract and Refractive Surgery Division, organized two cataract surgery courses, which included instruction by Drs. Saba Al-Hashimi, John D. Bartlett, Hugo Y. Hsu, Kenneth L. Lu, Colin A. McCannel, Barty J. Mondino, and the valuable contributions of UCLA volunteer faculty members.

The J&J Vision Basic Cataract Surgery Course in Santa Ana, California, on October 21, 2017, included all steps of cataract surgery from obtaining informed consent through postoperative instructions. In addition, afternoon skills-transfer laboratories provided attendees with hands-on experience.

The Bausch & Lomb Advanced Cataract Surgery course, May 5, 2018, in Irvine, California, presented an anterior and pars plana vitrectomy wet lab, an affiliated technologies dry lab, and a complex case video workshop.

For information about upcoming cataract courses, contact Dr. Miller at (310) 206-9951 or by email: kmiller@ucla.edu.

Comprehensive Ophthalmology Review Course

The Comprehensive Ophthalmology Review Course on February 15–18, 2018, at the UCLA Stein Eye Institute, reviewed the clinical essentials of each subspecialty in ophthalmology. The course was clinically oriented, with review concentrating on the epidemiology, clinical presentation, diagnosis, and management of ophthalmologic disease to prepare attendees for upcoming ophthalmology examinations and required continuing medical education recertification.

Directed by Drs. John A. Irvine and Sherwin J. Isenberg, the 4-day intensive review course is held annually by the UCLA Stein Eye and Doheny Eye Institutes. UCLA Course Faculty contributing to the 2018 program were Drs. Bruce B. Becker, Benjamin B. Bert, Hugo Y. Hsu, Alex A. Huang, Monica R. Khitri, Olivia L. Lee, Colin A. McCannel, Tara A. McCannel, Kevin M. Miller, Daniel B. Rootman, SriniVas R. Sadda, David Sarraf, Irena Tsui, and Federico G. Velez.

International Retinal Imaging Symposium and Case Conference

The International Retinal Imaging Symposium (IntRIS) held at the California Nano-Systems Institute at UCLA on February 20, 2018, featured lectures in retinal imaging, including adaptive optics, fundus auto fluorescence, ultra-wide field imaging, spectral domain and swept source optical coherence tomography (OCT), and OCT angiography.

Directed by Drs. David Sarraf, K. Bailey Freund, and SriniVas R. Sadda, IntRIS was a joint presentation by the UCLA Stein Eye and Doheny Eye Institutes and featured worldwide experts as guest speakers.

The Doheny/Stein Case Conference that followed on February 21, 2018, reviewed case presentations demonstrating diagnostic and/or management dilemmas.
23rd Annual Vision Science Conference

The Vision Science Conference, jointly sponsored by the Stein Eye Institute and the National Eye Institute Vision Science Training Grant, celebrated its twenty-third year October 13–15, 2017, at the UCLA Lake Arrowhead Conference Center. Basic scientists, clinical researchers, pre- and postdoctoral fellows, and invited guests participated in discussions and learning activities related to vision-science research. Dr. Gustavo Aguirre, professor of medical genetics and ophthalmology at the University of Pennsylvania, presented the keynote address.

UCLA Orbital Center Master’s Symposium and Dissection Workshop

The UCLA Orbital Center Master’s Symposium and Dissection Workshop February 23–24, 2018, at the UCLA Stein Eye Institute, was a tightly focused program of techniques and concepts related to orbital disease and its management. Targeted to practicing ophthalmologists and orbital surgeons, the workshop focused on practical techniques and conceptual pearls that participants could immediately apply to their own practice.

Dr. Dinesh Selva, foundation chair of ophthalmology at the University of Adelaide, Australia, presented The Jack Rootman Lectureship in Orbital Disease. Program Chairs Drs. Daniel Rootman and Robert Alan Goldberg, chief of the Orbital and Ophthalmic Plastic Surgery Division, oversaw the program, which was taught by a multidisciplinary faculty of renowned leaders in the field.

UCLA Department of Ophthalmology Clinical and Research Seminar

The Institute’s most prestigious educational event, the UCLA Department of Ophthalmology Clinical and Research Seminar, was held June 8–9, 2018, at the UCLA Stein Eye Institute.

The seminar covered current clinical and research aspects of each of the ophthalmic sub-specialties, and included the full-time faculties of the Stein Eye and Doheny Eye Institutes, along with nationally prominent invited lecturers.

Sessions addressed current best practices in management, advanced surgical techniques, latest diagnostic technology, and translational research, in multiple educational formats, including didactic lecture, panel discussion, and case-based interactive presentations.

The annual seminar also included keynote lectures.

16TH THOMAS H. PETTIT LECTURER
David S. Rootman, MD
Professor of Ophthalmology and Visual Sciences
University of Toronto

16TH BRADLEY R. STRAATSMA LECTURER
Vinit B. Mahajan, MD, PhD
Associate Professor of Ophthalmology
Stanford University

49TH JULES STEIN LECTURER
Carol L. Shields, MD
Professor and Director
Ocular Oncology Service
Wills Eye Hospital

49TH DOHENY MEMORIAL LECTURER
Stephen D. McLeod, MD
Professor and Chair
Department of Ophthalmology
University of California, San Francisco
The Ophthalmology Basic and Clinical Science Course is designed for ophthalmology residents and also serves as a review course for ophthalmologists. In 2017–2018, the following course components were offered under the direction of Course Chairman, Bartly J. Mondino, MD.

**Fundamentals and Principles of Ophthalmology**
Daniel B. Rootman, MD, MS
September 6, 2017–September 27, 2017

**Pathology**
Ben J. Glasgow, MD
October 4, 2017–October 25, 2017

**Orbit, Eyelids, and Lacrimal System**
Robert Alan Goldberg, MD
November 1, 2017–December 20, 2017

**External Disease and Cornea**
Anthony J. Aldave, MD
January 10, 2018–February 21, 2018

**Refractive Surgery**
David Rex Hamilton, MD, FACS
February 28, 2018–March 7, 2018

**Lens and Cataract**
Kevin M. Miller, MD
March 21, 2018–April 18, 2018

**Glaucoma**
Joseph Caprioli, MD
April 25, 2018–June 6, 2018

Study Groups
Regular study group meetings are an integral part of the Stein Eye residency and clinical fellowship training programs, and they also serve as an informal resource for practicing ophthalmologists in the community.

**Cornea Conference**
Coordinator: Anthony J. Aldave, MD

**Glaucoma Conference**
Coordinator: Joseph Caprioli, MD

**Neuro-Ophthalmology Conference**
Coordinator: Anthony C. Arnold, MD

**Oculoplastics Conference**
Coordinator: Robert Alan Goldberg, MD

**Ophthalmic Pathology Conference**
Coordinator: Ben J. Glasgow, MD

**Pediatric Ophthalmology and Strabismus Conference**
Coordinators: Sherwin J. Isenberg, MD, Federico Valez, MD, and Joseph L. Demer, MD, PhD

**Pediatric Rheumatology and Uveitis Conference**
Coordinator: Gary N. Holland, MD

**Retinal Imaging Conference**
Coordinators: Steven D. Schwartz, MD, and other members of the Retina Division

**Vision Science Seminar Series**
The seminar series, coordinated by Drs. Sophie X. Deng and David S. Williams, is conducted throughout the academic year and allows faculty to present their research to colleagues. The series often includes presentations by eminent visitors to the Stein Eye Institute vision-science campus.
Community Outreach

Access to a Cure is Access to Care

The UCLA Mobile Eye Clinic (UMEC) achieved extraordinary numbers this 2017–2018 academic year: 17,642 children and adults were served, 2,224 ocular abnormalities were diagnosed, and 789 trips were made throughout Los Angeles County. In addition, the Stein Eye Institute’s community outreach activities included the following:

Adult Vision Program

Through the Adult Vision Program, 1,343 free eye exams were given to individuals lacking access to adequate vision care due to reasons such as cost, transportation, and insurance. The program provided 133 adult community-outreach events at homeless shelters, libraries, federally qualified health centers, and other nonprofits in the Los Angeles County area.

Health Fairs

The UMEC attended five health fairs, saw 141 patients, and gave 29 referrals to individuals who needed follow-up care.

Care Harbor 2017

Continuing its annual tradition, the UMEC participated in Care Harbor Los Angeles, November 17–19, 2017, where 2,151 of the community’s most vulnerable patients received free medical, dental, vision, and preventive care conservatively valued at $2,110,000.

At the three-day event, 16 ophthalmologists, and over 20 nurses, technicians, and support staff volunteered their time and evaluated 233 patients. Comprehensive dilated exams were given to patients at risk for eye disease, which would include a history of diabetes or hypertension, a family history of glaucoma, or decreased vision not corrected with eyeglasses, and 187 patients were referred to community eye specialists for further evaluation and treatment, which is often given free of charge.

Learn More at the UMEC Website

Privately funded, the UMEC has been providing free eye care services and glasses for underserved communities in Los Angeles County for over 40 years and has been honored for exemplary leadership in shaping the future of health care.

Go to uclahealth.org/mobile-eye-clinic to find dates, times, and locations of upcoming UMEC clinics; listings of low-income clinics in the Los Angeles community; and organizations aligned with the UMEC’s mission to provide vision services at low or no cost to the most vulnerable members of our community.

Preschool Vision Program

The UCLA Preschool Vision Program offered no-cost services for underserved preschoolers in the Los Angeles area and provided:

- 14,861 vision screenings
- 1,903 fully dilated eye exams
- 1,630 pairs of eyeglasses
- 443 referrals for partner specialists for preschool students needing specialized medical or surgical treatments.

Below: Ken Kitayama, a UCLA medical student volunteering at the November 2017 Care Harbor free clinic, uses an FDT Matrix visual field machine to determine if a patient is experiencing any visual field loss.
Alumni News

David H. Aizuss, MD, resident alumnus (1981–1984) and assistant clinical professor of ophthalmology, was honored with the Independent Physician Leadership Award in Los Angeles, California, on November 1, 2017.

Resident alumnus Harry S. Brown, MD, FACS, (1967–1970), posthumously received the 2018 Biosyntrx Thornton Humanitarian Award for his humanitarian spirit and relentless passion to restore sight to nearly a half million people through Surgical Eye Expeditions (SEE) International. Dr. Brown founded the nonprofit organization over 40 years ago to offer medical services by volunteer ophthalmic surgeons to disadvantaged patients worldwide.

The award was presented to SEE in Dr. Brown’s honor at the Hawaiian Eye Foundation event in Wailea, Hawaii, on January 15, 2018.

John So-Min Chang, MD, resident alumnus (1987–1990), has been named president-elect of the International Society of Refractive Surgery.


Dr. Kokame founded The Retina Center in 1993—the same year as his clinical practice, Retina Consultants of Hawaii—and is its medical director of research and educational programs.

The Retina Center at Pali Momi has participated in over 50 multicenter clinical trials, with research resulting in over 90 publications and invited lectures throughout the world.

Dr. Kokame is also a co-founder of the Gass Fellowship Society, which celebrated its 7th meeting in New Orleans, Louisiana, on November 9, 2017.

Stein and Doheny Host Joint Alumni Reception

UCLA Stein Eye and Doheny Eye Institute faculty members, along with resident and fellow alumni from around the world, gathered in New Orleans on November 12, 2017, for the UCLA Stein Eye Institute Alumni Association and Doheny Eye Institute Professional Alumni Association’s reception. The annual gathering provided an opportunity for alumni from various graduating classes to reconnect with colleagues and classmates.

Find more photos at: www.facebook.com/JSEIAlumni/.
The JSEI Affiliates, the volunteer arm of the Stein Eye Institute established in 1990, accomplished impressive community outreach results this fiscal year—results that would not have been possible without the commitment of generous members and donors and the dedication of over 143 volunteers.

▶ The Vision IN-School (VIS) education program is offered free of charge to fourth- through seventh-grade public school students in Los Angeles. Students are taught about the anatomy of the eye, eye safety, and injury prevention. The highlight of each in-class presentation is a hands-on dissection of a bovine eye. Thirty-three VIS volunteers visited 18 classrooms this past year, presenting the curriculum to 579 elementary students.

▶ Two successful sponsorship drives were held this year for the Make Surgery Bearable program, an initiative that provides Dr. Teddy bears to each pediatric patient undergoing eye surgery at the Stein Eye Institute. This past year, the Affiliates introduced a bigger, cuddlier bear dressed in green scrubs and tagged with the name of the donor to help children feel comforted and secure during what could otherwise be a frightening time. UCLA Bruin Belle volunteers joined forces with the Affiliates to help tag the bears.

The informational children’s book, Making Eye Surgery Bearable, helps pediatric patients and parents prepare for their surgery at the Stein Eye Institute. Offered in both Spanish and English, the book was written at the suggestion of the Pediatric Ophthalmology and Strabismus Division.

▶ The MagniVision program provides financial support for the UCLA Vision Rehabilitation Center (VRC), which enables the purchase of low-vision tools for the VRC lending library. This year, under the direction of JSEI Affiliates Advisory Board Member Robin Carnesale, the Amazon Echo Dot and Kindle Fire devices were added to the library. Low-vision patients may borrow the voice-activated assistive devices for an indefinite period of time.

▶ The Preschool Vision Screening program began 18 years ago with the inspiration and support of Mrs. Glorya Kaufman and under the supervision of the late Dr. Leonard Apt, founding chief of the Division of Pediatric Ophthalmology and Strabismus. During the 2017–2018 school year, 44 JSEI Affiliates volunteers visited 32 preschools to screen 789 children between three and five years of age.

▶ The Shared Vision program collected and recycled approximately 2,600 donated eyeglasses for those in need. Recycled eyeglasses were cleaned, tagged with the vision correction, and distributed to Los Angeles homeless shelters, as well as clinic missions conducted by nonprofit groups in Africa, Central America, and other low-resource regions.

▶ Team Stein Eye participated in the eleventh annual Los Angeles Foundation Fighting Blindness Vision Walk, which was held at Woodley Park on October 21, 2017. The event, supported by both Stein Eye Institute employees and volunteers from the JSEI Affiliates, raised funds for retinal eye disease research.
A LEGACY FOR LOVED ONES

As a young resident at Stein Eye, Dr. Bronwyn Bateman was in the early stages of a brilliant career when tragedy struck. Her late husband, Roderick K. Smith, who was an orthopedic resident at UCLA, was diagnosed with mesothelioma, an asbestos-related cancer, and passed away after an 11-month battle with the disease.

This could have derailed her career, but her Stein Eye advisor, Dr. Bradley Straatsma, made sure Dr. Bateman had the support needed to stay on track. “He called me in,” Dr. Bateman recalls, “and asked what I wanted to do with my life, and I said I didn’t know. He suggested ophthalmic genetics. This was before DNA was really harnessed to identify gene defects in hereditary diseases. I said yes.” Dr. Bateman took the Boards in both Ophthalmology and Medical Genetics/Clinical Genetics. “I was able to have one foot in ophthalmology and one foot in medical genetics,” she explains. “Looking back, the professional opportunities offered by Dr. Straatsma and Dr. Bartly Mondino, director of the UCLA Stein Eye Institute and chairman of the UCLA Department of Ophthalmology, were pivotal in my career.”

BREAKING THE GLASS CEILING—Dr. Bateman segued into a faculty position at Stein Eye, and also became the first woman president of the American Association of University Professors, the organization for chairs of ophthalmology in the U.S. and Canada, and the president of the Pan American Association of Ophthalmology, strengthening ties with Latin American colleagues, many of whom are Stein Eye alumni.

GIVING FOR SOMEONE WHO COULD NOT—“I thought about a gift to benefit Stein Eye for a long time. I wanted to honor my first husband, who was not able to have a life and career. By endowing a chair in his name, I gave him the legacy that he could not create.”

With this in place, funded through an outright gift of cash and an additional future gift, pledged through her estate, Dr. Bateman is now focusing on further structuring her estate in a tax-sensible manner to fund an endowed chair named after her mother and grandmother. “My grandmother was a Norwegian farm girl who married a physician. She used to say ‘you better study otherwise you’re going to end up on a farm,’ ” Dr. Bateman laughs. “My mother graduated from medical school in 1941 and became a pediatrician while my father was busy with the U.S. military in the Pacific theater. She managed to work full-time and raise five children.”

Not one to forget kindness, Dr. Bateman also plans to create a “nurses travel fund” in honor of nurses Nan Fulton, Sue Yamada, and Leonore Vogel who were especially caring and helpful while she was dealing with her husband’s health and his passing.
For more than 50 years, the Stein Eye Institute at UCLA has joined with devoted donors to carry forward our mission to preserve sight and restore vision. We are tremendously grateful for the commitment our supporters have provided for vital research, education, patient-care, and community-outreach pursuits. Such an investment has a powerful and positive impact on ophthalmology and related disciplines locally, nationally, and worldwide, for which we remain enduringly thankful.
Major Gifts $25,000 and above:
Albert Sarnoff
Bert O. Levy
Kotick Family Foundation
Bradley R. Straatsma, MD, JD
Bruce Ford and Anne Smith Bundy Foundation
Carol and Timothy W. Hannemann
Dr. Peter F. Mason
Elaine Sarkaria
Estate of Jean Stein
Fairchild-Martindale Foundation
Frederic G. Rappaport Trust
Heidelberg Engineering GMBH
Heidelberg Engineering, Inc.
Hongbin Peng
J. Bronwyn Bateman, MD
Jan K. Takasugi, MD, and Robert A. Goldberg, MD
Jerome and Joan Snyder
Joan A. Payden and William R. Payden
Jules and Doris Stein UCLA Support Group
Karen and Franklin Dabby
Lavery Foundation
Lin Hsiung Chen Memorial Scholarship Foundation
Louis and Annette Kaufman Family Trust
Michael J. Groth, MD, and Ileana E. Zapatero, MD
Nancy and Allen Kramer
Patricia M. and Wayne T. Clemensen
Peter and Helen Bing
Research to Prevent Blindness, Inc.
Ruth and George E. Moss
Smidt Family Foundation
The Carl and Roberta Deutsch Foundation
The Foundation Fighting Blindness
The Karl Kirchgessner Foundation
The Simms/Mann Family Foundation
The Vision of Children Foundation, Sam Hardage and Vivian Hardage
The William & Margaret Fern Holmes Family Foundation
Theo and Wendy Kolokotrones
Tony and Marilyn Rossi Family Trust–1992
VHL Alliance
Wilbur May Foundation
A Year in Review
Stein Eye Institute

Individuals Recognized with a Tribute Gift

IN HONOR OF:
Braddock–Andrews Family
Dr. Dean Bok
Dr. Joseph Caprioli
Dr. Richard Casey
Dr. Joseph L. Demer
Mr. Robert J. Drabkin
Dr. Robert A. Goldberg
Dr. Michael B. Gorin
Mary Lou Harnden
Mrs. Karyn Jackson
Jennifer Kageyama, OD
Dr. Allan E. Kreiger
Debra Lauer
Mr. David A. Leveton
Ken Matsumoto
Dr. Kevin M. Miller
Dr. Steven D. Schwartz
Dr. Bradley R. Straatsma
Lon Tinney
Patricia Tussing

IN MEMORY OF:
Dr. Leonard Apt
Bob Artechevarria
Pat Busch
Duane Carter
Mr. Edward C. Cazier, Jr.
Donald M. Fetherolf
Janet Freeman
Ms. Peggy L. Giambrocco
Dr. Herbert J. Grossman
Jeanette M. Gunn
Chad J. Holman
Kenya Jamal
Ms. Ione J. Kanne
Dr. Ralph Kustoff
Joseph S. Mancuso
Paul H. Orlopp
Judy Page
Mr. Stanley K. Rothstein
Rose Silkiss
Pat Stel
Ruth Straatsma

Stein Eye Institute Endowed Chairs Supporting Department of Ophthalmology Faculty

The Ahmanson Chair in Ophthalmology
Established in 2006 by The Ahmanson Foundation as an administrative chair for the Retina Division Chief to further research, education, and clinical care programs.
Steven D. Schwartz, MD
2007–Present

Leonard Apt Endowed Chair in Pediatric Ophthalmology
Established in 2004 by Professor Emeritus of Ophthalmology and Founding Director of the Division of Pediatric Ophthalmology and Strabismus, Dr. Leonard Apt, with a gift from the trust of Frederic G. Rappaport, Dr. Apt’s nephew.
Joseph L. Demer, MD, PhD
2005–2015

Karen and Frank Dabby Endowed Chair in Ophthalmology
Established in 2007 by Dr. and Mrs. Dabby as a term chair to support the activities of a distinguished faculty member in the area of orbital disease.
Robert Alan Goldberg, MD
2008–2018

Charles Kenneth Feldman Chair in Ophthalmology
Established in 1982 by various donors in memory of Charles Kenneth Feldman, an entertainment industry executive.
Robert D. Yee, MD
Professor 1984–1987
Hillel Lewis, MD
Scholar 1989–1993
Gabriel H. Travis, MD
2001–Present

Laraine and David Gerber Chair in Ophthalmology
Established in 1998 as a term chair by Mr. and Mrs. Gerber and, with an additional pledge, converted to a permanent-appointment chair in 2009.
Joseph L. Demer, MD, PhD
2000–2004
Sherwin J. Isenberg, MD
2004–Present

Dolly Green Chair of Ophthalmology
Established in 1980 by Ms. Dorothy (Dolly) Green.
Dean Bok, PhD
1984–2013

Ernest G. Herman Chair in Ophthalmology
Established in 2008 by Mr. Ernest G. Herman to support a vision scientist or a clinician-investigator.
Xian-Jie Yang, PhD
2012–Present

Karl Kirchgessner Foundation Chair in Vision Science
Established in 2001 as a term chair by a colleague of Dr. Jules Stein to promote basic-science research initiatives.
Debora B. Farber, PhD, DPhhc
2001–2018

Kolokotrones Chair in Ophthalmology
Established in 2004 by Wendy and Theo Kolokotrones to support the teaching and research of a cataract surgeon and scientist.
Kevin M. Miller, MD
2005–Present

Grace and Walter Lantz Endowed Chair in Ophthalmology
Established in 1991 as a term chair by Mr. and Mrs. Lantz and, with an additional pledge, it was converted to a permanent-appointment chair in 2010.
J. Bronwyn Bateman, MD
Grace and Walter Lantz Scholar 1993–1995
Sherwin J. Isenberg, MD
Grace and Walter Lantz Scholar 1993–1995
Professor 1996–2004
Joseph L. Demer, MD, PhD
Professor 2004–2005

Walton Li Chair in Cornea and Uveitis
Established in 2013 by Walton W. Li, MD, as an administrative chair for the Cornea and Uveitis Division to further research and teaching activities.
Anthony J. Aldave, MD
2014–Present
David May II Chair in Ophthalmology
Established in 1998 as a term chair by the family of Mr. David May II, a founding member of the Institute’s Board of Trustees, to perpetuate, in memoriam, Mr. May’s association with the Stein Eye Institute; after an additional pledge from the Wilbur May Foundation, it was converted to a permanent-appointment chair in 2009.
Gary N. Holland, MD 1999–2004
Joseph Caprioli, MD 2004–Present

Mary Oakley Foundation Chair in Neurodegenerative Diseases
Established in 2013 by The Mary Oakley Foundation to support neurodegenerative diseases.
Anthony C. Arnold, MD 2017–Present

Oppenheimer Brothers Chair
Established in 2002 as a term chair by the Oppenheimer Brothers Foundation.
Joseph Horwitz, PhD 2003–2017

Harold and Pauline Price Chair in Ophthalmology
Established in 2000 by the Louis and Harold Price Foundation and, with an additional pledge, it was converted to a permanent-appointment chair in 2006.
Michael B. Gorin, MD, PhD 2006–Present

Arthur L. Rosenbaum, MD, Chair in Pediatric Ophthalmology
Established in 2007 by Mr. and Mrs. Gottlieb as an administrative chair for the Division of Pediatric Ophthalmology and Strabismus in honor of the late Dr. Arthur L. Rosenbaum. The chair was originally named the Brindell and Milton Gottlieb Chair in Pediatric Ophthalmology.
Arthur L. Rosenbaum, MD 2008–June 2010
Joseph L. Demer, MD, PhD 2015–Present

Jack H. Skirball Chair in Ocular Inflammatory Diseases
Initiated in 2008 by The Skirball Foundation in honor of Jack H. Skirball’s long-standing friendship with Dr. Jules Stein and Lew Wasserman.
Gary N. Holland, MD 2009–Present

Smotrich Family Optometric Clinician-Scientist Chair
Established in 2016 to support an optometric clinician-scientist at the UCLA Stein Eye Institute and will fund the appointee’s education and research programs.

Jerome and Joan Snyder Chair in Ophthalmology
Established in 2008 by Mr. and Mrs. Snyder to support the activities of a distinguished faculty member who directs the ophthalmology residency program, ensuring that UCLA’s accredited program continues to offer rigorous and comprehensive instruction for individuals of the highest caliber.
Anthony C. Arnold, MD 2008–2017
Stacy L. Pineles, MD 2017–Present

Joan and Jerome Snyder Chair in Cornea Diseases
Established in 2013 by Mr. and Mrs. Snyder to support the activities of a distinguished faculty member in the area of corneal diseases and research.

The Fran and Ray Stark Foundation Chair in Ophthalmology
Established in 1992 as a term chair by the Fran and Ray Stark Foundation, and with an additional commitment, it was converted to a permanent-appointment chair in 2009.
Joseph Caprioli, MD 1997–2004
Anne L. Coleman, MD, PhD 2004–Present

Jules Stein Chair in Ophthalmology
Established in 1982 as a memorial tribute to Dr. Jules Stein by his many friends, with the leadership of Mr. Samuel Goldwyn, Jr.
Wayne L. Hubbell, PhD 1983–Present

Bradley R. Straatsma, MD, Endowed Chair in Ophthalmology
Established in 1994 to honor founding director of the Stein Eye Institute, Bradley R. Straatsma, MD, JD.
Bartly J. Mondino, MD 2000–Present

Vernon O. Underwood Family Chair in Ophthalmology
Established in 1995 as a term chair by Mrs. Adrienne Underwood Pingree in memory of her late husband, Mr. Vernon O. Underwood.
John R. Heckenlively, MD 1997–2004
Gary N. Holland, MD 2004–2009
Lynn K. Gordon, MD, PhD 2012–Present

The Wasserman Professor of Ophthalmology
Established in 1977 by Edie and Lew Wasserman to honor Dr. Jules Stein.
Manfred Spitznas, MD 1979–1981
Ben J. Glasgow, MD 2003–Present
Doheny Eye Institute Endowed Chairs Supporting Department of Ophthalmology Faculty

Stephen J. Ryan-Arnold and Mabel Beckman Foundation Endowed Presidential Chair
SriniVas R. Sadda, MD
2015–Present

Rupert and Gertrude I. Stieger Vision Research Chair
Brian A. Francis, MD, MS
2015–Present

Flora L. Thornton Endowed Chair in Vision Research
Alfredo A. Sadun, MD, PhD
2014–Present

A. Ray Irvine, Jr. MD, Chair in Clinical Ophthalmology
John A. Irvine, MD
2014–Present

Mary D. Allen Chair in Vision Research
Deming Sun, MD
2015–Present

Gavin S. Herbert Endowed Chair for Macular Degeneration

Charles Stewart Warren and Hildegard Warren Endowed Research Chair
Vikas Chopra, MD
2017–present

Stein Eye Institute Fellowship Funds and Endowments

Rosalind W. Alcott Fellowship
Established in 1978 by the Rosalind W. Alcott Charitable Remainder Trust for the training of outstanding postdoctoral fellows.
Laura A. Vickers, MD, MA
2016–2017

Leonard Apt Endowed Fellowship in Pediatric Ophthalmology
Established in 2002 by founding chief of the Pediatric Ophthalmology and Strabismus Division, Leonard Apt, MD, to support outstanding clinical fellows in the field of pediatric ophthalmology and strabismus.
Rui Zhang, MD
2016–2017

Leonard Apt, MD, Pediatric Fellowship Fund
Established in 2015 by the trust of Leonard Apt, MD, founding chief of the Pediatric Ophthalmology and Strabismus Division, to support pediatric ophthalmology fellowships.

Thelma and William Brand Director’s Fund
Established in 2004 with a trust from Mr. William F. Brand to benefit worthy students at the Stein Eye Institute.

Cooperman Fellowship Fund
Established in 1988 by the Coopermans to support eye research and education, with emphasis on clinical ophthalmology.
Melinda Y. Chang, MD
2016–2017

David and Randi Fett Orbital and Ophthalmic Plastic Surgery Fellowship Endowment
Established in 2013 by Dr. David R. Fett and Ms. Randi Levine to support fellows in the Orbital and Ophthalmic Plastic Surgery Division.
Sathyadeepak Ramesh, MD
2016–2017

Klara Spinks Fleming Fellowship Fund
Established in 1985 by Klara Spinks Fleming to support cataract research.
David T. Truong, MD
2016–2017

Frances Howard Goldwyn Fellowship
Established in 1977 by Mr. Samuel Goldwyn, Jr., with gifts from Mrs. Goldwyn’s estate and Dr. and Mrs. Jules Stein.
Bora Chae, MD
2016–2017

Elsa and Louis Kelton Fellowship
Endowed by the Keltons in 1982 to support postdoctoral research and training.
Aaron Nagiel, MD, PhD
2015–2016
An Huynh, MD
2016–2017

Jerome Comet Klein, MD, Fellowship Fund
Established in 2007 by the Irving & Estelle Levy Foundation to provide fellowship and lecture support in the areas of orbital and ophthalmic plastic surgery.
Wenjing Liu, MD
2016–2017

Bert Levy Research Fellowship Fund
Established in 1995 by Mr. Bert Levy to enhance the educational opportunities of vision science scholars and advance research in neuro-ophthalmology.

David May II Fellowship Fund
Established in 1992 by the family of Mr. David May II to support advanced study and research in ophthalmology and vision science.
Sanket U. Shah, MD
2016–2017

Wilbur D. May Fellowship
Established in 2013 by the May family as a tribute to Mr. Wilbur D. May, the beloved uncle of Mr. David May II.

John and Theiline McCone Fellowship
Established in 1989 by the McCones to support and enhance education programs and fellowship training in macular disease.
Robert Arthur Lalane III, MD
2016–2017

Christian J. Sanfilippo, MD
2016–2017
Abe Meyer Memorial Fellowship Fund
Established in 1969 by various donors to support clinical fellows at the Institute.
David T. Truong, MD
2016–2017

Adelaide Stein Miller Research Fellowship
Established in 1977 by Mr. Charles Miller as a tribute to his wife, Adelaide Stein Miller, Dr. Jules Stein’s sister.
Nathaniel C. Sears, MD
2016–2017

The Harold and Pauline Price Fellowship
Established in 1987 by the Louis and Harold Price Foundation to support research and education in ophthalmology and vision care.
Laura A. Vickers, MD, MA
2016–2017

Frederic G. Rappaport Endowed Fellowship in Retina/Oncology
Established in 2004 by Mrs. Jeanne A. Rappaport as a memorial to her son Frederic.

Dr. Jack Rubin Memorial Fellowship
Established in 1987 by the family of Dr. Jack Rubin to support postdoctoral fellows.
Nathaniel Sears, MD
2016–2017

Sanford and Erna Schulhofer Fellowship Fund
Established in 1986 by Mr. Sanford Schulhofer to support postdoctoral research and training in vision science.
Bora Chae, MD
2016–2017

The Mae and Lee Sherman Fellowship Fund
Established in 1981 by the Sherman family to support postdoctoral fellows.
Andrew Salem, MD
2015–2016

Saba Al-Hashima, MD
2016–2017

Audrey and Jack Skirball Ocular Inflammatory Disease Fellowship
Established in 2011 by The Skirball Foundation to support the training of fellows specializing in ocular inflammatory disease.

Jules Stein Research Fellowship
Established in 1982 by various donors to honor the memory of Charles Kenneth Feldman.
Aaron Nagiel, MD, PhD
2016–2017

Endowments for Research, Education, and Patient Care
Albert Sarnoff Endowed Cataract Fund
Amalia Simon Roth Endowment
Anne H. West Estate Fund
Anthony Eannelli Fund
Arna Saphier Macular Degeneration Fund
Arthur Spitzer Fund
Audrey Hayden-Gradle Trust
Barbara P. Taylor Fund
Bradley R. Straatsma Research Fund
Card Family Research Fund
Chesley Jack Mills Trust
Daniel B. Whipple Fund
Dr. William F. Stein and Esther Elizabeth Stein Memorial Fund
Edward and Hannah Carter Fund
Elsie B. Ballantyne Regents Fund
Elsie B. Ballantyne UCLA Foundation Fund
Emily G. Plumb Estate and Trust
Emma B. Gillespie Fund
Endowment for Children with Uveitis
Esther Shandler Research Fund
Gerald Oppenheimer Family Foundation Center for the Prevention of Eye Disease Endowment Fund
Harold B. and Bernice L. Belfer Fund
Henry I. Baylis, MD, Endowed Fund in Orbital and Ophthalmic Plastic Surgery
Herb Ritts, Jr., Memorial Vision Fund
Herman King Fund
Hintze Glaucoma Research Fund
J. Richard Armstrong and Ardis Armstrong Fund
Jerome T. Pearlman, MD, Fund
John and Theiline McConne Macular Disease Research Fund
JSEI Maintenance Fund
Katherine L. Gardner Research Fund
Louis and Annette Kaufman Fund
Maggi Kelly Vision Fund
Marie and Jerry Hornstein Family Endowed Macular Degeneration Research Fund
Michael Huffington Ophthalmology Scholarship Fund
Pat and Joe Yzuriaga Endowed Cataract Fund
Patricia and Joseph Yzuriaga Endowed Vision Science Research Fund
Patricia Pearl Morrison Research Fund
Paul J. Vicari Endowed Cataract Research Fund
Raymond and Ruth Stotter Vision Science Research Fund
Richard B. Shapiro Vision Fund
Sara Kolb Memorial Fund
Stella F. Joseph Fund
The Annenberg Foundation Fund
The Karl Kirchgessner Foundation Ophthalmology Endowment Fund
The Leonard Apt, MD, Pediatric EyeSTAR Residency Training Fund
The Leonard Apt, MD, Pediatric Ophthalmology Fund
The Skirball Foundation Fund
UCLA Center for Eye Epidemiology
Uncle Claude Fund
Virginia Burns Oppenheimer Endowment Fund
Wickham Retina Research Fund
William R. Payden Fund for Glaucoma Research
William, Richard, & Roger Meyer Fund
The legacy of Dr. and Mrs. Jules Stein arises from their role in the 20th century as visionaries. Through brilliance and beneficence, they created a multitude of programs aimed specifically at one goal: preserving and restoring eyesight. They approached this task dauntlessly, integrating the worlds of business, medicine, and philanthropy in such a way as to enhance each and leave in trust the promise of limitless accomplishment in the advancement of eye research and treatment. The Stein Eye Institute was established as a result of their philanthropy.
Jules Stein

Jules Stein is the foremost benefactor in the world history of vision science and blindness prevention. He combined his love for music and medicine with a unique talent for analysis and organization to produce a lifetime of celebrated achievements as musician, physician, business leader, and humanitarian.

Born in South Bend, Indiana, in 1896, Jules Stein received a bachelor of philosophy degree from the University of Chicago at age 18 followed by a medical degree from Rush Medical College. After completing postgraduate studies at the University of Vienna and Chicago’s Cook County Hospital, he began medical practice and was certified by the American Board of Ophthalmology.

A musician from an early age, he financed his education by playing in and leading his own band. As his reputation increased, he began booking other musicians for professional engagements, and in 1924, founded Music Corporation of America (MCA). Shortly thereafter, he gave up the practice of medicine to concentrate on this enterprise. Within 10 years, MCA represented most of the great name bands and corporate activities began to extend to representation of film stars, directors, writers, and musical artists. MCA entered the promising new field of television at its inception, eventually acquiring the Universal City property, Universal Pictures, and other enterprises to become preeminent in the entertainment industry.

Throughout his phenomenally successful career, Jules Stein maintained a strong interest and emotional investment in medicine, particularly his own field of ophthalmology. In the late 1950s, urged by his wife, Doris, he chose to direct his considerable talents to blindness prevention. The result was a concert of ideas and achievements that encompassed philanthropy, government, and academic medicine.

By his efforts, Research to Prevent Blindness was created, now recognized as the world’s leading voluntary organization in support of studies of the eye and its diseases. Jules Stein was largely responsible for the passage of legislation to establish the National Eye Institute as a separate entity in the National Institutes of Health. Under his leadership, the Stein Eye Institute was founded as a multidisciplinary center for vision science. Since its establishment, the Institute has become internationally identified as the focus for coordinated programs of research in the sciences related to vision, ophthalmic education, and the care of patients with eye disease. Jules Stein died in 1981, leaving a legacy of hope to the world. Through his accomplishments and philanthropy, he created ever-replenishing resources for eye research and the means to preserve and restore sight for future generations.

Doris Stein

Doris Stein’s purposeful, yet richly varied life, earned the respect and affection of the many people who benefited from her humanitarianism. Inspiring partner of her husband for more than half a century, Doris Stein shared with him the accomplishments of his philanthropic endeavors and guided his interests in ophthalmology, beginning with a visit to the New York Lighthouse for the Blind in the late 1950s. Deeply moved, Doris Stein urged her husband to “do something!” From that passionate beginning came a broad base of programs that catalyzed eye research.

Doris Stein was a major force in this vision renaissance. She served as an officer and director of Research to Prevent Blindness, personally leading the appeal to establish more resources for investigations into eye diseases. She suggested that Jules Stein assume the principal role in the creation of an eye institute at UCLA, and her unflagging enthusiasm nurtured the Institute’s development as a unique provider of every facet of vision research and patient care. Serving as Trustee, she focused special attention on Institute initiatives to combat blindness throughout the world. She devoted her last days, until her death in 1984, to the development of an expansion and companion building for eye research. In 1989, dedication ceremonies were held for the Doris Stein Eye Research Center.

With grace, vision, and meaningful action, Doris Stein enhanced the lives of all privileged to know her, stimulated a cascade of progress in eye research, co-founded the Institute with its boundless scientific potential, and extended the miracle of sight to untold numbers of people.
Board of Trustees

Board of Trustees, established in 1977, ensures the Institute’s orderly growth and development. The Board meets regularly during the year, with each Trustee providing his/her unique counsel. Collectively, their invaluable contributions have included fiscal planning for the Institute, adoption of measures to facilitate recruitment of the world’s finest vision scientists, allocation of funds for the purchase of vision research equipment, and recommendations for expansion programs.

Norman Abrams, Esq.
Distinguished Professor of Law Emeritus
Acting Chancellor Emeritus
UCLA
2015–present

Edward A. Landry, Esq.
Partner
Musick, Peeler & Garrett
2016–present

Bartly J. Mondino, MD
Director
Stein Eye Institute
1994–present

Ronald L. Olson, Esq.
Partner
Munger, Tolles & Olson
1995–present

Gerald H. Oppenheimer
President, Gerald Oppenheimer Family Foundation
President, Systems Design Associates
1992–present

Nelson C. Rising, Esq.
Chairman and Chief Executive Officer
Rising Realty Partners
2011–present

Katrina vanden Heuvel
Publisher and Editor
The Nation
1984–present

Casey Wasserman
President and Chief Executive Officer
The Wasserman Foundation
1998–present

Observer
Marissa Goldberg
Executive Director and Chief Financial Officer
Doheny Eye Institute
2015–present
The Executive Committee

The Executive Committee of the Stein Eye Institute and UCLA Department of Ophthalmology meets regularly during the year, with each member providing their unique expertise. The Committee ensures the orderly growth and development of the Institute and Department. It is involved in fiscal planning, expansion, recruitment, program development, and resolution of interdivisional issues.

Bartly J. Mondino, MD
Director, Stein Eye Institute
Chairman, UCLA Department of Ophthalmology
Affiliation Chairman, Doheny Eye Institute

Anthony C. Arnold, MD
Vice Chairman, Education

Anne L. Coleman, MD, PhD
Vice Chairman, UCLA Department of Ophthalmology

SriniVas R. Sadda, MD
President and Chief Scientific Officer, Doheny Eye Institute

Alfredo A. Sadun, MD, PhD
Vice Chairman, Doheny Eye Center UCLA

Alapakkam P. Sampath, PhD
Associate Director, Stein Eye Institute

Jonathan D. Smith
Chief Administrative Officer, Stein Eye Institute

Gabriel H. Travis, MD
Special Advisor
The UCLA Stein Eye Institute is a vision-science campus dedicated to the preservation and restoration of vision through its global programs in innovative research, quality patient care, and multidisciplinary, integrative education, all with community outreach.
Faculty
Anthony J. Aldave, MD

Walton Li Chair in Cornea and Uveitis
Professor of Ophthalmology
Chief of the Cornea and Uveitis Division
Member of the Stein Eye Institute

Discovering the Genetic Basis of the Corneal Dystrophies

The Cornea Genetics Laboratory, under Dr. Aldave’s direction, is involved in identifying and elucidating the genetic basis of inherited corneal disorders, such as posterior polymorphous and Lisch corneal dystrophies.
Saba Al-Hashimi, MD

Health Sciences Assistant Clinical Professor

Cornea, External Disease, and Refractive Surgery Specialist

Dr. Al-Hashimi is a clinician with a research interest in keratoconus and corneal crosslinking. His research focus involves halting the progression of corneal disease by using light and chemicals to strengthen the cornea.

Specializing in infections of the cornea, Dr. Al-Hashimi performs surgical procedures that include corneal transplantation, Descemet membrane stripping endothelial keratoplasty, Descemet membrane endothelial keratoplasty, deep anterior lamellar keratoplasty, corneal patch grafts, pterygium surgery, corneal repair, cataract surgery, and premium cataract surgery with femtosecond laser.

Patients can see “Dr. Saba” at the UCLA Stein Eye Institute.
Anthony C. Arnold, MD

Mary Oakley Foundation Chair in Neurodegenerative Diseases
Professor of Clinical Ophthalmology
Chief of the Neuro-Ophthalmology Division
Director of the UCLA Optic Neuropathy Center
Vice Chairman, Education
Member of the Stein Eye Institute

Ischemic and Inflammatory Diseases of the Optic Nerve

Dr. Arnold directs a neuro-ophthalmology research program concerned with diseases of the optic nerve. The overall goals of the program are the development of new techniques for imaging the optic nerve and its blood supply; an improved understanding and classification of ischemic and inflammatory optic nerve diseases; and the development and evaluation of new therapeutic modalities for these diseases.

Dr. Arnold was a principal investigator in the National Eye Institute-sponsored clinical study of optic nerve sheath decompression surgery for nonarteritic anterior ischemic optic neuropathy, and he was on the study’s Visual Field Data Analysis Committee. He is a primary advisor for an international multi-center study of risk factors for nonarteritic anterior ischemic optic neuropathy.

Ongoing additional research studies include clinical characteristics of ischemic optic neuropathy in young patients; improved differentiation of arteritic from nonarteritic anterior ischemic optic neuropathy; identification of ischemic aspects of other rare optic neuropathies, such as diabetic papillopathy, uremic optic neuropathy, and chemotherapy-induced optic neuropathy after bone marrow transplantation; and classification of unusual optic neuropathies, such as ethambutol-induced optic neuropathy and focal congenital optic nerve hypoplasia. A study of differentiation of optic disc drusen from papilledema has recently been completed. A major thesis entitled, The Spectrum of Optic Disc Ischemia, has been submitted to the American Ophthalmological Society.
Gavin G. Bahadur, MD

Health Sciences Assistant Clinical Professor of Ophthalmology

Informatics and Health Care Policy

Dr. Bahadur is a full-time ophthalmologist at the Stein Eye Center–Santa Monica, specializing in comprehensive ophthalmology, including cataract, pterygium, and glaucoma surgery.

In addition to his clinical duties, Dr. Bahadur teaches medical students during their ophthalmology surgical subspecialties rotation. His research interests include medical informatics and health care policy.

Public Service
Volunteer, Care Harbor Los Angeles
Richard S. Baker, MD

Associate Professor of Ophthalmology
Associate Director, Stein Eye Institute Center for Community Outreach and Policy, UCLA Center for Eye Epidemiology
Executive Director, Center for Health Services Research
Charles R. Drew University of Medicine and Science
Chairman, Department of Ophthalmology
Charles R. Drew University of Medicine and Science
Member of the Stein Eye Institute
Vice Dean for Medical Education, Wayne State University School of Medicine

Ophthalmic Epidemiology and Health Services Research

Dr. Baker’s primary areas of research interest are in the fields of ophthalmic epidemiology, health services research, and health information technology, including telemedicine. Current projects in ophthalmic epidemiology include statistical analysis of national and statewide databases to produce definitive population-based estimates of the distribution and the determinants of major ophthalmic diseases and their treatments.

As executive director of the Charles R. Drew Center for Health Services Research, Dr. Baker works closely with collaborators at the Stein Eye Institute and across UCLA on multiple projects related to improving access to care, optimizing the quality of care, and eliminating health disparities in diverse and underserved populations.

Public Service
Trustee, California Medical Association
Chairman, Council for Scientific and Clinical Affairs, California Medical Association
Secretary, Board of Trustees, Los Angeles County Medical Association
Chairman, African American Physician Advisory Committee, Los Angeles County Medical Association
Secretary, Board of Trustees, Latino Physicians of California
Reviewer for multiple National Institutes of Health and Agency for Healthcare Research and Quality Special Emphasis Panels
Reviewer for many scientific journals
John D. Bartlett, MD

Health Sciences Assistant Clinical Professor of Ophthalmology
Member of the Stein Eye Institute

Cataract and Refractive Surgery

Dr. Bartlett has an ongoing clinical interest in cataract surgery, particularly refractive cataract surgery where the goal is to improve the focusing of the eyes and reduce dependence on glasses, while restoring vision potential. He is involved with teaching these surgical techniques to the Stein Eye residents, training the next generation of eye surgeons to deal with challenging cases.

Clinical Informatics

As one of UCLA’s physician informaticists, Dr. Bartlett is involved in the ongoing implementation and optimization of electronic health records (EHRs). UCLA physician informaticists engage in all aspects of understanding and promoting effective organization, analysis, management, and use of clinical information. Dr. Bartlett is interested in using EHRs to reach the “Triple Aim” of improved patient care and satisfaction, improved population health, and decreased cost of health care.
Dr. Bhat’s laboratory studies the regulation of gene activity during differentiation and development of the vertebrate eye. This involves isolation and characterization of genes and gene products, identification of the regulatory elements and factors, and elucidation of their mechanisms employing both in vivo and in vitro paradigms with manipulated gene sequences.

Two areas of research currently under investigation are focused on gaining deeper insight into molecular mechanisms that developmentally predispose the eye to visual impairment through ocular lens pathologies such as cataracts, and through retinal diseases including age-related macular degeneration (AMD).

One area of attention is the study of the developmental and tissue-specific control of the αB-crystallin gene and its involvement in cataractogenesis. Another is the elucidation of the physiological function of the αB-crystallin protein in the ocular lens, in the neuroretina and retinal pigment epithelium (RPE), and in the brain. Technically this work involves gene manipulations and the study of their consequences on the phenotype, both in vitro (cultured cells) as well as in vivo (transgenic animals).

Studies on the regulation of the expression of the small heat-shock protein gene, αB-crystallin, are focused on heat-shock transcription factor 4 (HSF4), which Dr. Bhat’s laboratory has reported to be the predominant heat-shock transcription factor of the developing lens, and its post-natal expression correlating with the most prevalent form of early childhood lamellar cataracts. Dr. Bhat’s group has generated mouse models of this cataract, thus enabling first-time investigation of this childhood pathology.

Studies on the function of the αB-crystallin protein in the lens and the RPE (in particular its relation to AMD) are focused on elucidating its “non-crystallin” function, which is relevant both in the transparent and nontransparent physiology. These investigations have led Dr. Bhat’s laboratory to the discovery of the secretion of αB-crystallin from the RPE in lipoprotein vesicles known as exosomes, and to initiate studies on elucidation of intercellular communication (via exosomes) in the RPE, in health, and in disease.
Nicholas C. Brecha, PhD

Distinguished Professor of Neurobiology, Ophthalmology, and Medicine  
Member of the Stein Eye Institute  
Member of the Brain Research Institute  
Member of CURE: Center for Digestive Diseases  
Member of the California NanoSystems Institute

Functional and Structural Organization of the Mammalian Retina

Dr. Brecha’s research focuses on the elucidation of the structural and functional organization of the outer and inner retina for understanding visual information processing by the retina. Morphological studies are focused on defining the different cell types and their microcircuitry in the outer and inner retina. Neurochemical studies have investigated the action of the excitatory and inhibitory neurotransmitters and neuroactive peptides in these retinal microcircuits. Experimental work has clarified the functional role of neuropeptides in the inner retina and supports the current hypothesis that certain dopamine and neuropeptides are modulators of retinal neurons and circuitry that influence light and dark adaptation; they also influence retinal circuitry that mediate pupillary reflexes and eye movements.

Other experimental work has investigated the photoreceptor synaptic triad, a specialized synaptic complex that is the site of initial transfer of visual information from photoreceptors and is critically important for visual processing. Experimental studies are testing the idea that a gamma-Aminobutyric acid (GABA) mediated vesicular release underlies horizontal cell feedback and feed forward signaling, to cones and bipolar cells, respectively. The horizontal cell microcircuitry is critically important for both local and global image processing, including the formation of visual receptive fields, blue-yellow color opponency, and ganglion cell gain. These investigations are fundamental steps in establishing the retina’s functional organization and provide the basis for understanding the pathophysiology of retinal dysfunction concomitant with retinal disease and injury.
Dr. Caprioli’s long-term objective in his clinical and basic research is to identify those individuals at greatest risk for visual loss and to implement new treatment strategies to prevent blindness. Currently, the only tool that physicians have to treat glaucoma is reduction of intraocular pressure. This treatment does not prevent visual loss in a substantial proportion of patients whose damage progresses quickly. The development of effective neuroprotective avenues of treatment will be a hallmark advance to eliminate blindness from this disease.

Evaluation of Methods to Measure Rates of Glaucomatous Optic Nerve Damage
Accurate assessment of optic nerve and nerve fiber layer is important to the early detection and timely treatment of glaucoma. Studies are underway to develop novel structural measures of the optic nerve and nerve fiber layer, which are sensitive and specific for early and progressive glaucomatous optic nerve damage. The goals of this work include identifying clinically implementable techniques to measure the rate of progressive damage. It is unlikely that a single structural or functional technique will be best throughout the course of the disease, and different methods will need to be applied at different stages to best measure disease progression.

Molecular Mechanisms of Retinal Ganglion Cell Damage and Neuroprotective Approaches to Treatment
Basic science research under Dr. Caprioli’s direction involves the mechanisms of glaucomatous optic nerve damage. The stress protein response in a glaucoma model is being intensively studied. An important goal in this research is to identify neuroprotective drugs that prevent the death of retinal ganglion cells in mammalian models of glaucoma, and to apply these findings to clinical trials of human glaucoma.
Richard Casey, MD

Health Sciences Clinical Professor of Ophthalmology
Associate Member of the Stein Eye Institute

Cornea External Disease

Dr. Casey’s research is focused on understanding the causes of a variety of ocular surface and corneal disorders, with the intended goal to develop or improve treatments for patients with these disorders. He is currently collaborating with both the Retina and Ophthalmic Pathology Divisions in separate clinical research projects. One study evaluates the ocular surface of patients undergoing corneal transplantation surgery to establish previously undescribed clinical-pathologic correlation with tear insufficiency and corneal epithelial abnormalities. A major outcome is to improve the success of corneal transplantation in high-risk patients with the comorbid conditions of tear insufficiency. He is also working with the Retina Division to determine which variables improve corneal transplant survival when corneal transplantation is combined with vitreoretinal surgery.

Public Health Services/Health Access

Dr. Casey has elected to dedicate a significant portion of his professional career to improving access to health care in specific underserved communities of Los Angeles. He has focused on assessing unmet needs in vision health to develop innovative strategies that address these deficits. He established the Los Angeles Ophthalmology Medical Group in 2001, which provides comprehensive eye care services in South Los Angeles.
Anne L. Coleman, MD, PhD

The Fran and Ray Stark Foundation Chair in Ophthalmology
Professor of Ophthalmology
Professor of Epidemiology
Director of the Stein Eye Institute Centers for Community Outreach and Policy, Eye Epidemiology, and the UCLA Mobile Eye Clinic
Vice Chairman of Academic Affairs, UCLA Department of Ophthalmology
Member of the Stein Eye Institute

Glaucoma, Cataract, and Age-Related Macular Degeneration

Dr. Coleman’s research is directed toward the diagnosis, treatment, and societal impact of glaucoma, cataracts, and age-related macular degeneration, including the study of lifestyle limitations imposed on patients with these kinds of eye diseases. Clinical projects include studies that analyze the prevention of visual impairment and blindness in school-age children, comparative effectiveness research, and glaucomatous visual field and optic nerve progression.

Public Service
Associate Editor, Editorial Board, American Journal of Ophthalmology
Mentor, Women’s Leadership, Association for Research in Vision and Ophthalmology
Council Chair, American Ophthalmological Society
Member, Fight for Sight Scientific Review Committee
Member, Glaucoma Research Foundation Scientific Advisory Committee
Member, Board of Trustees, Helen Keller International
Board Member, International Council of Ophthalmology Foundation
Member, National Academy of Sciences, Engineering, and Medicine, Committee on Human Rights
Member, NIH/CSR Neurological, Aging and Musculoskeletal Epidemiology (NAME) Study Section Review Group
Member, National Glaucoma Research Review/Bright Focus
Member, Research to Prevent Blindness Scientific Advisory Board Panel
Director/Trustee, St. John of Jerusalem Eye Hospital Group
US Hospitalier, The Most Venerable Order of the Hospital of St. John of Jerusalem
Joseph L. Demer, MD, PhD

Arthur L. Rosenbaum, MD, Chair in Pediatric Ophthalmology
Professor of Ophthalmology
Professor of Neurology
Chief of the Pediatric Ophthalmology and Strabismus Division
Member of the Stein Eye Institute

Motility and Vision

Dr. Demer studies the role of the brain and extraocular muscles in the control of eye movements and visual perception. He is directing a National Eye Institute research project aimed at developing an understanding of the role of orbital connective tissues and nerves in the development of binocular coordination disorders, such as strabismus, and is developing new technologies for magnetic resonance imaging of extraocular muscles and nerves. This research has contributed to the knowledge of the functional anatomy of extraocular muscles and connective tissues, allowing development of new types of surgeries. An emerging research topic is the possible role of extraocular muscle forces in the development of optic neuropathies, such as glaucoma and anterior ischemic optic neuropathy.

Dr. Demer’s research also employs novel micro- and nano-technological techniques to study the biomechanical properties of the extraocular muscles and associated tissues, as well as optical and x-ray imaging of the effects of physiological forces in the tissues.
Limbal Stem Cell Deficiency

Dr. Deng’s research is focused on improving the current diagnosis and treatments for patients with limbal stem cell deficiency. One of her ongoing clinical studies using laser scanning in vivo confocal microscopy in patients with limbal stem cell deficiency shows correlated cellular changes in the cornea and limbus. Damages to the limbal stem cells could be detected and correlated with clinical presentation. This new technique could allow for a better understanding of the pathophysiology of limbal stem cell deficiency. Another study focuses on finding a better diagnostic marker for limbal stem cell deficiency. By using the new diagnostic marker and in vivo confocal imaging, a timely diagnosis and staging of disease progression could be achieved.

Dr. Deng’s laboratory studies the microenvironment/niche of the limbal stem cells to elucidate those factors that govern the fate of limbal stem cells. The role of the Wnt signal transduction pathway in human limbal stem/progenitor cells is under investigation. Recent study in her laboratory reveals that activation of the Wnt/β-catenin promotes self-renewal of limbal stem cells and that Frizzled 7 might be the receptor that mediates the Wnt activation. Use of small molecules to modulate Wnt signaling is being investigated to increase the efficiency of ex vivo expansion of limbal stem cells for transplantation.

Cornea Endothelial Dysfunction

Another area of Dr. Deng’s research is the development of cell therapy to treat endothelial dysfunction by regeneration of human corneal endothelial cells. Currently, her laboratory focuses on investigating the signature genes of corneal endothelial cells and the regulation of these quiescent cells. Another project aims to increase the efficiency of expansion of corneal endothelial cells in culture and derivation of these cells from pluripotent stem cells.

developed xenobiotic-free and feeder-free culture methods to expand autologous limbal stem cells in culture. Pre-clinical studies are ongoing to bring this stem cell therapy to restore vision in patients who suffer from limbal stem cell deficiency.
Dr. Farber’s research focuses on the study of genes involved in inherited retinal diseases, and on the characterization and use of human extracellular vesicles released by embryonic stem cells (ESEVs) for retinal therapy. Her team has worked on several genes encoding proteins that play a key role in vision and that when mutated cause blinding diseases. These include the β-PDE gene (mutated in rd mice, Irish setter dogs, and in humans with autosomal recessive retinitis pigmentosa (arRP); the RP1 gene (responsible for a type of autosomal dominant RP); the gene causing disease in the rd7 mouse, a model for Enhanced S-Cone Syndrome; the α-transducin gene, disrupted in the Rd4 mouse, another model of retinal disease; the mouse homologue of the gene causing X-linked juvenile retinoschisis (Xirs1); and the cone genes ZBED4 and RHBD2, that when mutated cause arCRD and arRP, respectively. Utilizing gene therapy methods, Dr. Farber and collaborators delivered the normal β-PDE gene to rd mouse retinas and rescued their photoreceptors. Dr. Farber’s group also worked on the mechanisms that regulate transcription and expression of retinal genes. They found that the transcription factor SP4 controls the activity of the β-PDE promoter and mutations in both SP4 and α-transducin cause digenic arRP and cone-rod dystrophy (arCRD).

Other projects center on the study of animal models of ocular albinism, which lack the OA7 gene and are affected with permanent visual impairment. An important discovery of Dr. Farber’s team related to this work is that mutations in another gene, Gai3, also cause ocular albinism.

Currently, the main focus of Dr. Farber’s group is the study of human ESEVs, nanoparticles that may have a pro-regenerative potential: by triggering molecular changes in Müller glia they may favor regeneration of damaged retinas.

Debora B. Farber, PhD, DPhhc
Karl Kirchgeessner Foundation Chair in Vision Science
Distinguished Professor of Ophthalmology
Member of the Brain Research Institute
Member of the Molecular Biology Institute
Member of the Stein Eye Institute

Retinal Biochemistry, Molecular Biology, Genetics of Retinal Degenerations, and Studies on Embryonic Stem Cell-Derived Extracellular Vesicles

Public Service
Scientific Advisory Board Member, The Foundation Fighting Blindness; Visionary Scientists Board Member, Hope for Vision. Scientific Advisor and Board Member, The Vision of Children Foundation
Editorial Board Member: Molecular Vision; The Open Ophthalmology Journal; Journal of Ocular Biology, Diseases, and Informatics; and Stem Cells and Cloning Advances and Applications
Grant Reviewer: National Eye Institute; The Foundation Fighting Blindness; The Vision of Children
Reviewer for many scientific journals
**Simon Fung, MD**

Assistant Professor of Ophthalmology

**Pediatric Ophthalmology and Cornea Specialist**

Dr. Fung's clinical interests are childhood cornea and anterior segment diseases. His research focuses on evaluation of pediatric cornea conditions using novel imaging technologies.

After finishing his residency in 2015, Dr Fung undertook a fellowship in adult cornea and external disease at Moorfields Eye Hospital in London, England, followed by a second fellowship in pediatric cornea and anterior segment at The Hospital for Sick Children in Toronto, Canada. Dr. Fung became a UCLA Department of Ophthalmology faculty member in 2018.

Dr. Fung provides clinical care at the UCLA Stein Eye Institute in Westwood.
JoAnn A. Giaconi, MD

Health Sciences Associate Clinical Professor of Ophthalmology
Chief of the Ophthalmology Section at the Greater Los Angeles VA Healthcare System
Co-Director of Medical Student Education at the David Geffen School of Medicine, UCLA
Member of the Stein Eye Institute

Glaucoma

Dr. Giaconi’s research focuses on the treatment of glaucoma. She is interested in glaucoma surgery outcomes and side effects. She is currently working on various projects in the Veteran population, including examination of the over-treatment or undertreatment of glaucoma. She is enrolling patients in two clinical studies at the Stein Eye Institute. One study is examining the effect of various glaucoma surgeries on the corneal endothelium, which is the layer of cells that keeps the cornea clear, and the other study is investigating a new surgical device.
Ben J. Glasgow, MD

The Wasserman Professor of Ophthalmology
Professor of Pathology and Laboratory Medicine
Chief of the Ophthalmic Pathology Division
Member of the Stein Eye Institute

Ophthalmic Pathology

Dr. Glasgow’s research interests are primarily in the field of ophthalmic pathology. His major focus is the role of human lacrimal gland proteins in the protection and maintenance of the eye. His laboratory is investigating the structure-function relationship of tear lipocalin, the principal lipid carrier protein of tears. Currently, the laboratory has developed a technique called site-directed tryptophan fluorescence to probe and report information regarding molecular motion and solution structure. By studying the molecular mechanisms of tear proteins, Dr. Glasgow is seeking to learn the normal functions of tear lipocalin and its role in maintaining the health of the ocular surface and in the prevention of dry eye diseases. It is hoped that this research will lead to new treatments for dry eye and have broad application to numerous other members of this protein family that transport small, insoluble molecules through the body.
Robert Alan Goldberg, MD

Karen and Frank Dabby Endowed Chair in Ophthalmology
Professor of Ophthalmology
Chief of the Orbital and Ophthalmic Plastic Surgery Division
Director of the UCLA Orbital Disease Center
Co-Director of the UCLA Aesthetic Center
Member of the Stein Eye Institute

Diseases and Therapy of the Eyelid and Orbit

Research into the various surgical approaches to Graves orbitopathy (thyroid eye disease) has resulted in new techniques that include less invasive small incision surgical approaches. In addition, detailed clinical information gathered from patients with Graves orbitopathy is being recorded in a shared database as a way to understand the natural history and response to treatment of this multifaceted disease, which is a cause of significant visual loss and discomfort. Multicenter studies are underway. Dr. Goldberg is also investigating the underlying causes of thyroid-related orbitopathy. The goal of this research is to develop better tests to monitor disease activity, as well as new treatments to address the basic cause of the disease.

Research into orbital and eyelid anatomy, currently in progress, is resulting in improved techniques and approaches to deep orbital disease. Included is the use of high-resolution magnetic resonance imaging and high-resolution dynamic ultrasonography to evaluate motility problems following trauma and orbital surgery, and three-dimensional analysis of orbital anatomy. Improved understanding of eyelid and orbital physiology and anatomy is the basis for developing improved surgical techniques. Instrumentation and devices that allow less invasive surgical approaches, such as hyaluronic acid gels, are being developed and studied. In collaboration with the Department of Engineering, custom materials for orbital reconstruction are investigated.

Outcomes of medical and surgical treatment of orbital and eyelid disorders are being studied in an organized, prospective fashion in order to better understand which treatments are most effective.
Dr. Gordon’s laboratory is involved in two primary areas of research. One project investigates the role for epithelial membrane protein 2 (EMP2) in controlling ocular pathologic responses. Dr. Gordon and her colleagues identified that EMP2 plays an important role in an in-vitro model of proliferative vitreoretinopathy (PVR) and have evidence that EMP2 is highly expressed in human retinal diseases. In addition, they recently identified that EMP2 controls VEGF production in epithelial cells and in specific tumors. The laboratory, in collaboration with others at UCLA, has recently developed a designer antibody fragment that has demonstrated efficacy in in-vitro studies in the PVR model and in other animal models in vivo. This antibody has now been successfully used to control pathologic neovascularization in a corneal burn model, achieving proof of principle for using this antibody to control disease.

The second area of interest of Dr. Gordon’s group is the role of programmed death 1 (PD-1), a molecule that is known to play an important role in immune regulation in the eye. PD-1 has a major function as a negative regulator in the immune system. Although previous studies identified PD-1 expression in the lymphoid system, Dr. Gordon and her colleagues identified its expression in neuronal cells of the retina. Additionally her laboratory has identified that blockade of the PD-1 pathway may be protective in uveitis. Studies are ongoing to identify the mechanisms of that protection.
Michael B. Gorin, MD, PhD

Harold and Pauline Price Chair in Ophthalmology
Professor of Ophthalmology
Professor of Human Genetics
Chief of the Division of Retinal Disorders and Ophthalmic Genetics
Member of the Stein Eye Institute

Hereditary Eye Disorders and Molecular Genetics of Age-Related Maculopathy

Dr. Gorin’s primary research focus is molecular genetics of hereditary eye disorders, specifically age-related macular degeneration (AMD). His research group was the first to identify specific regions of the genome that contributed to ARM development in families, leading to discovery of gene variations that contribute to the risk of developing ARM. He continues to work on studies of the genetics of AMD, in particular the use of genetic risk profiles to test for clinical markers, including sensitive methods for detecting changes in retinal structure and function that precede the onset of clinical disease.

Dr. Gorin investigates the molecular genetics of complex disorders such as cystoid macular edema, age-related cataracts, and glaucoma, as well as monogenic disorders such as hereditary retinal degenerations, glaucoma, cataracts, and ocular syndromes. He is pursuing studies to identify genetic variations that contribute to the severity, complications, and therapeutic responses of these conditions. Dr. Gorin and his clinical team work with the clinical and research human genetics group at UCLA to explore use of new technologies, including next-generation sequencing for clinical utility in ophthalmic genetics.

Research also focuses on the neurobiology of ocular pain and photophobia (sensitivity to light) to understand the basic biology and neural pathways that contribute to photophobia so that new therapeutic strategies can be developed. Based upon preliminary work, opportunities have emerged to investigate the pathogenesis of light sensitivity for individuals who suffer from migraines and/or mild traumatic brain injury.

Clinical research efforts are directed towards developing methods to monitor and quantify retinal function in progressive retinal disorders (such as diabetic retinopathy, Stargardt disease, and retinitis pigmentosa) and in patients with potential ocular toxicities from systemic medications. Applied research interests include bioinformatics in clinical ophthalmic practice and public health issues pertaining to ocular disease.
David Rex Hamilton, MD, FACS

Health Sciences Clinical Professor of Ophthalmology
Director of the UCLA Laser Refractive Center
Member of the Stein Eye Institute

Advanced Intraocular Lenses

Dr. Hamilton’s research interests are in the areas of corneal biomechanics and tomography (3D imaging of the cornea), screening for corneal ectatic disorders, and the clinical study of intraocular lenses (IOLs) for the treatment of high myopia (phakic IOLs), astigmatism (toric IOLs), and presbyopia (multifocal and accommodating IOLs). Dr. Hamilton is actively involved in training residents and fellows in the surgical treatment of refractive errors and cataracts.

Public Service
Editorial Board Member, Ophthalmology, Journal of Refractive Surgery, and Journal of Cataract and Refractive Surgery
Member, Refractive Leadership Council, Alcon Laboratories
Member, ASCRS Refractive Surgery Clinical Committee
Member, ASCRS Refractive Surgery/Cataract Clinical Subcommittee
Member, American Academy of Ophthalmology, Preferred Practice Pattern Committee for Refractive Surgery
Member, American Academy of Ophthalmology, ONE Network, Refractive Surgery
Gary N. Holland, MD

Jack H. Skirball Chair in Ocular Inflammatory Diseases
Professor of Ophthalmology
Director of the Ocular Inflammatory Disease Center
Director of the UCLA Department of Ophthalmology Clinical Research Center
Co-Director of Medical Student Education
Member of the Stein Eye Institute

Uveitis and Cornea-External Ocular Diseases

Dr. Holland’s research deals with infectious and inflammatory diseases of the eye, including ocular toxoplasmosis; HIV-related eye disease; chronic anterior uveitis in children; and birdshot chorioretinopathy. Clinical studies are being performed to identify populations at greatest risk for these ocular diseases and factors that influence disease severity. Studies also investigate the course of these diseases and response to new treatments. Better understanding of these conditions may lead to improved disease management.

Ocular toxoplasmosis, caused by a parasite, is the most common retinal infection in the general population. With investigators in North America, Brazil, and Europe, Dr. Holland is studying human and parasitic genetic factors that influence risk for ocular involvement among people infected with the parasite.

Dr. Holland continues to study cytomegalovirus (CMV) retinitis, the most serious eye problem among HIV-infected individuals, and still a major public-health problem in many areas of the world because of the AIDS pandemic. He is also investigating HIV-related “neuroretinal disorder” (NRD), a degenerative condition that causes deterioration of vision and reduced quality of life, even among individuals whose immune function has improved because of antiretroviral drugs. NRD is also a marker of non-ocular, life-threatening diseases among HIV-infected people.

Chronic anterior uveitis is a common complication of juvenile idiopathic arthritis (JIA). Dr. Holland is studying risk factors for, and treatment of, vision-threatening complications of JIA-associated uveitis, including glaucoma, and he is interested in the psychosocial impact of uveitis on children and their families.

Birdshot chorioretinopathy is a chronic autoimmune disease of the eye. Dr. Holland is participating in several multicenter studies involving retinal imaging and electrophysiologic techniques to understand the basis for vision loss among people with the disease. He also helped to organize and is analyzing data from a 10-year longitudinal clinical study of the disease in Paris, France, that involves a large cohort of patients.

Public Service
Associate Editor, American Journal of Ophthalmology
Editorial Board, EyeNet Magazine (American Academy of Ophthalmology), Section Editor, Uveitis
Executive Committee Member, American Uveitis Society
Hamid Hosseini, MD

Assistant Professor of Ophthalmology

Retinal and Macular Conditions

Dr. Hosseini specializes in retinal and macular conditions, such as macular degeneration, diabetic retinopathy, and retinal detachment.

Dr. Hosseini completed two fellowships at the UCLA Stein Eye Institute, the first in glaucoma and the second in retina. He participates in all activities of the Retina Division, including research, education, and clinical care. He sees patients at the Stein Eye Institute in Westwood and Harbor-UCLA Medical Center.
Wayne L. Hubbell, PhD

Jules Stein Chair in Ophthalmology
Distinguished Professor of Ophthalmology
Distinguished Professor of Chemistry and Biochemistry

Molecular Basis of Phototransduction in the Vertebrate Retina

Dr. Hubbell’s research is focused on understanding the complex relationship between molecular structure, plasticity, and conformational changes that control protein function in the visual system. Of particular interest are proteins that behave as “molecular switches,” that is proteins whose structures are switched to an active state by a physical or chemical signal. Examples include rhodopsin, the membrane-bound photoreceptor protein of the retina, and transducin and arrestin, proteins that associate with rhodopsin during function. The overall goal is to determine the structure of these proteins in their native environment, monitor the changes in structure that accompany the transition to an active state, and to understand the role of protein flexibility in function.

To investigate these and other proteins, Dr. Hubbell’s laboratory has developed the technique of site-directed spin labeling, a novel and powerful approach to the exploration of protein structure and dynamics. By changing the genetic code, a specific attachment point in the protein is created for a nitroxide spin label probe. Analysis of the electron paramagnetic resonance (EPR) spectrum of the spin label provides information about the local environment in the protein. With a sufficiently large set of labeled proteins, global information on structure is obtained and changes in the structure during function can be followed in real time. While determination of static protein structure is important to understanding function, current research has highlighted a crucial role for protein flexibility (dynamics), which has not been previously appreciated. To explore molecular flexibility in proteins of the visual system, Dr. Hubbell’s group is developing novel methods using time-domain and high-pressure EPR.
Jean-Pierre Hubschman, MD

Associate Professor of Ophthalmology
Member of the Stein Eye Institute

Advanced Vitreoretinal Surgical Interventions and Robotics

Dr. Hubschman’s clinical research focuses on the development and evaluation of new vitreoretinal surgical techniques and robotics for ophthalmic surgery. Automated surgery utilizing robotics promises to increase surgical precision and accuracy, as well as improve access to medical care. Dr. Hubschman’s publications include research papers on the development of a new retinal patch for the treatment of retinal detachment, on the feasibility of robotic surgery in ophthalmology, and results of various clinical trials. Currently, he is also investigating the use of the terahertz laser for the evaluation of ocular tissue hydration.
Sherwin J. Isenberg, MD

Laraine and David Gerber Chair in Ophthalmology
Distinguished Professor of Ophthalmology
Professor of Pediatrics
Member of the Stein Eye Institute

Pediatric Ophthalmology, Amblyopia, and Ophthalmic Pharmacology

Dr. Isenberg’s research activities have concentrated on various aspects of surgical and medical diseases of children’s eyes. The goal is to decrease the frequency of blindness in children worldwide. In a series of studies of newborns, Dr. Isenberg has characterized a number of elements, including: the type and source of bacteria of the external eye at birth; the evolution of iris structural changes; the development of the macula, which is the source of central vision; and pupillary responses after birth. Recent publications have characterized the production and nature of tears of infants and the development of the cornea in the first year of life. He has also reported the ocular signs in newborns whose mothers abuse cocaine, facilitating the diagnosis of newborn cocaine intoxication.

In another avenue of research, povidone-iodine eyedrops have been found to treat bacterial conjunctivitis successfully in a three-year, international study with the University of the Philippines. The eyedrops were also found to be safer and more effective in preventing eye infections than the currently used agents. Dr. Isenberg and other investigators have now proven that the povidone-iodine eyedrops can treat the number one cause of preventable pediatric blindness in the world—corneal infections due to bacteria. These studies, conducted in children and adults in India and the Philippines, should reduce the number of 400,000 children now blind from corneal infections. A new study investigating fungal infections of the eye, which blind approximately 10,000 children annually, has been completed at three sites in India.

Lastly, a new device that reports blood gases from the conjunctiva, such as oxygen and carbon dioxide, is being developed. Preliminary trials have been completed in animals and in adults undergoing cardiac bypass surgery. The hope is to apply the device to the eyes of premature newborns. The continuous readout of tissue blood gas levels should enable the pediatrician to prevent damage to the baby’s brain and keep the oxygen at an appropriate level, minimizing the possibility of blindness from retinopathy of prematurity.

Public Service
Past-President, American Association for Pediatric Ophthalmology and Strabismus
Member, Medical Advisory Board and Board of Directors; and Research Committee Chair, Blind Children’s Center
Past President, Costenbader Pediatric Ophthalmology Society
Co-Founder and Delegate, International Pediatric Ophthalmology and Strabismus Council
**Simon K. Law, MD, PharmD**

Health Sciences Clinical Professor of Ophthalmology  
Member of the Stein Eye Institute

**Optic Disc Evaluation**

Dr. Law’s principal research interest focuses on the structural appearance of the optic disc in different ocular diseases, including patients with high myopia. Assessment of optic disc size is an important component of the diagnostic evaluation for glaucoma. Patients with high myopia are at greater risk of developing glaucoma, and they also have an atypical optic disc that makes diagnosis difficult. The purpose of Dr. Law’s research is to characterize the appearance of the optic disc in eyes with high myopia and to identify the related risk factors for development of glaucoma.

**LASIK and Glaucoma**

LASIK refractive procedure has been popular for many years for patients with high myopia. As high myopia is a risk factor for glaucoma, some middle-aged patients with prior LASIK have developed the disease. Because of LASIK’s effect on the cornea, eye pressure estimation has been inaccurate after LASIK, and monitoring of glaucoma is difficult in these eyes. Dr. Law is currently studying the outcomes of glaucoma management in glaucoma patients who have had a prior LASIK refractive procedure.

**Glaucoma Filtering Procedure**

Trabeculectomy is the traditional time-honored procedure for glaucoma, and it is considered the gold standard by which newer procedures are compared. The success rate of trabeculectomy, however, is lower in eyes that have undergone prior intraocular surgery. Dr. Law is interested in perfecting the procedure in these cases and in developing a surgical technique to improve the pressure reduction function in current trabeculectomy.
Ralph D. Levinson, MD

Health Sciences Clinical Professor of Ophthalmology
Member of the Stein Eye Institute

Ocular Inflammatory Diseases

Dr. Levinson’s research interest is in both the clinical aspects of uveitis and the basic mechanisms and immunogenetics of ocular inflammation. Current projects include a collaborative longitudinal study of a chronic inflammatory disease, birdshot chorioretinopathy, with investigators in France. The study focuses on the interrelationship of disease factors, as well as the course of disease and response to treatment. Dr. Levinson is also conducting laboratory research on cell-based therapies for uveitis and is a co-investigator for National Eye Institute-funded laboratory research on the effects of cancer immunotherapy on uveitis.
Colin A. McCannel, MD

Professor of Clinical Ophthalmology
Member of the Stein Eye Institute

Vitreoretinal Surgery

Dr. McCannel has a longstanding interest in the management of vitreoretinal conditions, particularly complex retinal detachments, complications of diabetic retinopathy, macular holes and epimacular membranes, and age-related macular degeneration. His clinical research efforts are directed at the improvement of vitreoretinal surgical techniques and outcomes, including the prevention of endophthalmitis following intravitreal injections.

Dr. McCannel devotes time to educational research as well. Currently, he is investigating the utility of virtual reality surgery simulation in teaching ophthalmic surgery. He has several ongoing protocols that assess ophthalmic surgical simulation in surgical teaching.
Tara A. McCannel, MD, PhD

Health Sciences Associate Clinical Professor of Ophthalmology
Director of the Ophthalmic Oncology Center
Member of the Stein Eye Institute

Metastatic Ocular Melanoma

Dr. McCannel’s primary research interest is metastatic ocular melanoma. Under her direction, the Ophthalmic Oncology Laboratory is studying molecular markers in ocular melanoma to provide prognostic information to patients and advance understanding of metastatic disease. Discovery of candidate genes from tissue of patients undergoing surgical treatment for ocular melanoma is being explored. This information will be important to establish a better understanding of the biology of metastatic ocular melanoma and help develop better treatments for this cancer. New modalities are being investigated to predict, detect, and ultimately treat choroidal melanoma metastasis.

Surgical Approaches to Vitreoretinal Disease and Cancer

Dr. McCannel is both a vitreoretinal surgeon and an ophthalmic oncologist. She manages the spectrum of vitreoretinal disease in addition to the surgical management of ocular melanoma, allowing patients to benefit maximally from her wide range of surgical prognostic and therapeutic expertise.

Vitrectomy with silicone oil placement is a novel therapeutic strategy, which was discovered at UCLA to reduce radiation exposure to the healthy structures of the eye during plaque surgery for melanoma treatment. Dr. McCannel offers this potentially sight-saving technique to patients who need radiation treatment.

Health Psychology and Ocular Melanoma

Central to incorporating an integrative approach to health care, the concerns and wishes of the patient as a whole are important aspects of cancer management. In collaboration with the UCLA Department of Health Psychology and the Jonsson Comprehensive Cancer Center, Dr. McCannel works closely with health psychologists who are interested in providing clinical care while researching factors, which predict psychological adjustment to cancer.
Kevin M. Miller, MD

Kolokotrones Chair in Ophthalmology
Professor of Clinical Ophthalmology
Chief of the Cataract and Refractive Surgery Division
Director of the Anterior Segment Diagnostic Laboratory
Member of the Stein Eye Institute

Cataract and Refractive Surgery

Dr. Miller’s research interests are in cataract and refractive surgery, intraocular lenses, artificial iris implants, ophthalmic optics, surgical devices, and surgical outcomes.

Dr. Miller’s clinical practice focuses primarily on refractive cataract surgery and the surgical correction of presbyopia and astigmatism with premium technology intraocular lenses. He developed an astigmatism management service for treating corneal astigmatism at the time of cataract surgery that optimizes postoperative uncorrected visual acuity. He developed a nomogram for peripheral corneal relaxing incisions and participated in the clinical trial of the world’s most popular toric intraocular lens. He was instrumental in bringing femtosecond laser technology to UCLA for use in cataract surgery. He described a non-parametric multivariate technique for comparing astigmatism outcomes between treatment groups. In addition to refractive cataract surgery and ICL implantation, he also performs DSEK, LASIK, PRK, and other cornea-based laser refractive procedures.

Dr. Miller runs several clinical trials of artificial iris implants to treat congenital and acquired aniridia. He completed the multicenter Ophtec 311 clinical trial. He has an individual device exemption from the FDA to study Morcher artificial iris implants. He is the only surgeon in the United States who is permitted by the FDA to implant Morcher devices at this time. He is also studying a custom artificial iris implant from Dr. Schmidt Intraocularlinsen, a subsidiary of HumanOptics. All of these devices are showing promising results in patients who suffer from congenital and acquired iris defects.

Finally, he is an investigator in the RxSight light adjustable lens study and the Alcon Laboratories high-power toric lens post-market approval study.
Bartly J. Mondino, MD

Bradley R. Straatsma, MD, Endowed Chair in Ophthalmology
Distinguished Professor of Ophthalmology
Chairman, UCLA Department of Ophthalmology
Director, Stein Eye Institute
Member, UCLA Brain Research Institute
Board of Directors (Observer), Doheny Eye Institute
Affiliation Chairman, Doheny Eye Institute

Cornea and External Ocular Diseases and Immunological Disorders

Dr. Mondino’s research activity is focused on cornea-external ocular diseases, with particular emphasis on immunological disorders. He has studied the role of lymphocytes and the complement system in the immunopathogenesis of anterior segment diseases. In addition, a model of staphylococcal hypersensitivity lesions of the cornea was explored as well as the immune response to staphylococcal endophthalmitis. Other research interests included corneal dystrophies, peripheral corneal ulcers, bullous diseases of the skin and mucous membranes, collagen shields, and contact lens-related corneal ulcers.
Kouros Nouri-Mahdavi, MD, MSc

Associate Professor of Ophthalmology
Director of the Glaucoma Advanced Imaging Laboratory
Member of the Stein Eye Institute

Role of Structural and Functional Measurements for Detection of Glaucoma and Its Progression

Dr. Nouri-Mahdavi’s research is focused on improving methods to detect early glaucoma and glaucoma deterioration with spectral-domain optical coherence tomography (SD-OCT) and various perimetry techniques. More specifically, he is interested in detection of glaucoma progression in patients with advanced disease. Dr. Nouri-Mahdavi is currently exploring the role of macular imaging for detection of glaucoma progression in a cohort of advanced glaucoma patients.

Glaucoma Treatment Outcomes and Role of Ethnicity

Dr. Nouri-Mahdavi is also interested in studying glaucoma treatment outcomes and their variations as a function of ethnicity. An ongoing study is comparing the long-term outcomes of trabeculectomy with adjunctive mitomycin C in patients of African descent to those of European descent.

Public Service

Member, American Academy of Ophthalmology Glaucoma Registry Measures Working Group
Member, American Glaucoma Society Patient Care Committee, Document Subcommittee
Member, Residency Program Evaluation Committee
Member, Stein Eye Institute Electronic Medical Record Implementation Committee
Member, Glaucoma Progression Scholars
Member, International Education Subcommittee, Education and Communication Committee, American Glaucoma Society
Advisory Board Member, Journal of Current Ophthalmology
Editorial Board Member, Journal of Ophthalmic and Vision Research
Glaucoma Section Editor, Journal of Vision and Eye Research
Methodologist, American Academy of Ophthalmology Ophthalmic Technology Assessment Committee
Volunteer, EyeCare America, provide ophthalmic patient screening at annual Los Angeles charity clinic events
Reviewer for many scientific journals
Steven Nusinowitz, PhD

Professor of Ophthalmology  
Co-Director of the Visual Physiology Laboratory  
Director of the Live Imaging and Functional Evaluation (LIFE) Core  
Member of the Stein Eye Institute

Mechanisms of Retinal Degeneration

Dr. Nusinowitz’s primary research interest is focused on understanding the cellular contributions to noninvasive measures of visual function and defining the sites and mechanisms of disease action in inherited retinal and visual pathway disorders. In his research laboratory, Dr. Nusinowitz’s main approach to gaining an understanding of the site and mechanism of vision loss in humans is to study the patterns of electrophysiological responses obtained from mice in which the disruption of different cells or pathways in the visual system are specifically targeted by genetic manipulation. By comparing the patterns of responses in human disease with the patterns of responses from rodents with targeted cellular disruption, Dr. Nusinowitz is able to test hypotheses about the underlying pathophysiology in human disease and to provide a mechanism for the development of specific diagnostic tools that are sufficiently sensitive for early detection and better diagnosis of clinical disease. In addition, on a more applied level, Dr. Nusinowitz’s research studies in both humans and mice have involved investigations testing the efficacy of multiple therapeutic interventions for retinal disease, including pharmacological, viral, and stem cell therapies.
Stacy L. Pineles, MD

Jerome and Joan Snyder Chair in Ophthalmology  
Associate Professor of Ophthalmology  
Member of the Stein Eye Institute

**Pediatric Neuro-Ophthalmology, Amblyopia, and Neurologic Causes of Strabismus**

Dr. Pineles’ research interests include evaluating the surgical outcomes of strabismus surgery and studying pediatric optic nerve diseases. With her dual training in pediatric ophthalmology and neuro-ophthalmology, she has a special interest in pediatric neuro-ophthalmic diseases, as well as adult patients with amblyopia and neurologic causes of strabismus.
Natik Piri, PhD

Professor of Ophthalmology
Member of the Stein Eye Institute

Retinal Ganglion Cell Biology, Glaucomatous Neurodegeneration, and Neuroprotection

The main directions in Dr. Piri’s research are defining the mechanisms leading to retinal ganglion cell (RGC) degeneration in glaucomatous neuropathy; developing strategies for preserving RGCs against neurodegeneration; and identifying and characterizing the genes critical for RGC function and integrity. Different types of RGCs have been identified based on their morphological and physiological characteristics, yet current knowledge of RGC molecular biology is very limited. Characterization of RGC-expressed genes is fundamental to a better understanding of normal RGC physiology and pathophysiology.

Another area of investigation focuses on understanding the degeneration of RGCs and their axons, which is a hallmark of glaucoma. Dr. Piri’s laboratory is analyzing retinal gene expression profiles from the glaucoma model with the aim of identifying factors involved in the initiation and execution of RGC apoptosis. Study results have implicated several members of the crystallin superfamily in this process, including alpha crystallins. Dr. Piri is also studying the involvement of oxidative stress and proteins of the thiol-redoxin system, particularly in RGC degeneration in the glaucoma model, and the neuroprotective effects of these proteins against glaucomatous RGC death.

Public Service
Reviewer for many scientific journals
Pradeep S. Prasad, MD, MBA

Health Sciences Assistant Clinical Professor
Chief, Division of Ophthalmology, Harbor-UCLA Medical Center
Member of the Stein Eye Institute

Vitreoretinal Surgery and Disease Management

Dr. Prasad specializes in the medical and surgical management of diseases of the retina and vitreous. His research is focused on teleretinal screening for diabetic retinopathy, applications of wide-field fundus photography for retinal vascular disease, and health care delivery for low-income populations. Dr. Prasad also serves as the chief of the Division of Ophthalmology at Harbor-UCLA Medical Center where he provides clinical supervision and instruction to UCLA medical students as well as to Stein Eye residents and vitreoretinal fellows.
Roxana A. Radu, MD

Assistant Professor of Ophthalmology

Retina Biochemistry and Clinical Disease Modeling Laboratory

Dr. Radu is a basic science researcher at the Stein Eye Institute. She is a medical doctor who trained as a biochemist during her postdoctoral fellowship at the Institute. The focus of Dr. Radu’s laboratory research is studying the formation and pathogenic roles of bisretinoid-pigments (vitamin A condensation products) in the retinas of humans with macular degeneration, such as recessive Stargardt disease (STGD1) and age-related macular degeneration (non-vascularized form). The main aim of this research is to develop and characterize disease models—cell-based and mouse lines—to advance understanding of the pathogenesis of maculopathies and potentially lead to novel therapeutic approaches to treat these blinding diseases. Dr. Radu’s group investigates the mechanisms by which ABCA4 mutations result in the STGD1 phenotype, and they explore the bisretinoid-mediated complement dysregulation in the retinal pigment epithelium cells as a key player in visual loss from early and late-onset macular degenerations. Other areas of study include the regulation of the visual cycle for chromophore regeneration by non-visual opsins.

Public Service
Member, Association for Research in Vision and Ophthalmology
Reviewer for Fight for Sight grant applications in the United States and United Kingdom
Board Member, JSEI Affiliates
Reviewer for many scientific journals
Molecular Mechanisms Underlying Early Visual Processing

The Sampath laboratory is interested in understanding the molecular mechanisms underlying early visual processing. In particular, the focus of laboratory researchers has been on elucidating mechanisms that set the sensitivity of night vision. Night blindness, or nyctalopia, is a condition that results from abnormal signaling by the rod photoreceptors, or the retinal circuits that process rod-driven signals. Using physiological and genetic methods, the laboratory studies signal transmission in these retinal rod pathways to identify how these processes are optimized to allow our exquisite visual sensitivity.
David Sarraf, MD

Health Sciences Clinical Professor of Ophthalmology
Member of the Stein Eye Institute

Age-Related Macular Degeneration and Retinal Imaging

Dr. Sarraf is a member of the Retinal Disorders and Ophthalmic Genetics Division of the Stein Eye Institute. He has published approximately 200 research papers, case reports, reviews, and book chapters and is co-author of *The Retinal Atlas*, 2nd edition.

Dr. Sarraf’s focus of research interest includes the dry and wet forms of age-related macular degeneration (AMD) and specifically the evaluation of pigment epithelial detachment (PED) and retinal pigment epithelial tears. He was nominated to the American Ophthalmological Society because of his research work on the subjects of PED and AMD. Dr. Sarraf leads various national and international trials at UCLA for the diagnosis and treatment of AMD and diabetic retinopathy.

Dr. Sarraf has been awarded achievement and secretariat awards by the American Academy of Ophthalmology, and he is a leader in advanced retinal imaging. He has published extensively in the area of spectral domain optical coherence tomography (SD-OCT) analysis of AMD and other novel and established macular disorders. He was one of the first researchers to describe ischemia of the deep retinal capillary plexus using advanced SD-OCT imaging, and he is a world expert on the clinical application of OCT angiography.
Faculty

Steven D. Schwartz, MD

The Ahmanson Chair in Ophthalmology
Professor of Ophthalmology
Chief of the Retina Division
Director of the UCLA Diabetic Eye Disease and Retinal Vascular Center
Director of the Macula Center
Member of the Stein Eye Institute

Stem Cell Research

Dr. Schwartz is leading two new clinical trials testing the use of stem cell-derived retinal pigment epithelial cells to address vision loss in people suffering from Stargardt macular dystrophy and dry age-related macular degeneration.

Retinal Diseases

Dr. Schwartz’s primary areas of research include early diagnosis and treatment of diseases such as retinopathy of prematurity (ROP), diabetic eye disease, and macular degeneration. Additionally, his focus includes development and evaluation of novel medical device technologies, imaging technologies, surgical equipment (including surgical robots), and drug-delivery systems, with particular emphasis on diagnostic and treatment applications. Dr. Schwartz’s clinical research focuses on trials of novel pharmacotherapeutic agents to discover treatments for both wet and dry age-related macular degeneration, ROP, and diabetic retinopathy.

Through innovative teleophthalmological approaches to screen for eye diseases, such as diabetic retinopathy and ROP, Dr. Schwartz is dedicated to improving both the quality of and access to specialized ophthalmology care. Currently, a collaborative program with UCLA’s Gonda Diabetes Center and Venice Family Clinic is underway, in which screening for diabetic retinopathy is conducted with a nonmydriatic camera (a camera that does not require dilation of the eyes) as part of each patient’s regular diabetes treatment. Results are telecommunicated to specialists at the Stein Eye Institute for interpretation and further action.

Public Service

Program Committee Member, Association for Research in Vision and Ophthalmology
Diabetic Eye Disease Screening, Venice Family Clinic
Molecular Mechanism of Vitamin A Transport for Vision; Identification of New Therapeutic Targets for Blinding Diseases

Dr. Sun’s laboratory studies the molecular mechanism of vitamin A transport for vision and new therapeutic targets for blinding diseases. Vitamin A is essential for vision because it is the precursor for the chromophore of photoreceptor proteins and also plays critical roles in eye development. Plasma retinol binding protein (RBP) is the principal carrier of vitamin A in the blood. Dr. Sun’s laboratory identified the long-sought RBP receptor, which functions simultaneously as a membrane receptor and a membrane transporter that mediates cellular uptake of vitamin A. His laboratory is using a variety of techniques to study this membrane transport system.

Dr. Sun’s lab is also identifying new therapeutic targets. Specifically, his lab identified new factors that protect cone photoreceptor cells and is testing these factors in vivo in collaboration with Dr. Xian-Jie Yang’s lab. A second project is studying the newly identified membrane receptors for a factor that has broad therapeutic value in treating diverse cancer types and blinding diseases, such as diabetic retinopathy, ischemia-induced retinopathy, and age-related macular degeneration. In addition to studying the signaling mechanism, Dr. Sun’s lab has developed an innovative screening technique that allows the identification of chemical compounds that specifically target the receptors of this therapeutic factor and mimic its function in vitro and in vivo. These compounds are potential first-in-class medicine to treat major human blinding diseases.
Gabriel H. Travis, MD

Charles Kenneth Feldman Chair in Ophthalmology
Professor of Ophthalmology

Biochemistry of Vertebrate Photoreceptors and Mechanisms of Retinal Degeneration

Dr. Travis’ laboratory uses biochemical and genetic approaches to study the visual cycle and its role in retinal and macular degenerations. Vision in vertebrates is mediated by two types of light-sensitive cells: rods and cones. These cells contain light-detecting molecules called opsin pigments. Detection of a single light particle bleaches the opsin pigment. Restoring light sensitivity to a bleached opsin involves an enzymatic pathway called the visual cycle. Mutations in the genes for many proteins of the visual cycle cause inherited blinding diseases.

One project in Dr. Travis’ laboratory studies the function of a transporter protein in rods and cones called ABCA4. Mutations in the human ABCA4 gene cause recessive Stargardt macular degeneration and cone-rod dystrophy. Dr. Travis’ group generated mice with a null mutation in this gene. Biochemical analysis of the phenotype in these ABCA4 “knock-out” mice led them to the function of ABCA4 in photoreceptors, and the biochemical etiology of Stargardt disease. This understanding suggested a pharmacological strategy to reverse the biochemical defect in patients with Stargardt disease and age-related macular degeneration. A phase II clinical trial is currently underway to test a drug based on this strategy as a treatment for age-related macular degeneration.

Another ongoing project in Dr. Travis’ laboratory characterizes Rpe65, which catalyzes the critical isomerization step in the visual cycle. Previously, Dr. Travis and co-workers identified Rpe65 as the retinoid isomerase.

Still another project in Dr. Travis’ laboratory concerns the mechanism of visual-pigment regeneration in cone photoreceptors. Despite the importance of cones, little is known about how visual pigments are replenished to permit sustained vision under daylight conditions. Recent results from Dr. Travis’ group point to the existence of a new enzymatic pathway for regenerating visual pigments in cones. His group is currently working to purify and clone the enzymes that define this new biochemical pathway.

Public Service
Scientific Advisory Panel Member, The Karl Kirchgessner Foundation Vision Science Program
Grant Reviewer, National Institutes of Health, the Biology and Diseases of the Posterior Eye Study Section
Reviewer, Howard Hughes Medical Institute Investigators
Reviewer for many scientific journals
Irena Tsui, MD

Assistant Professor of Ophthalmology
Member of the Stein Eye Institute

Clinical Vitreoretinal Research

Dr. Tsui’s research focuses on improving clinical outcomes in patients with retinal diseases. Her areas of interest include retinopathy of prematurity, diabetic retinopathy, ultra-wide field imaging, surgical techniques, and studying patient-centered outcomes in veterans.

In addition to providing patient care at the Stein Eye Institute in Westwood, Dr. Tsui also sees patients at the Doheny Eye Center UCLA–Arcadia.
Federico G. Velez, MD

Health Sciences Associate Clinical Professor of Ophthalmology
Member of the Stein Eye Institute

Strabismus and Childhood Eye Disorders

Dr. Velez’s primary research interest is studying the mechanisms of congenital and acquired forms of strabismus. He has participated in the development of guidelines for preoperative assessment and surgical approaches to patients with convergent (esotropia), divergent (exotropia), and vertical forms of strabismus, and has developed new techniques to treat pediatric patients with eyelid abnormalities and cataracts.

Dr. Velez has recently completed studies that apply bioengineering technology to the correction of ocular motility disorders. He has also identified a new ocular motility disorder in patients with the human immunodeficiency virus. He provides patient care at the Stein Eye Institute in Westwood and the Doheny Eye Center UCLA–Orange County.

Public Service
Vice-Chair, Adult Strabismus Committee, American Association of Pediatric Ophthalmology and Strabismus
Editorial Board Advisory Panel Member, Treatment Strategies—Pediatrics, The Cambridge Research Centre
Editorial Board Member, Journal of the American Association of Pediatric Ophthalmology and Strabismus, and Journal of the Colombian Society of Ophthalmology
Member, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, Latin American Council of Strabismus, Latin American Pediatric Ophthalmology Society, Colombian Society of Ophthalmology, and Colombian Society of Pediatric Ophthalmology and Strabismus
Reviewer for many scientific journals
David S. Williams, PhD

Professor of Ophthalmology and Neurobiology
Member of the Stein Eye Institute

Cell Biology of the Retina and Inherited Retinal Disease

Dr. Williams’ laboratory focuses on the cell biology of photoreceptor and retinal pigment epithelium cells. His group is especially interested in proteins that function in transport and compartmentalization within these cells. These proteins include those that underlie Usher syndrome and macular degeneration. Translational areas of his research involve gene therapy experiments aimed at preventing the blindness that ensues from Usher syndrome type 1B and studies on stem cell-derived RPE cells, which may be transplanted into retinas afflicted by macular degeneration.
Xian-Jie Yang, PhD

Ernest G. Herman Chair in Ophthalmology
Professor of Ophthalmology
Member of the Stein Eye Institute

Development and Disease Therapy of the Retina

Dr. Yang’s laboratory studies the molecular and cellular mechanisms underlying retinal development and repair. Blinding diseases such as retinitis pigmentosa, geographic atrophy, and glaucoma involve the permanent loss of photoreceptors or retinal ganglion cells. A potential treatment strategy is to supply diseased retinas with protective agents that can prolong neuronal survival. One area of current research focus in the Yang laboratory is to understand how certain growth factors enhance neuronal viability under retinal degeneration conditions. These investigations use genetic and biochemical approaches to dissect cellular events triggered by growth factor treatments in disease models, thus providing insight into clinical application of neuroprotective therapies for patients afflicted with retinal degenerative diseases. Another major research direction of the Yang laboratory is to enable stem cell-based derivation of human retinal organoids in culture and to induce differentiation of retinal neurons, especially retinal ganglion cells. These studies utilize cutting-edge stem cell technologies and apply known developmental regulatory principles to establish in vitro models of human retinogenesis. Outcomes of the research will provide stem cell-based tools to study human retinal differentiation and diseases, and opportunities to develop new therapeutic treatments.
Jie J. Zheng, PhD

Professor of Ophthalmology
Member of the Molecular Biology Institute
Member of the Jonsson Comprehensive Cancer Center
Member of the Stein Eye Institute

Therapeutic Development in Ophthalmology

Dr. Zheng’s research is at the interface of biochemistry, computational biology, systems pharmacology, and drug discovery with an emphasis on therapeutic development in ophthalmology. Taking advantage of increasing computer capability, Dr. Zheng’s research group finds that the combination of experimental and computational studies gives them a unique strength, and on the basis of this strength, Dr. Zheng’s laboratory has achieved great successes.

The current focus of the laboratory is to develop proteins and small molecules that can modulate signal transduction pathways, such as Wnt, Hedgehog, BMP, and Hippo pathways, in an effort to better understand the biological functions of these signaling pathways and to explore the therapeutic potential of these compounds and proteins. Aiming to establish new translational research within the vision research community at UCLA, the goal of Dr. Zheng’s research is to develop novel therapies for retinal degenerative diseases, glaucoma, and corneal disorders.
Benjamin B. Bert, MD  
Health Sciences  
Assistant Clinical Professor  
Cornea-External Ocular Disease and Refractive Surgery  
Dr. Bert provides comprehensive ophthalmic care and is a subspecialist in cornea/external disease. His areas of expertise include: dry eye/blepharitis, conjunctivitis, uveitis, acute corneal injury, and genetic corneal disorders, as well as cataract surgery with advanced intraocular lenses and refractive surgery.  
Dr. Bert sees patients at the Doheny Eye Center UCLA offices in Orange County and Pasadena.  

Vikas Chopra, MD  
Health Sciences  
Associate Clinical Professor  
Charles Stewart Warren and Hildegard Warren Endowed Research Chair  
Medical Director, Doheny Eye Center UCLA–Pasadena  
Glucoma  
Specializing in glaucoma, Dr. Chopra’s research activities include advanced optic nerve and retinal nerve fiber layer imaging for early glaucoma detection, as well as development and validation of novel parameters for use in anterior segment optical coherence tomography devices as principal investigator at the Doheny Image Reading Center. Dr. Chopra also evaluates laser and surgical techniques for the management of glaucoma.  
Dr. Chopra provides patient care at the Doheny Eye Center UCLA locations in Arcadia and Pasadena.  

Brian A. Francis, MD, MS  
Health Sciences Clinical Professor  
Rupert and Gertrude I. Stieger Vision Research Chair  
Director of Glaucoma Services, Doheny Eye Center UCLA  
Medical Director, Doheny Eye Center UCLA–Orange County  
Glucoma  
Dr. Francis’ clinical specialties are glaucoma and complex cataract. His research activities include: innovative glaucoma surgeries, minimally invasive glaucoma surgery, novel visual field techniques, glaucoma diagnostic and functional imaging, anterior segment imaging (ultrasound biomicroscopy, Fourie domain optical coherence tomography), and glaucoma laser surgery.  
Dr. Francis sees patients at the Doheny Eye Center UCLA locations in Arcadia, Orange County, and Pasadena.
Gad Heilweil, MD  
Health Sciences  
Assistant Clinical Professor  

Degenerative Retinal Disease  
Dr. Heilweil’s research activities include stem-cell therapy for degenerative retinal disease; retinal and uveal drug toxicity; and pharmacokinetics of intravitreal drugs.  

In addition to providing patient care at the Stein Eye Institute in Westwood, Dr. Heilweil also sees patients at the Doheny Eye Center UCLA locations in Arcadia, Orange County, and Pasadena.

Hugo Y. Hsu, MD  
Health Sciences  
Associate Clinical Professor  

Cornea and External Diseases  
Dr. Hsu specializes in corneal infection and inflammation, corneal transplantation, anterior segment reconstruction, and cataract surgery. His research interests include corneal and ocular infections and ophthalmic antibiotics.  

Dr. Hsu sees patients at the Doheny Eye Center UCLA locations in Arcadia, Orange County, and Pasadena.

Alex A. Huang, MD, PhD  
Assistant Professor of Ophthalmology  

Glaucoma  
Dr. Huang’s clinical specialties include glaucoma, minimally invasive glaucoma surgery, trabeculectomy, glaucoma drainage devices, cyclodestruction, and complex cataracts. His research activities involve characterizing post-trabecular meshwork and scleral changes in glaucoma, optical coherence tomography visualization of aqueous humor outflow pathways in the eye, and angiographic visualization of aqueous humor outflow in the eye. His goal is to provide the most individual centric care, and through the use of research, develop means to customize glaucoma management and surgery for each patient.  

Dr. Huang provides patient care at the Doheny Eye Center UCLA–Pasadena.
**Michael S. Ip, MD**
Professor of Ophthalmology

**Vitreoretinal Disease**
Dr. Ip’s research focuses on the design and conduct of clinical trials investigating treatments for diabetic retinopathy, age-related macular degeneration, and retinal venous occlusive disease. He has served as the national director for numerous National Eye Institute funded ophthalmic clinical trials. Additionally, as director of the Doheny Image Reading Center, Dr. Ip assists with the collection, analysis, and dissemination of important secondary outcomes in many important clinical trials in the field of ophthalmology.

Dr. Ip sees patients at the Doheny Eye Center UCLA–Pasadena.

---

**John A. Irvine, MD**
Health Sciences
Clinical Professor

A. Ray Irvine, Jr., MD,
Chair in Clinical Ophthalmology

Medical Director,
Doheny Eye Center UCLA

**Cornea and External Diseases**
Dr. Irvine’s clinical specialties are cornea and external diseases (e.g., tumors, infections), anterior segment surgical consultation, and prosthetic replacement of the ocular surface ecosystem (PROSE). His research activities focus on ocular infections.

Dr. Irvine provides patient care at the Doheny Eye Center UCLA locations in Arcadia, Orange County, and Pasadena.

---

**Ram Kannan, PhD**
Adjunct Professor of Ophthalmology

**Eye Physiology and Pathology**
Dr. Kannan’s research focuses on eye physiology and pathology. He currently investigates age-related macular degeneration, a leading cause of blindness in high-resource countries.

---

The Doheny Eye Center UCLA–Orange County, located at the Orange Coast Memorial Medical Center, provides comprehensive ophthalmology and subspecialty services.
M. Ali Khan, MD
Assistant Professor of Ophthalmology

Vitreoretinal Disease
Dr. Khan specializes in the medical and surgical treatment of vitreoretinal disease, and his research interests include proliferative vitreoretinopathy, diabetic retinopathy, and retinal imaging modalities.

Dr. Khan sees patients at the Doheny Eye Center UCLA locations in Arcadia, Orange County, and Pasadena.

Olivia L. Lee, MD
Health Sciences
Assistant Clinical Professor

Cornea/External Diseases and Uveitis; Corneal Imaging
Focusing on cornea/external diseases and uveitis, Dr. Lee’s particular interest is in inflammatory ocular surface disease, corneal melts, pterygia, and anterior segment complications of uveitis. Dr. Lee performs all types of corneal transplants, as well as complex cataract surgery in uveitic eyes.

Dr. Lee’s research interests are anterior segment imaging applied to the tear film, cornea, and conjunctiva. With her expertise in corneal imaging, a specular microscopy reading center was developed at the Doheny Image Reading Center, where she serves as an investigator.

Dr. Lee provides patient care at the Doheny Eye Center UCLA locations in Arcadia, Orange County, and Pasadena.

Kenneth L. Lu, MD
Health Sciences
Assistant Clinical Professor

Medical Director,
Doheny Eye Center UCLA–Arcadia

Cataract and Refractive Surgery
Dr. Lu specializes in cataract and refractive surgery, and his research activities are focused in the same areas.

Dr. Lu sees patients at the Doheny Eye Center UCLA–Arcadia.
Peter A. Quiros, MD
Health Sciences
Associate Clinical Professor

Neuro-Ophthalmology
Specializing in neuro-ophthalmology, the clinical specialties of Dr. Quiros are: optic nerve disease, including optic neuritis and multiple sclerosis; double vision and adult strabismus; eye pain, headache, and idiopathic intracranial hypertension; Graves disease; orbital inflammatory syndromes; and stroke. Dr. Quiros’ research activities include idiopathic intracranial hypertension, headache, ocular myasthenia gravis, Graves disease, optic neuritis and multiple sclerosis, and visual rehabilitation after stroke. Dr. Quiros was the principal investigator for the recently completed idiopathic intracranial hypertension treatment trial and is currently the principal investigator for the longitudinal idiopathic intracranial hypertension treatment trial. Dr. Quiros is also a member of the Neuro-Ophthalmology Researcher and Disease Investigators Consortium (NORDIC) and is the local NORDIC director.

Dr. Quiros provides patient care at the Doheny Eye Center UCLA locations in Orange County and Pasadena.

Daniel B. Rootman, MD, MS
Assistant Professor of Ophthalmology
Orbit and Ophthalmic Plastic Surgery
Dr. Rootman is an orbit and ophthalmic plastic surgery specialist. His clinical expertise includes Graves disease, orbital surgery, orbital tumors, ptosis, lacrimal disorders, blepharoplasty, blepharospasm, Botox®, cosmetic dermal fillers, endoscopic eyebrow lift, eyelid surgery, eyelid tumors, and trauma. Research activities are on developing and refining patient-centered outcome measures for surgical care; randomized clinical trials in surgery, including ptosis, Graves orbitopathy and lacrimal disease; health economics of eyelid and facial surgery; sociodemographics of facial trauma; physiology and pathobiology of ptosis; new approaches to surgery; and measurement and assessment in medical education.

Dr. Rootman sees patients at the Stein Eye Institute in Westwood, as well as the Doheny Eye Center UCLA locations in Orange County and Pasadena.

SriniVas R. Sadda, MD
Professor of Ophthalmology
Stephen J. Ryan-Arnold and Mabel Beckman Foundation Endowed Presidential Chair
President and Chief Scientific Officer, Doheny Eye Institute

Retinal and Macular Diseases
Dr. Sadda specializes in age-related macular degeneration, hereditary retinal degenerations, diabetic retinopathy, venous occlusive disease, telemedicine screening and consultation programs, as well as retinal disease diagnosis and classification. His research activities include: quantitative, automated retinal image analysis; retinal substructure assessments; advanced retinal imaging technologies; genotype-phenotype correlative studies; and vision restoration technologies, such as stem cells and prosthetic vision.

Dr. Sadda provides patient care at the Doheny Eye Center UCLA locations in Arcadia and Pasadena.
Alfredo A. Sadun, MD, PhD  
Professor of Ophthalmology  
Flora L. Thornton Endowed Chair in Vision Research  
Vice Chairman of Ophthalmology, Doheny Eye Center UCLA  

**Neuro-Ophthalmology**  
Clinical specialties of Dr. Sadun include neuro-ophthalmology, optic nerve, optic neuropathies (eg, posterior ischemic optic neuropathy, anterior ischemic optic neuropathy, and traumatic optic neuropathy), Leber hereditary optic neuropathy, toxic and nutritional optic neuropathies, vision in Alzheimer’s, AIDS, and other central nervous system disorders. Dr. Sadun’s research activities focus on human visual neuroanatomy; retinal ganglion cell degeneration and regeneration; axon populations in the human optic nerve in development, aging, and disease; and mitochondrial impairments as a cause of optic neuropathy and other forms of neurodegeneration.  

Dr. Sadun sees patients at the Doheny Eye Center UCLA–Pasadena.

Deming Sun, MD  
Professor of Ophthalmology  
Mary D. Allen Chair in Vision Research  
Research Scientist  
Dr. Sun is a researcher whose primary areas of investigation include uveitis, autoimmune diseases, optic neuritis, animal disease models, and T-cell biology.

James C. Tan, MD, PhD  
Associate Professor of Ophthalmology  

**Glaucoma**  
Dr. Tan is a dual fellowship-trained glaucoma specialist. He treats the full spectrum of cataract and glaucoma conditions, ranging from mild to complex. His treatments and surgeries focus on safe and effective outcomes using advanced techniques. Dr. Tan has authored over 100 scientific papers, abstracts, book chapters, and books. His glaucoma research addresses advanced imaging, molecular pathogenesis, drug development, and surgical techniques. He has received awards from the National Institutes of Health, Research to Prevent Blindness, and the American Glaucoma Society.  

Dr. Tan provides patient care at the Doheny Eye Center UCLA locations in Arcadia and Pasadena.
James W. Bisley, PhD
Associate Professor of Neurobiology and Psychology
Member of the Stein Eye Institute
Member of the Brain Research Institute

Cognitive Processing of Visual Information
Dr. Bisley’s research revolves around understanding the neural mechanisms underlying the cognitive processing of visual information. These cognitive processes include visual perception, visual memory, and visual attention. His recent work has focused on how the responses of neurons in the posterior parietal cortex are involved in the allocation of visual attention to neurons in visual cortices and how they guide eye movements in goal-directed visual search.

Patrick T. Dowling, MD, MPH
Chair, UCLA Department of Family Medicine
The Kaiser Endowed Professor of Community Medicine
Member of the Stein Eye Institute

Health Care Policy and Access for Underserved Populations
Dr. Dowling has received grant funding for more than 30 years to link medical education to underserved neighborhoods thereby providing access to care. Further, he has worked with Dr. Anne Coleman and the Care Harbor program to provide free medical, dental, and eye care to low-income families and the medically indigent of Los Angeles.

Antoni Ribas, MD
Professor of Medicine, Surgery, and Molecular and Medical Pharmacology
Member of the Stein Eye Institute

Dr. Ribas is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, anti-PD-1 antibodies, and BRAF and MEK inhibitors.

Dario L. Ringach, PhD
Professor of Neurobiology and Psychology, Biomedical Engineering Program
Member of the Stein Eye Institute

Visual Perception and Neurophysiology
Dr. Ringach’s research focuses on the relationship between eye movements and visual perception, as well as how motor planning and execution, such as reaching, grasping, navigating, and adjusting body posture, is influenced by visual information and impaired vision. In collaboration with a team of neurosurgeons at UCLA, Dr. Ringach’s laboratory is also recording the brain activity of patients with epilepsy who are undergoing clinical evaluation for surgical treatment, shedding new light into the processes involved in object recognition and perception.
Christian Altenbach, PhD  
Research Ophthalmologist

Structure and Function of Rhodopsin  
The membrane protein rhodopsin is a critical first step in visual transduction, converting light energy into a chemical form in the photoreceptor cell of the eye. To understand this process on a detailed molecular level, Dr. Altenbach is using site-directed spin labeling and electron paramagnetic resonance spectroscopy to study the structure of rhodopsin in the absence of light, as well as the changes in structure caused by light.

Navid Amini, PhD  
Assistant Research Ophthalmologist

Biomedical Imaging and Mobile Health  
Dr. Amini develops signal processing and machine learning techniques in ophthalmic research, and he utilizes these techniques in quantitative assessment of major ocular diseases, including glaucoma. He also investigates the behavior of nonvisual sensory systems and the effects of low vision on activities of daily living.

Michael Bridges, PhD  
Assistant Project Scientist

Paramagnetic Resonance Methodologies  
Dr. Bridges’ research in the laboratory of Dr. Wayne Hubbell is centered on the development and application of new pulsed electron paramagnetic resonance methodologies. Protein conformational dynamics and structural relaxation are his central focus with the goal of characterizing the timescales and motional amplitudes of functional activation.

Barry L. Burgess, BS  
Research Specialist

Degenerative Retinal Disease Research  
Mr. Burgess provides research support for the Photoreceptor/RPE Cell Biology Laboratory of Dr. David Williams. Research interests include production of differentiated RPE cells from human stem cell precursors and developing in vitro models of oxidative stress involved in degenerative retinal disease progression.

Rajendra Gangalum, PhD  
Assistant Research Specialist

Function and Regulation of Small Heat Shock Protein αB-crystallin in Health and Disease  
Dr. Gangalum’s research seeks to gain understanding of the physiological function of αB-crystallin in the developing ocular lens and non-ocular tissues. αB-crystallin has been shown to associate with pathologies such as cataracts, cancer, age-related macular degeneration, and various neurodegenerative diseases.

Jeremy D. Cook, PhD  
Assistant Project Scientist

Regulation of the Visual Cycle  
Dr. Jeremy Cook is studying the role of peropsin, the non-visual opsin, in retinal pigment epithelial cells. This protein appears to regulate the metabolism of visual retinoids in a light-dependent fashion.

Rikard Frederiksen, PhD  
Assistant Research Ophthalmologist

Adaptation  
Dr. Frederiksen’s main research interest is adaptation, specifically how the rods and cones in the retina adapt to different light intensities.

Sheyla Gonzalez, PhD  
Assistant Project Scientist

Limbal Stem Cells  
Dr. Gonzalez’s research aims to improve the ex vivo expansion of limbal epithelial stem cells (LSCs) by modulating Notch signaling in individuals suffering from limbal stem cell deficiency (LSCD). The identification of niche factors could help to improve the in vitro production of LSCs for transplantation.

Sonia Guha, PhD  
Assistant Project Scientist

Unraveling New Therapeutic Targets for Ocular Albinism  
Dr. Guha studies genes that may be associated with the misrouting of retinal ganglion cell (RGC) axons at the brain’s optic chiasm in individuals affected with X-linked ocular albinism type 1 (OA1). This disease is also characterized by hypopigmentation and presence of macromelanosomes in the RPE. How the reduced pigmentation of OA1 RPE exerts its effects on the RGCs to influence the misrouting of their axons at the optic chiasm remains unsolved, and Dr. Guha’s findings have the potential to unravel new therapeutic targets for OA1.
Joanna J. Kaylor, PhD
Assistant Project Scientist

Visual Chromophore Regeneration in the Retina of the Eye

Dr. Kaylor has discovered that light plays a vital role in regeneration of visual chromophore in the retina. She recently identified a non-enzymatic process that generates visual pigment in photoreceptor membranes in light. Her research now focuses on the function of retinal G-protein coupled receptor (RGR).

Jacky M. K. Kwong, PhD
Research Ophthalmologist

Degeneration of Retinal Ganglion Cells and Neuroprotection

Dr. Kwong identifies novel neuroprotective and regenerative therapies for glaucoma that preserve and restore the nerve cells. He utilizes animal models related to optic nerve injury and glaucoma to understand the progression of retinal ganglion cell degeneration, and pharmacologic techniques and functional assessments to evaluate therapies.

Qihua Le, MD, PhD
Visiting Assistant Project Scientist

Diagnostic Potential of Ocular Imaging in the Diagnosis of Limbal Stem Cell Deficiency

Dr. Le’s research aims to study the diagnostic potential of a newly developed ocular imaging technique, in vivo confocal microscopy, and anterior segment optical coherence tomography, in the diagnosis of limbal stem cell deficiency.

Anna Matynia, PhD
Associate Research Ophthalmologist

Optimal Processing of Sensory Signals in the Retina

Dr. Matynia’s research investigates the mechanisms underlying photicallodynia, a condition in which normal levels of light produce or enhance ocular or headache pain. Using behavioral, molecular, genetic, and cellular approaches, the laboratory focuses on corneal, retinal, and central mechanisms from dry eye injury, achromatopsia, and migraine, respectively.

Johan Pahlberg, PhD
Assistant Project Scientist

Optimal Processing of Sensory Signals in the Retina

Dr. Pahlberg is interested in how noise in the mammalian retina is mitigated to allow for highly sensitive night vision. The research is focused on how rod photoreceives are processed and parsed into the retinal circuitry, the correlations between retinal physiology and behavior for low light level vision, and thus, how sensory systems increase their signal-to-noise ratio and the information encoded in the neural pathway.

Alejandra Young, PhD
Assistant Project Scientist

Ocular Albinism

Dr. Young’s research is focused on the study of the molecular mechanisms that cause ocular albinism type 1 (OA1), a disease caused by mutations in the OA1 gene and characterized by hypopigmentation of the retinal pigment epithelium and abnormal crossing of the optic axons at the optic chiasm. In addition, she investigates the potential therapeutic use of engineered human embryonic stem cell-derived extracellular vesicles for the treatment of ocular albinism.

Alberto C. Ruiz-Morales
Research Specialist

Visual Cycle

Mr. Ruiz, a molecular biologist, is directly involved in the cloning and characterization of enzymes critical for the proper functioning of the visual cycle. Currently, Mr. Ruiz is analyzing genes, such as ARMS2 and HTRA1, which are thought to be involved in age-related macular degeneration.
Laura Bonelli, MD  
Associate Physician Diplomate  

Neuro-Ophthalmology  
Dr. Bonelli provides clinical supervision to resident physicians at the University Ophthalmology Associates and teaches medical students during their ophthalmology surgical subspecialties clinical rotation. She is collaborating on a study to learn and better understand giant cell arteritis (GCA), an inflammation of the lining of the arteries. GCA frequently causes blurred or double vision, and if left untreated, may result in loss of vision. She is also a co-investigator for the National Eye Institute-sponsored study of idiopathic intracranial hypertension.

Eli L. Chang, MD  
Associate Physician Diplomate  

Reconstructive Surgery  
Dr. Chang is a specialist in ophthalmic plastic, orbital, and reconstructive surgery. He specializes in treatment of diseases of the eyelids, tear drainage system, and orbit. His expertise includes eyelid cancers, thyroid eye disease, fractures, and trauma of the area surrounding the eye, tearing, and cosmetic surgery of the eyelids.

Melissa W. Chun, OD  
Associate Clinical Professor of Ophthalmology  

Director of the UCLA Vision Rehabilitation Center  

Vision Rehabilitation  
Dr. Chun’s clinical research interests are in vision rehabilitation outcomes and training techniques that maximize visual function. She is a member of the Low Vision Research Network, a nationwide collaboration of low vision specialists for multicenter clinical studies. She is also involved in visual outcome measures for various clinical studies on macular degeneration.

Rachel Feit-Leichman, MD  
Associate Physician Diplomate  

Cataract Surgery  
Dr. Feit-Leichman divides her time between supervising residents and providing patient care at the Stein Eye Institute’s Urgent Care Clinic, and teaching cataract surgery and overseeing residents at the ophthalmology clinic of the Harbor-UCLA Medical Center. Dr. Feit-Leichman is also active in striving to improve patient access to eye care in the greater Los Angeles County Healthcare System.

Batool Jafri, MD  
Associate Physician Diplomate  

Cornea/External Disease/Refractive Surgery  
Dr. Jafri provides patient care as well as supervision to resident physicians and cornea fellows. Her focus is medical and surgical treatment of diseases of the cornea, external disease, and refractive conditions like near and far sightedness. She also provides general ophthalmic care and offers cataract surgery with premium intraocular lens implants.
Monica R. Khitri, MD
Associate Physician Diplomat

Pediatric Ophthalmic Diseases and Strabismus
Dr. Khitri specializes in the evaluation and treatment of pediatric ophthalmic diseases, including pediatric cataracts, nasolacrimal duct obstructions, amblyopia, and retinopathy of prematurity. She also treats and operates on strabismus in both children and adults. Dr. Khitri sees patients at the Doheny Eye Center UCLA locations in Arcadia and Pasadena. She also teaches residents and fellows at Harbor-UCLA Medical Center, where she is chief of the pediatric ophthalmology service.

Phillip Le, MD, PhD
Associate Physician Diplomat

Retinal and Macular Diseases
Dr. Le is a comprehensive ophthalmologist who specializes in retinal and macular diseases. He sees patients at the Doheny Eye Center UCLA–Pasadena.

Mitra Nejad, MD
Associate Physician Diplomat
Clinical Instructor of Ophthalmology

Comprehensive Ophthalmology
Dr. Nejad practices comprehensive ophthalmology at the Stein Eye Institute and the Stein Eye Center–Santa Monica. Her practice involves general ophthalmic care, as well as cataract and refractive surgery. In addition, Dr. Nejad teaches UCLA medical students and residents at the Stein Eye Institute, as well as supervising resident cataract surgery at Harbor-UCLA Medical Center.

Tania Onclinx, MD
Associate Physician Diplomat
Clinical Instructor of Ophthalmology

Urgent Care and Clinical Supervision
Dr. Onclinx attends at the Urgent Care Walk-In service at the Stein Eye Institute. She teaches resident physicians and medical students at the University Ophthalmology Associates during their subspecialty clinical rotation. She also provides clinical supervision to resident physicians at Ronald Reagan UCLA Medical Center and UCLA Medical Center, Santa Monica.

Susan S. Ransome, MD
Associate Physician Diplomat
Clinical Instructor of Ophthalmology

HIV and Diabetic Retinopathy
Dr. Ransome is participating in a clinical research study involving HIV-infected patients who have diabetes to see whether there is increased risk of development or progression of diabetic retinopathy when subjects are treated for abdominal lipodystrophy with Egrifta (tesamorelin).

Meryl L. Shapiro-Tuchin, MD
Associate Physician Diplomat
Assistant Clinical Professor of Ophthalmology
Co-Director of the Ophthalmology Inpatient Consultation Service

Comprehensive Ophthalmology
Dr. Shapiro-Tuchin provides clinical supervision to resident physicians. She functions as Co-Director of the Ophthalmology Inpatient Consultation Service, assisting resident physicians in their evaluation of inpatients admitted to the Ronald Reagan UCLA Medical Center and the UCLA Medical Center, Santa Monica.

Ronald J. Smith, MD
Associate Physician Diplomat

Objective Assessment of Surgical Technique and Training
Dr. Smith’s research interest is the objective assessment of surgical technique and development of evidence-based surgical training for residents to improve patient care. In addition to teaching residents at the Veterans Affairs Greater Los Angeles Healthcare System and in the UCLA Microsurgery Laboratory, Dr. Smith provides cornea and comprehensive eye care to patients at the Stein Eye Center–Santa Monica.

Laura A. Syniuta, MD
Associate Physician Diplomat

Pediatric Ophthalmology and Strabismus
Dr. Syniuta completed her fellowship training in pediatric ophthalmology and strabismus at the Stein Eye Institute in 1999. With children’s eye and learning disorders being her passion, she sees patients at UCLA’s Stein Eye Center in Santa Monica and has staffed UCLA’s Mobile Eye Clinic since 2011.

Victoria Yom, MD
Associate Physician Diplomat

LECTURER

Kathleen L. Boldy, VMD
Lecturer in Ophthalmology
Dean Bok, PhD
Dolly Green Chair of Ophthalmology
Professor of Ophthalmology Emeritus (Active Recall)
Distinguished Research Professor of Neurobiology
Member of the Brain Research Institute
Member of the Stein Eye Institute

Gordon L. Fain, PhD
Distinguished Professor of the Departments of Integrative Biology/Physiology and of Ophthalmology (Active Recall)
Member of the Stein Eye Institute

Michael O. Hall, PhD
Professor of Ophthalmology Emeritus
Founding Member of the Stein Eye Institute

Robert S. Hepler, MD
Professor of Ophthalmology Emeritus (Active Recall)
Founding Chief of the Neuro-Ophthalmology Division
Member of the Stein Eye Institute

Joseph Horwitz, PhD
Distinguished Professor of Ophthalmology (Active Recall)
Member of the Stein Eye Institute

Allan E. Kreiger, MD
Professor of Ophthalmology Emeritus (Active Recall)
Founding Chief of the Retina Division

Bradley R. Straatsma, MD, JD
Professor of Ophthalmology Emeritus
Founding Chairman of the Department of Ophthalmology
Founding Director of the Stein Eye Institute

Barry A. Weissman, OD, PhD
Professor of Ophthalmology Emeritus

Marc O. Yoshizumi, MD
Professor of Ophthalmology Emeritus
Member of the Stein Eye Institute
The Institute’s program of care for patients encompasses the full range of eye diseases. Nationally and internationally renowned faculty, along with highly skilled clinical fellows and physician residents, provide integrated consultation and treatment, including new diagnostic and therapeutic procedures that have been made available through recent scientific advances. Skilled optometrists, orthoptists, technicians, and nurses support institute ophthalmologists in their efforts. Care is delivered in distinctive subspecialty treatment centers, service areas, and clinical laboratories, as well as in specially equipped ophthalmic surgical suites. In addition, the Stein Eye Center–Santa Monica and the Doheny Eye Center UCLA offer premier eye care services in convenient neighborhood locations.

Find detailed information about our locations, including providers and services offered, by going to: www.uclahealth.org/eye/our-locations.

Faculty Consultation Service

Institute faculty members provide direct consultation and treatment, including emerging therapies, to patients through the Ophthalmology Faculty Consultation Service. Faculty members have extensive, advanced training in ophthalmic subspecialties, providing referring physicians and patients with a valuable resource for special eye problems.

Inpatient Consultation Service

The Ophthalmology Inpatient Consultation Service, operating 24 hours a day through the Ronald Reagan UCLA Medical Center and UCLA Medical Center Santa Monica, provides ophthalmic consultation and treatment to pediatric and adult patients who are admitted to the hospital for inpatient care.

Led by Drs. Laura Bonelli and Meryl L. Shapiro-Tuchin, the consultation team consists of physician-residents at the UCLA Stein Eye Institute, with subspecialty coverage provided as needed by UCLA Department of Ophthalmology faculty.
Surgical Services

Ophthalmic surgery of every kind, from cataract extraction to removal of ocular and orbital tumors, is performed in the Institute’s dedicated operating rooms. Additionally, laser vision-correction surgeries, such as laser-assisted in situ keratomileusis (LASIK) and certain aesthetic and retinal laser surgeries and injection procedures, are performed in designated outpatient procedure rooms. Faculty members perform surgical procedures according to their specific ophthalmic specialty. They are joined by other medical specialists, including anesthesiologists, nurses, and technicians to ensure the highest quality preoperative and postoperative care.

The award-winning Edie & Lew Wasserman Building houses the Institute’s expanded surgery center, which enables the Stein Eye Institute to provide a greater number of surgical services to patients in need.

Six operating suites, a sterile processing area, procedure treatment units, and postoperative areas serve all ophthalmic specialties, including retina, glaucoma, cataract, strabismus, cornea, and oculoplastics. In addition, there are three procedure rooms for physicians to perform minor laser treatments and ophthalmologic surgical procedures.

Comprehensive Ophthalmology

Comprehensive and subspecialty eye care in all medical and surgical areas of ophthalmology is offered at the Stein Eye Institute through the service formally known as University Ophthalmology Associates. Dr. John D. Bartlett is medical director, and ophthalmologists who are members of the UCLA Medical Group staff the practice.

Stein Eye Institute, Westwood
100 Stein Plaza, UCLA
Los Angeles, CA 90095
Referral Service: (310) 825-5000
Emergency Service: (310) 825-3090
After-Hours Emergency Service: (310) 825-2111

Stein Eye Center–Santa Monica

The Stein Eye Center–Santa Monica, under the direction of Dr. Colin A. McCannel, offers the world-renowned comprehensive and subspecialty eye care of the Stein Eye Institute at a convenient location in Santa Monica. Established in 2011, the Stein Eye Center–Santa Monica features well-equipped exam rooms, an optical shop, on-site parking for easy access, and testing facilities offering a wide range of examinations, including visual field, corneal mapping (corneal topography), intraocular lens measurement, fluorescein angiography, spectral domain optical coherence tomography, and other diagnostic retinal imaging techniques. Nearly all the evaluation, diagnosis, testing, and treatment services available at the Stein Eye Institute in Westwood are offered at the Stein Eye Center–Santa Monica by experts in retinal disorders, corneal disorders, glaucoma, neuro-ophthalmology, and laser refractive surgery. For surgeries and seldom-needed tests requiring specialized laboratories, patients can be referred to the Institute’s main facility in Westwood.

Stein Eye Center–Santa Monica
1807 Wilshire Boulevard, Suite 203
Santa Monica, CA 90403
Telephone: (310) 829-0160
Fax: (310) 829-0170

UCLA Department of Ophthalmology
Summary of Patient Care Statistics

<table>
<thead>
<tr>
<th>Service</th>
<th>2016–2017</th>
<th>2017–2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Faculty Consultation Service</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient visits</td>
<td>142,535</td>
<td>149,771</td>
</tr>
<tr>
<td>Comprehensive Ophthalmology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient visits</td>
<td>22,380</td>
<td>24,223</td>
</tr>
<tr>
<td>Inpatient Consultation Service</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient evaluations</td>
<td>1,098</td>
<td>985</td>
</tr>
<tr>
<td>Clinical Laboratories</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procedures</td>
<td>75,139</td>
<td>83,122</td>
</tr>
<tr>
<td>Surgery Services</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of procedures (^1)</td>
<td>33,617</td>
<td>34,446</td>
</tr>
<tr>
<td>Intravitreal Injections</td>
<td>12,164</td>
<td>12,476</td>
</tr>
<tr>
<td>Mobile Eye Clinic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of patients seen</td>
<td>26,184</td>
<td>17,646</td>
</tr>
<tr>
<td>Ocular abnormalities</td>
<td>17%</td>
<td>31%</td>
</tr>
<tr>
<td>Number of trips</td>
<td>1,212</td>
<td>789</td>
</tr>
</tbody>
</table>

\(^1\)Includes lasers
The UCLA Department of Ophthalmology and the Doheny Eye Institute formed a historic affiliation in 2014, and patient access to eye care was immediately broadened across Los Angeles and into Orange County, with the opening of three Doheny Eye Center UCLA locations: Arcadia, Orange County, and Pasadena. The Doheny and Stein Eye Institutes share a long tradition of excellence, and through this partnership, the respective strengths that gained each Institute an international reputation have been combined. The board-certified Doheny ophthalmologists that patients and referring physicians know and trust are now members of the UCLA Department of Ophthalmology. The Doheny Eye Center UCLA is under the supervision of Vice Chairman Dr. Alfredo A. Sadun and Medical Director Dr. John A. Irvine. Dr. SriniVas R. Sadda is the president and chief scientific officer of the Doheny Eye Institute.

Doheny Eye Center UCLA–Arcadia

As Medical Director of the Doheny Eye Center UCLA–Arcadia, Dr. Kenneth L. Lu oversees a renovated office that includes 12 exam rooms, dedicated diagnostic equipment, and attractive patient areas. The Center provides comprehensive ophthalmology, and nearly all subspecialty services, including glaucoma, retina, and cornea.

The Doheny Eye Center UCLA–Arcadia, which opened April 1, 2014, serves patients in the broader Arcadia region and San Gabriel area, expanding the UCLA Department of Ophthalmology’s reach in Los Angeles County. The Arcadia Center is easily accessible from two freeways and provides on-site, free parking.

Doheny Eye Center UCLA–Arcadia
622 W. Duarte Road, Suite 101
Arcadia, CA 91007
Telephone: (626) 254-9010
Fax: (626) 254-9019
The Research and Treatment Centers provide subspecialty care from faculty physicians who are actively involved in related research, enabling emerging and experimental treatment options to be developed for a gamut of eye disorders. In addition to comprehensive treatment, the centers provide both patients and physicians with expert diagnostic and consultation services for diseases that are difficult to identify and treat. Ophthalmology faculty work closely with other specialists, both within the Stein Eye Institute and in other UCLA clinical departments, to create a multidisciplinary team customized for each patient’s unique medical needs.

Learn more about our research and academic Centers at: www.uclahealth.org/eye/academic-centers.

Aesthetic Center

The Aesthetic Center, under the direction of Dr. Robert Alan Goldberg, provides services to patients who are interested in enhancing their appearance through aesthetic surgery. Dr. Daniel B. Rootman also sees patients. Established in 1998, the Center has earned a reputation for high quality, individualized care delivered by surgeons trained in both ophthalmic and plastic surgery.

Surgical services include upper and lower eyelid blepharoplasty, endoscopic forehead lifting, endoscopic midface surgery, lifting of the neck and face, liposuction, fat transfer, and skin treatment, as well as dermal filler and other cosmetic injections to smooth facial lines. Minimally invasive approaches are utilized to provide the optimal aesthetic result. A major goal of the Center is to conduct research focused on improving understanding of facial aging, surgical healing, and on developing new techniques for aesthetic surgery. Center physicians have pioneered minimal incision surgical techniques to enhance the normal function and appearance of the eyes and face, and often receive referrals for complex and re-operative plastic surgery cases.

Center for Community Outreach and Policy

The Stein Eye Institute’s Center for Community Outreach and Policy, under the direction of Dr. Anne L. Coleman, is dedicated to the principle that all individuals deserve the best vision attainable. Building upon the Institute’s long tradition of community service and leadership at the interface of ophthalmology and public health, the Center conducts vital research in public-health ophthalmology through the UCLA Center for Eye Epidemiology and provides high-impact community-based services, such as the UCLA Mobile Eye Clinic.

UCLA Center for Eye Epidemiology

The UCLA Center for Eye Epidemiology was established in 1997 to promote interdisciplinary investigations into blinding diseases of public health importance. It is supported by private donations, including an endowment established by The Ahmanson Foundation. The Center maintains and improves vision health through public health research and intervention, and serves as a coordinating body for expanding and sharing information.

Center members have expertise in epidemiology, biostatistics, health policy, public health, and international health. Members draw on their diverse backgrounds and complementary skills to promote an understanding of issues related to vision health as it affects individuals, communities, and society. The Center encourages collaborative research among faculty and investigators from various UCLA departments and other institutions around the world to advance knowledge related to the causes and prevention of specific eye diseases.

UCLA Mobile Eye Clinic

For more than 40 years, the UCLA Mobile Eye Clinic has supported patient care and screening programs in neighborhoods where poverty and vision disabilities intersect. The dedication and hard work of UCLA Mobile Eye Clinic ophthalmologists, technicians, and volunteers have touched the lives of hundreds of thousands of individuals.

The UCLA Mobile Eye Clinic, a 39-foot-long bus specially outfitted with eye examination equipment, is supported by charitable contributions to the Stein Eye Institute. The UCLA Mobile Eye Clinic’s staff of trained ophthalmic personnel provides general eye care to over 25,000 underserved adults and children annually throughout Southern California. Services include vision screening, ophthalmic examination and refraction, diagnosis of potential or existing eye disorders, treatment of some ocular diseases, and appropriate referral of patients who need additional care.

Center to Prevent Childhood Blindness

The Center to Prevent Childhood Blindness, under the direction of Dr. Sherwin J. Isenberg, is committed to reducing pediatric blindness. UCLA physicians and basic scientists, including Drs. Gary N. Holland, Steven Nusinowitz, and Irwin Weiss, collaborate on research, education, and patient care programs designed to increase awareness and help treat pediatric blindness. Significant emphasis is on the development and evaluation of ophthalmic medical and surgical options for children.
Center members are developing a new noninvasive method of measuring blood gases from the surface of the eye, which may be critical in preventing retinopathy of prematurity, a leading cause of blindness in premature newborns. In another avenue of research, the Center developed an extremely inexpensive antiseptic solution to treat pediatric corneal infections in developing areas of the world and completed a study showing its effectiveness in treating corneal ulcers that now blind more than 400,000 children worldwide. A second study, which evaluated the solution’s effectiveness in treating fungal corneal infections, a major cause of pediatric blindness in tropical countries, has shown promise in treating the milder fungal infections.

**Center for Regenerative Medicine in Ophthalmology**

Representing a milestone in the therapeutic use of stem cells, in 2011, Stein Eye Institute clinician-scientists successfully transplanted the first human embryonic stem-cell-derived retinal pigment epithelial cells into the eyes of legally blind patients with Stargardt disease and dry macular degeneration.

The Center for Regenerative Medicine in Ophthalmology (CRMO), under the co-direction of Drs. Sophie X. Deng and Gabriel H. Travis, is building upon these efforts, using stem cells for the treatment of corneal disorders and retinal degenerative diseases. The CRMO fosters collaboration between basic scientists and clinicians, including Drs. Debora Farber, Jean-Pierre Hubschman, Steven D. Schwartz, and Xian-Jie Yang, to translate advances in basic science research into new and improved clinical therapies.

Many of the blinding eye diseases, including glaucoma, macular degeneration, and corneal diseases, are due to the loss of functional tissue. The development of effective and safe individualized stem-cell-based therapies relies on robust basic science, as well as translational and clinical research. The CRMO supports current stem cell studies and pursues new research programs to diagnose, treat, and ultimately cure and prevent blinding eye diseases.

**Clinical Research Center**

The UCLA Department of Ophthalmology Clinical Research Center (CRC) was established in 1998 to provide core support to faculty members who are conducting patient-based research studies. This support involves vital, behind-the-scenes activities that facilitate the clinical research process. Dr. Gary N. Holland serves as Director of the CRC working with full-time administrator, Ms. Ellen Pascual, and a Board of Directors composed of Department of Ophthalmology faculty members. The CRC has an in-house statistician, Fei Yu, PhD. CRC staff members interact with granting agencies and government regulatory bodies, assist with the preparation of grant applications, participate in the design and management of clinical studies, and perform data collection and analytic functions for investigators at both the UCLA Stein Eye Institute and the Doheny Eye Institute.

Institute faculty members are currently conducting over 80 clinical research studies (listed in the Appendices). Patients can volunteer to participate in studies that contribute to a better understanding of ocular disorders or that evaluate new, potentially better treatments for various diseases of the eye.

**Diabetic Eye Disease and Retinal Vascular Center**

Under the direction of Dr. Steven D. Schwartz, the Diabetic Eye Disease and Retinal Vascular Center provides diabetic patients with comprehensive ophthalmic care. Established more than a decade ago, the Center has contributed significantly to the understanding, treatment, and prevention of diabetic eye disease. Current focus is on innovation in technologies and techniques that expand the standard of treatment, such as drugs and pharmacotherapeutic strategies, new lasers and laser strategies, refinement of microsurgical techniques specific to diabetic eye diseases, and nontraditional treatment approaches.

The Center’s treatment philosophy is based upon the systemic nature of diabetes. Patient care is coordinated with other UCLA departments to address the special needs of diabetics that lie outside the field of ophthalmology. Center treatment interventions include pharmacotherapy, laser and ophthalmic surgery. Recognizing the special care needed for diabetics in any surgical situation, Center physicians perform all eye surgeries for diabetics, including those specific to the disease, as well as vitrectomy, cataract surgery, and retinal reattachment.
Eye Trauma and Emergency Center

The Eye Trauma and Emergency Center, under the direction of Dr. Robert Alan Goldberg, provides immediate response to ophthalmic emergencies through an eye trauma team available 24 hours a day for consultative, medical, and surgical care involving both primary and secondary ocular repairs. Ophthalmic emergency care has been provided by the UCLA Department of Ophthalmology since its inception. In 1980, the Eye Trauma and Emergency Center was formally established to encompass all levels of ocular trauma within the UCLA hospital system, including support to affiliated institutions.

Patients are commonly referred to the Center for such ocular traumas as ruptured globe, intraocular foreign bodies, acute orbital hypertension, retinal detachment, chemical burns of the cornea and conjunctiva, and acute vitreous hemorrhage. The Center offers complete evaluation and treatment of the traumatically injured eye, including vitreoretinal and/or orbital and ophthalmic plastic surgery, anterior segment surgery, and medical follow up. Expertise is provided for both urgent primary repair and scheduled secondary repair.

Gerald Oppenheimer Family Foundation Center for the Prevention of Eye Disease

Established with a generous pledge from Gail and Gerald H. Oppenheimer, the Gerald Oppenheimer Family Foundation Center for the Prevention of Eye Disease is committed to the discovery of agents and methods to prevent ophthalmic diseases. Areas of study supported by the Foundation include genetic and environmental factors that may cause eye disease, and pharmacologic and natural agents to prevent eye disease. The Center complements an expanding array of research in many other fields at UCLA, where rigorous scientific methods are being applied to study novel approaches to health care.

Glaucma Center for Excellence in Care and Research

In the United States, glaucoma is the second cause of irreversible legal blindness. If glaucoma is detected early, however, vision loss can be slowed or even prevented. Under the direction of Dr. Joseph Caprioli, the Glaucoma Center for Excellence in Care and Research is committed to giving each patient a chance for a brighter future and a life filled with sight.

Stein Eye Institute researchers, Drs. Anne L. Coleman, JoAnn A. Giaconi, Jacky M. K. Kwong, Simon K. Law, Kouros Nouri-Mahdavi, and Natik Piri, are working with researchers and statisticians from the UCLA School of Public Health to identify individuals at greatest risk for vision loss, to develop and assess therapeutic strategies, and to implement new treatments to preserve vision.

Macular Disease Center

The Macular Disease Center, under the direction of Dr. Steven D. Schwartz, was created in 1994 in response to the growing national incidence of macular degeneration. The Center’s mission is threefold: provide high-quality patient care, utilizing standard and developing treatments; offer associated rehabilitation services, such as low-vision aids and counseling, in order to enhance quality of life for patients; and promote collaborative translational research between clinicians and basic science researchers into the cause of macular disease.

Patients with the atrophic or dry form of macular disease are evaluated and often considered for clinical trials, such as the stem cell programs, and their cases are followed at the Macular Disease Center in conjunction with services offered by the Vision Rehabilitation Center. Patients with the exudative or wet form of macular disease are diagnosed and treated with cutting-edge therapies. Treatment options for wet macular disease include therapy and participation in clinical studies that are matched to the patient’s disease status. A patient coordinator is available to answer questions and provide information on an ongoing basis.

Ocular Inflammatory Disease Center

The Ocular Inflammatory Disease Center, under the direction of Dr. Gary N. Holland, was established in 1985 to coordinate research, educational activities, and patient-care services related to a broad spectrum of inflammatory eye disorders, including uveitis, infectious corneal ulcers, endophthalmitis, autoimmune diseases of the cornea and ocular surface, and the ophthalmic manifestations of HIV disease. The Center has a long history of participating in clinical studies and drug-therapy trials that have furthered the understanding and treatment of these diseases.

Center faculty members were the first to describe cytomegalovirus retinitis as an ophthalmic manifestation of AIDS; today the Center is a nationally recognized site of expertise for AIDS-related ophthalmic disease. Other special clinical and research programs have been developed in the following areas: ocular toxoplasmosis, uveitis in children, birdshot chorioretinopathy, immunogenetics of inflammatory eye diseases, unusual corneal infections, and mediators of intraocular inflammation.
Ophthalmic Oncology Center

The Ophthalmic Oncology Center, under the direction of Dr. Tara A. McCannel, is renowned for its expertise in teaching, research, and clinical management of adult posterior segment tumors. Established in the early 1980s by the Institute’s Founding Director, Dr. Bradley R. Straatsma, the Center is internationally recognized for the diagnosis and management of ocular melanoma. The Center serves as a hub for national, long-term studies investigating ocular melanoma, and played an important role in the Collaborative Ocular Melanoma Study sponsored by the National Eye Institute.

The Center’s clinical goal is successful treatment of the primary eye tumor. Patients diagnosed with ocular melanoma may be offered highly sophisticated treatment plans coordinated with UCLA radiation physicists and radiation oncologists. Patients may also qualify to participate in clinical research studies in partnership with the UCLA Jonsson Comprehensive Cancer Center. The Center’s primary research goal is to gain a fundamental understanding of the molecular biology of metastatic ocular melanoma. In addition to providing genetic prognostic information to patients on their risk of tumor metastasis, the Center has identified key genes associated with metastatic tumors.

Optic Neuropathy Center

Under the direction of Dr. Anthony C. Arnold, the Optic Neuropathy Center provides multidisciplinary consultation, diagnosis, and treatment for patients with complex diseases involving the optic nerve. Established in 1991, the Center incorporates specialized facilities and equipment for diagnostic testing and offers consultation from neuro-ophtalmologists, orbital surgeons, neurologists, neuro-radiologists, and neurosurgeons.

Patients referred to the Optic Neuropathy Center receive advanced diagnostic testing of the orbit and optic nerve to assist in evaluation. Extensive analysis of diagnostic data, together with information from the patient’s medical history and comprehensive physical examination, enables Center physicians to determine the nature of the disease and devise a treatment plan. Treatment may be medical or surgical depending on the nature of the referral and the patient’s disease status. As part of the Center’s clinical research effort, physicians are refining disease classifications along with diagnostic and treatment approaches to further the field of optic neuropathy and improve options for patients with these complex disorders.

Orbital Disease Center

The Orbital Disease Center, under the direction of Drs. Daniel B. Rootman and Robert Alan Goldberg, was founded in 1991. The Center brings multidisciplinary expertise to the treatment and study of orbital diseases arising from trauma, cancer, inflammation, and infection. Care is organized around a team of experts in ophthalmology, interventional neuroradiology, neurosurgery, head and neck surgery, radiation oncology, and craniofacial surgery, bringing to the treatment of orbital diseases a depth of knowledge and experience not available elsewhere in Southern California.

The Center provides both medical and surgical management of orbital diseases. The team performs procedures that are not usually available in the community, including orbital decompression, microsurgery for orbital apical tumors, optic canal decompression, combined interventional neuroradiology procedures for vascular tumors, and bony reconstruction to address traumatic or congenital defects. The Center has an active program in thyroid eye disease, where new surgical techniques are evaluated, and basic science research is carried out to advance understanding about the disease. A fellowship program trains future leaders, and teaching courses draw international audiences of highly trained orbital specialists to learn the latest advances in the field.

UCLA Laser Refractive Center

The UCLA Laser Refractive Center is under the direction of Dr. David Rex Hamilton. Founded in 1991, the Center specializes in refractive surgery of both the cornea and lens of the eye, including clinical and research applications of new laser technology. The Center is one of a few in the United States to pioneer investigations into laser eye surgery.

The UCLA Laser Refractive Center offers all cornea refractive procedures, including LASIK and LASEK/PRK, astigmatic keratotomy, conductive keratoplasty, and intracorneal ring implantation. Advanced intraocular lens (IOL) procedures are also available, including presbyopia-correcting IOLs (multifocal and accommodating), toric IOLs, and phakic IOLs. Patients referred to the Center undergo a complete ocular examination that includes corneal topographic mapping, wavefront analysis, and corneal biomechanical measurements to identify conditions that may interfere with surgical correction of refractive errors. Candidates for laser or intraocular lens surgery receive intensive education to understand the benefits, risks, and alternatives to surgery. Participation in clinical trials for new refractive devices and techniques to treat nearsightedness, farsightedness, and presbyopia may be an option for qualified patients. For more information about the UCLA Laser Refractive Center, go to: www.uclaser.com and lasik.ucla.edu.
Vision Genetics Center

Initially established in 1978 as the UCLA Retinitis Pigmentosa Registry, the Vision Genetics Center, under the direction of Dr. Michael B. Gorin, is an integrated clinical and research program that addresses the full spectrum of hereditary eye disorders. Center members, representing multiple disciplines, combine their efforts to understand the underlying molecular basis of a broad range of ocular conditions, including those involving the development of the eye, cornea, lens, extraocular muscles, retina, vitreous, and optic nerve. Areas of interest include both simple inherited conditions caused by alterations in single genes, as well as conditions in which multiple genetic variations and other risk factors play a role.

The Center offers patients and their family members state-of-the-art diagnosis and care of the hereditary eye or vision condition. Services include genetic counseling, and when appropriate, DNA testing either as a clinical diagnostic service, a research program, or in combination. The Center’s faculty members collaborate with a number of genetic research groups around the world to ensure that patients can participate in the most advanced research for their particular condition.

During the past year, the Center has initiated involvement in a natural history study and clinical trial for gene therapy for choroideremia and a therapeutic clinical trial for Stargardt Disease.

Vision Proteomics Center

Genes encode the sequences of proteins, and knowledge of the structure and function of these proteins is required to unlock the secrets of the cell. That task is now set before current and future generations of scientists, and a new field of study, Proteomics, has been born. It is only through an understanding of protein function at the molecular level that researchers can learn the fundamental origins of disease and develop rational therapeutic designs to correct defects in the molecular machinery.

The Vision Proteomics Center at the Stein Eye Institute, under the direction of Dr. Wayne L. Hubbell, with researchers Drs. Ben J. Glasgow, Dean Bok, Joseph Horwitz, and Gabriel H. Travis, has pioneered the development of site-directed spin labeling—the only one of its kind in the world, ushering in a new era of exploration of structure/function relationships in proteins. Research groups at the Stein Eye Institute, departments at UCLA, and other major institutions throughout the United States and abroad, are taking advantage of the singular opportunities provided by the Vision Proteomics Center.

Vision Rehabilitation Center

The Vision Rehabilitation Center, under the direction of Dr. Melissa W. Chun with Dr. Steven D. Schwartz as medical advisor, was established to provide rehabilitation to maximize visual function and quality of life of patients with low vision, defined as best corrected vision of 20/70 or worse in the better eye. These outcomes are accomplished with a rehabilitation plan tailored to each patient’s specific needs and goals.

The Center provides assistance in the form of patient consultation and training, including reading and computer training, as well as evaluation with the latest low-vision devices that can help patients adapt to their visual restrictions. The Center utilizes a wide array of technologically advanced devices, such as magnifiers, telescopes, and digital and computer technology. Customized for each patient’s individual needs, services may range from simple solutions to specialized approaches. One unique feature of the Center is a special “lending library” of select low-vision devices that enables patients to try devices at home or in the office prior to purchase. When appropriate, referrals are provided to assist independent living through occupational therapy and orientation and mobility training.

Low-vision devices, available from the Vision Rehabilitation Center, help patients adapt to their visual restrictions.
The Ophthalmology Clinical Laboratories provide precise measurements, photographs, and quantitative studies of the eye and the visual system. Quantitative information of this type enhances patient care by increasing the accuracy of diagnosis and enlarging the parameters employed to assess the clinical course and effectiveness of treatment. Additionally, the clinical laboratories expand the scope of treatment alternatives, promote clinical research, and generally augment the effectiveness of ophthalmic disease management. The laboratories are available to all ophthalmologists in the community.

Find out more about UCLA Department of Ophthalmology research by going to: www.uclahealth.org/eye/research-laboratories.

**Corneal Diagnostic Laboratory**

The Corneal Diagnostic Laboratory, under the direction of Dr. Anthony J. Aldave, offers a comprehensive array of corneal imaging modalities. Services include imaging of the anterior and posterior corneal surfaces with the Marco OPD-Scan III and Optovue RTVue, and imaging of the corneal endothelium for assessment of corneal endothelial cell morphology and density using the KONAN CellChek XL specular microscope. Full-thickness confocal microscopic imaging of the cornea, a useful tool in the diagnosis of suspected fungal, acanthamoebic, and other parasitic infections of the cornea, is performed with the Heidelberg HRT3 confocal microscope. This instrument and the Optovue RTVue can also perform optical pachymetry to noninvasively measure LASIK residual bed thicknesses and flap thicknesses as well as evaluate the LASIK interface for possible infections, diffuse lamellar keratitis, and ingrowth.

**Glaucoma Photography Laboratory**

The Glaucoma Photography Laboratory, under the direction of Dr. Joseph Caprioli, provides specialized photographs for new and follow-up patients to assist the ophthalmologist in the management of patients with glaucoma. The GDX Nerve Fiber Analyzer utilizes polarized light in place of dilation to measure the thickness of the nerve fiber layer. This test is particularly useful in diagnosing new glaucoma. Heidelberg retinal tomography, using confocal laser light, measures additional parameters of the optic nerve and provides more information on the nerve fiber layer. Optical coherence tomography utilizes reflected light to measure the nerve fiber layer as well as to measure macular holes as a staging procedure for surgical repair. An ophthalmic fundus camera photographs the optic nerve in stereo. The Laboratory is conducting clinical studies to evaluate the effectiveness of each photographic modality in terms of predictive accuracy and early detection of glaucoma.

**Live Imaging and Functional Evaluation (LIFE) Core Laboratory**

The Live Imaging and Functional Evaluation (LIFE) Core Laboratory is jointly supervised by Drs. Steven Nusinowitz and Alapakkam Sampath. The LIFE Module directors are committed to the provision of state-of-the-art noninvasive in vivo imaging and functional analysis of animal models of ocular disease and treatments. Testing provided by the module includes full-field and multi-focal electroretinography (ERG), pattern electroretinography (pERG), and flash and pattern visually-evoked cortical potentials (fVECP and pVECP, respectively). For all of these tests, the ERG component of interest is extracted from the waveform targeting a specific cell type of interest. Structural analysis is provided by direct fundus imaging, auto-fluorescence imaging, angiography, and optical coherence tomography (OCT).
Ocular Motility Clinical and Basic Science Laboratory

The Ocular Motility Clinical and Basic Science Laboratory, under the direction of Dr. Joseph L. Demer, records and quantitatively analyzes eye movement abnormalities resulting from ocular and neurological disorders, such as ocular myasthenia gravis. Several types of tests are performed. The Hess test utilizes specialized eye charts and lenses to assist in the diagnosis of a number of problems, including double vision. Magnetic scleral search coil techniques are utilized in clinical research studies to detect fine movements not evident through normal visual examination. Another test involves the visual recording of eye movement using a video camera. The Laboratory also engages in basic science research to further understanding of eye movement, as well as diseases of the eye, brain, and muscles, and related tissues of the inner ear.

Ophthalmic Photography Clinical Laboratory

The Ophthalmic Photography Clinical Laboratory, under the direction of Dr. Tara A. McCannel, provides a wide array of photographic techniques important in patient care, research, and teaching. The primary purpose of ophthalmic photography in patient care is to record the present state of the eye, and in cases of abnormality, to establish a baseline and monitor the patient’s condition over time. Patient care services include photographic documentation of anterior segment diseases involving corneal problems like growths, infection, and trauma; photographs of ocular motility to record abnormalities in eye movement; fundus photography, which captures pictures of the retina; and diagnostic testing using fluorescein and indocyanine green angiography, which records the dynamics of blood flow in the eye. The Laboratory also supports the research and teaching activities of the Stein Eye Institute by preparing and duplicating graphic materials for presentation and publication.

Ophthalmic Ultrasonography Clinical Laboratory

The Ophthalmic Ultrasonography Clinical Laboratory, directed by Dr. Steven D. Schwartz, performs clinical examinations that are useful in diagnosing both ocular and orbital eye diseases. Diagnostic examinations include standardized A-scan, B-scan, and ultrasound biomicroscopy. Standardized A-scan is useful in tissue differentiation and is commonly employed to diagnose ocular and orbital tumors, including choroidal melanoma. B-scan provides location and contour information and is particularly useful in differentiating vitreous membranes from retinal detachment. Ultrasound biomicroscopy provides exquisitely detailed, high-resolution views of the anterior segment of the eye and is a critical tool for the evaluation of ocular pathology, especially in opaque corneas.

Biometry and intraocular lens calculations are also performed in the Laboratory. Biometry measures the axial eye length, anterior chamber depth, and lens thickness; intraocular lens calculations are performed to determine the power of the lens implant for cataract patients.

Perimetry Laboratory

The Perimetry Laboratory, under the direction of Dr. Joseph Caprioli, performs visual field examinations that determine the sensitivity of central and peripheral vision. Examinations are conducted with advanced Humphrey automated perimetry equipment. Testing detects visual field deficits associated with certain kinds of eye diseases such as glaucoma, retinal disorders, and neuro-ophthalmic conditions. Utilizing pinpoints of light around a perimetry bowl, the test evaluates different areas of the field of vision. Test results are computerized and compared to a range of normal values by age group. Patterns of diminished fields of vision are related to specific eye diseases. Perimetry testing is employed for diagnostic purposes and to monitor visual field sensitivity over time, especially for glaucoma patients. Both standard and shortwave automated techniques are available, in addition to frequency-doubling perimetry and motion-detection perimetry.

Visual Physiology Clinical Laboratory

The Visual Physiology Clinical Laboratory, under the direction of Drs. Michael B. Gorin and Steven Nusinowitz, quantitatively evaluates the function of the retina and visual pathways. Patients are referred for functional testing to confirm a specific diagnosis, or in cases where the etiology is unknown, to rule out alternative diagnostic possibilities. Electrophysiological tests, including both the full-field and multifocal electroretinograms (ERG and mfERG), the electro-oculogram (EOG), and visually evoked cortical potentials (VECP), record electrical signals from different layers of the visual system to identify the site responsible for visual symptoms. Psychophysical tests require the participation of the patient in specific tasks to evaluate visual functions like color blindness, contrast sensitivity, and visual acuity. In many cases, both electrophysiological and psychophysical tests are performed together to obtain the optimum amount of information for diagnosis.
Training Programs

The Stein Eye Institute and the UCLA Department of Ophthalmology jointly provide comprehensive training in ophthalmology and vision science to medical students, residents, and clinical and research fellows. The programs encompass the gamut of ophthalmic and vision science education, representing every level of training and incorporating a full range of subjects in the study of the eye. The residency program is rated one of the top in the country. A large patient population with diverse vision problems offers innumerable training opportunities for both residents and clinical fellows. The availability of more than 15 research laboratories ensures a wide choice of vision science projects for all trainees. Predoctoral and postdoctoral research fellows particularly benefit from the wealth of new and unfolding research generated by vision scientists at the Institute.

Learn more about UCLA Department of Ophthalmology Training Programs at: www.uclahealth.org/eye/ophthalmology-fellowship-training-programs.

UCLA Medical Student Program

Each academic year, the UCLA Department of Ophthalmology and the Institute extend instruction to UCLA medical students in their second, third, and fourth years of instruction. Through lectures, small group discussions, and clinical experience, all students have numerous training sessions from which to gain knowledge about eye diseases and develop eye examination skills that should be known by all physicians, regardless of their specialties. Those students who are interested in ophthalmology as a career have additional learning opportunities in elective courses.

In their second year of instruction, all medical students attend a series of lectures distributed throughout their year-long Human Biology and Disease course, covering various topics related to eye diseases. Students also attend several afternoon workshops during which they learn eye examination skills and treatments for eye problems that can be managed by non-ophthalmologists. During their third year of instruction, medical students interested in additional training and experience can elect to spend two weeks of their surgical clerkship on the Ophthalmology Service, examining patients in clinic and observing eye surgeries. During the fourth year of instruction, a series of advanced clinical electives are available to medical students who plan eventually to practice ophthalmology as their specialty.

UCLA Medical Student Research Program

At the Stein Eye Institute, medical students have taken short-term laboratory and clinical research electives for decades. In addition, there is now a Medical Student Research Program that provides select medical students with a year-long opportunity to participate in laboratory or clinical research in the field of ophthalmology. Each year, a committee selects one or two medical student researchers to receive salary and research support for 12 months in the laboratory or clinical research area of the student’s chosen mentor. The goal of the program is to encourage medical students to pursue careers in academic ophthalmology.

UCLA Ophthalmology Residency Program

The Department of Ophthalmology conducts an accredited three-year residency program for 24 residents; eight new residents begin training each July. The full breadth of ophthalmology training is offered, including experience in general ophthalmology and ophthalmic subspecialties. Training incorporates the resources of the UCLA Stein Eye Institute, Harbor-UCLA Medical Center, Olive View-UCLA Medical Center, and the Veterans Affairs Greater Los Angeles Healthcare System at West Los Angeles and Sepulveda. Every resident has exposure to each medical center during the course of training, thereby ensuring clinical experience with a wide range of problems and patient populations. Certification by the American Board of Ophthalmology is a natural objective of the program.
Clinical Rotations

Clinical rotations at the Stein Eye Institute include both general ophthalmology and subspecialties. In general, ophthalmology residents work as a team, handling clinics, emergencies, and walk-in patients. They also serve as an ophthalmology consult service for inpatients in the UCLA Medical Center. Residents assigned to subspecialty service rotations are provided with intensive exposure to the various divisions within the Department, working closely with faculty members in a private practice environment. At the UCLA-affiliated medical centers, residents work in teams that provide both general and subspecialty patient care.

Didactic Education

Residents receive didactic education in the classroom on an ongoing basis. Once each week, all residents attend a mandatory half-day program that includes faculty lectures that, over the course of the three-year program, cover each of the required subjects in the American Academy of Ophthalmology Basic and Clinical Sciences Course. These lectures are followed by Grand Rounds, which consist of presentation and discussion of specific patient cases, and faculty lectures on clinical topics related to ophthalmic subspecialties. Throughout the week, clinical conferences in ophthalmic subspecialties are held where problems are presented and discussed.

Surgery Training

Residents begin to perform surgery in their first year of training and continue to operate throughout their residency. Surgical cases are assigned commensurate with level of training and experience. First-year residents begin in the Institute’s Microsurgery Laboratory, an organized surgical course that includes computerized surgical simulators. This facility is available to residents throughout their training. Residents first assist on selected surgical cases, and by the end of their residency, they are performing procedures independently.

Research

An understanding of and an appreciation for research are major prerequisites for assimilating future developments in ophthalmology. Accordingly, ophthalmic research is an integral component of residency training. Residents are expected to undertake independent investigation or to participate in ongoing clinical or basic science research projects in ophthalmology. Residents present the results of their work at the Stein Eye Institute Clinical and Research Seminar during their second and third years of residency. They are also encouraged to report their studies at regional and national meetings and publish their results in scientific journals. Residents with special clinical or research interests have an opportunity to use elective time to increase their exposure to a particular area of ophthalmology. This time can be spent with full-time or volunteer faculty at UCLA or at other institutions.

EyeMBA: Innovation in Medical Education

The Institute recently created another national first for medical education by working with the David Geffen School of Medicine at UCLA and the UCLA Anderson School of Management to develop EyeMBA, a master’s of business administration degree that is earned in tandem with an ophthalmology residency—the only joint program of its kind.

EyeMBA was developed in recognition that future leaders in ophthalmology will need the financial, management, and measurement skills that are at the core of an MBA curriculum. Residents in the EyeMBA program gain skills that are broadly applicable to ophthalmologic leadership in academia, translational research, health system management, health care delivery, and the biomedical industry.

EyeSTAR Program

For physicians who are interested in academic careers and professional leadership as clinician-scientists, the Stein Eye Institute offers an Ophthalmology Specialty Training and Advanced Research Program, referred to as EyeSTAR, which offers vision science training combined with an ophthalmology residency. Appointees complete a residency program leading to certification in ophthalmology, as well as laboratory research experience leading to a doctorate, or postdoctoral training in the event that the trainee already has a doctorate. EyeSTAR trainees work under the guidance of a faculty advisory panel representing the trainee’s clinical and research interests.

The unique program began in 1995 and is geared to physicians committed to academic careers in ophthalmology, combining basic science with clinical practice in a five-year or six-year curriculum. EyeSTAR graduates are trained to compete not just with clinical scientists but also with top basic scientists from all institutions. Trainees select their faculty mentors from the Vision Research Division of the Stein Eye Institute or from the David Geffen School of Medicine at UCLA, College of Letters and Sciences, School of Public Health, Clinical Scholars Program, and RAND Graduate School.

EyeSTAR is recognized by the National Eye Institute and the Association of University Professors of Ophthalmology as a model training program for clinician-scientists in ophthalmology.
Training Programs

UCLA Clinical Ophthalmology and Vision Science Fellowship Programs

The Stein Eye Institute offers particularly well-qualified persons the opportunity to receive fellowship training in specific areas of clinical ophthalmology or vision-science research.

Following successful completion of a residency program, a clinical fellowship combines outpatient, inpatient, and surgical experience in an ophthalmic subspecialty. The clinical fellow assumes increasing responsibility for patient care under the supervision of faculty members responsible for the program. In addition to receiving training from faculty, the fellow instructs medical students and residents. Research is considered an important aspect of specialty training and a major prerequisite for assimilating future developments in ophthalmology. Clinical fellows are expected to undertake independent investigation or to participate in one of the ongoing research projects in a field related to their specialty.

Vision-science fellowship training is laboratory based and offers both predoctoral and postdoctoral opportunities to trainees in specific areas of vision science that encompass a wide range of topics. Trainees work under the supervision of Institute faculty members who are engaged in basic science research and have active laboratories. The scope and nature of the training program for each predoctoral or postdoctoral fellow is developed by the trainee and his/her faculty mentor.

Fellowship in Cornea—External Ocular Diseases and Refractive Surgery

Under the direction of Drs. Anthony J. Aldave, Sophie X. Deng, David Rex Hamilton, and Kevin M. Miller, one-year fellowships are offered in the study of diseases of the cornea, external eye, anterior segment, and refractive surgery. Clinical experience consists of participation in the cornea faculty practices, including surgery, and in the care of emergency cornea cases at the Stein Eye Institute. Fellows work in the microsurgical laboratory and assist in teaching microsurgical skills to ophthalmology residents. Under the direction of faculty, fellows also perform primary surgical procedures in the UCLA Laser Refractive Center. In addition to in-depth training at the Institute, fellows provide medical and surgical care to patients at the Veterans Affairs Greater Los Angeles Healthcare System at West Los Angeles and at Harbor-UCLA Medical Center. Fellows typically complete an original clinical or laboratory research project, and frequently co-author a book chapter or review during their training.

Fellowship in Glaucoma

Under the direction of Drs. Joseph Caprioli, Anne L. Coleman, JoAnn A. Giaconi, Simon K. Law, and Kouros Nouri-Mahdavi, the one-year or two-year glaucoma fellowship provides clinical and laboratory experience in glaucoma diagnosis and management. Fellows gain clinical experience by examining patients in the consultation suite and participating in the clinical and surgical management of patients. Fellows work in the Glaucoma Microsurgery Laboratory, participate in microsurgery courses, assist in the Glaucoma Clinic, and develop expertise in the various diagnostic techniques used in glaucoma treatment through preceptor-type relationships with faculty. Fellows participate in glaucoma teaching at the Stein Eye Institute and affiliated institutions, present cases at teaching rounds, and prepare presentations for regularly scheduled glaucoma conferences. Fellows also undertake at least one research project, which may be a clinical study or an applied research project in the laboratory, in cooperation with the faculty advisor.

Fellowship in Medical Retina

This combined Stein Eye Institute and Doheny Eye Institute one-year fellowship, under the co-directorship of Drs. Michael B. Gorin and Srinivas R. Sadda, provides clinical knowledge pertaining to the diagnosis and management of a broad array of retinal disorders, including age-related macular degeneration, diabetic retinopathy, retinal vascular disease, inflammatory retinopathies, drug-related toxic retinopathies, and retinal and macular degenerations and dystrophies. Fellows are instructed in the proper use and interpretation of non-invasive diagnostic tools, and training includes genetic counseling and the proper use of molecular genetic diagnostics. Fellows gain experience with a diverse set of interventional skills, including a wide spectrum of retinal laser procedures and pericocular and intravitreal injection of various classes of drugs.

Fellows divide their time among the clinical practices of Drs. Gorin, David Sarraf, and Colin A. McCannel within the Division of Retinal Disorders and Ophthalmic Genetics, the Retina Division of the Doheny Eye Institute, as well as in the Retinal Diagnostics Unit and the Visual Physiology Laboratory directed by Dr. Steven Nusinowitz at UCLA. Dr. McCannel’s clinic provides exposure to surgical retinal decision-making and management issues. The fellows also provide care and teach residents in retina subspecialty clinics at two UCLA-affiliated hospitals. Fellows are strongly encouraged to engage in translational clinical research and/or clinical trials and descriptive retrospective studies and develop an in-depth working knowledge of the current scientific literature of medical and genetic retina. They are expected to participate in genetic and imaging conferences as well as other relevant meetings.

Fellowship in Neuro-Ophthalmology

The one-year fellowship in neuro-ophthalmology, under the direction of Dr. Peter A. Quiros, involves a close preceptor-preceptee relationship, participation in teaching rounds, and work in the private consultation suite. The David Geffen School of Medicine at UCLA maintains major clinical and research programs in neurology, neurosurgery, and neuroradiology. Fellows attend the weekly Neurology and
Neurosurgery Grand Rounds, take an active part in seeing relevant inpatient consultations throughout the Medical Center, and assist in selected surgical procedures of interest to neuro-ophthalmologists. Attendance at the weekly neuroradiology teaching conferences is encouraged. Time is allotted for scientific reading and for research activities. Participation in clinical research, such as studies of eye movement disorders and disturbances of visual pathways, is expected.

Fellowship in Ophthalmic Pathology

Under the direction of Dr. Ben J. Glasgow, this fellowship provides preparation for an academic career in ophthalmic pathology. One-year, two-year, and three-year training programs are available depending on the background of the applicant. Training encompasses many aspects of ophthalmic pathology. Fellows may choose between a research-based or clinical-based curriculum. Clinical fellows gain expertise in surgical pathology; autopsy pathology; cytology, including fine-needle aspiration; electron microscopy; immunohistochemistry; DNA in situ hybridization; Southern blot analysis; and polymerase chain reaction techniques for diagnostic work. The fellowship programs are individualized according to the credentials and capabilities of each fellow.

Fellowship in Orbital and Ophthalmic Plastic Surgery

Fellowships in orbital and ophthalmic plastic surgery, under the overall supervision of Drs. Robert Alan Goldberg and Jonathan Hoenig, provide training for ophthalmologists who are interested in specializing in orbital and adnexal disorders, and in aesthetic and reconstructive orbitofacial surgery. Fellows participate in orbital and ophthalmic plastic surgery outpatient consultation, inpatient care, and surgical procedures at the Stein Eye Institute and affiliated hospitals. They also participate extensively in the teaching and research activities of the Orbital and Ophthalmic Plastic Surgery Division. In addition to publishing results of original research in peer-reviewed scientific journals, fellows complete a formal thesis that partially satisfies the membership requirements of the American Society of Ophthalmic Plastic and Reconstructive Surgery. International research fellows also participate in the program annually. The two-year fellowship program is approved by the American Society of Ophthalmic Plastic and Reconstructive Surgery.

Fellowship in Pediatric Ophthalmology and Strabismus

The division of Pediatric Ophthalmology and Strabismus offers one-year fellowships, under the directorship of Drs. Sherwin J. Isenberg and Joseph L. Demer. Clinical experience consists of supervised participation in the ophthalmic care of pediatric patients seen at the Stein Eye Institute, Harbor-UCLA Medical Center, and Olive View-UCLA Medical Center. Specific activities include participation in University Ophthalmology Associates, the Nursery and Neonatal Intensive Care Units, Ophthalmic Plastic and Reconstructive Surgery Service, and the Pediatric Retinal Service. Other activities in pediatric ophthalmology include experience in the private consultation suites and participation in pediatric cases that are handled through other services. Fellows may collaborate with vision scientists, including biochemists, physiologists, pathologists, and anatomists, on research projects of mutual interest.

Fellowship in Vision Science

Predoctoral and postdoctoral fellowships in vision science are offered to individuals who have an interest in specific research areas being pursued by Institute faculty in highly specialized laboratory environments. These fellowships are supported either by individual funds available to Institute professors or as part of a special program offered under the auspices of a National Eye Institute Vision Science Training Grant directed by Dr. Gabriel H. Travis.
Training Programs

Predoctoral fellows take a defined program of core courses and carry out eye-related research, obtaining doctorates in about six years. Fellows are required to present their research at informal and formal seminars, and are encouraged to participate in national and international meetings and publish scientific papers. They gain a broad background in the vision sciences by interacting with members of adjacent laboratories and collaborating with faculty members other than their own preceptors. Postdoctoral research fellowships are offered for one to three years. Each one is unique with research programs established according to mutual agreement between trainees and mentors. Research areas for postdoctoral fellows include molecular biology, genetics, biophysics, biomechanics, cell biology, eye development, and biochemistry. Upon completion of their fellowships, trainees usually pursue careers in academia or industry.

Fellowship in Vitreoretinal Diseases and Surgery

Under the co-directorship of Drs. Allan E. Kreiger and Steven D. Schwartz, the Vitreoretinal Diseases and Surgery Fellowship in the Department of Ophthalmology at the Stein Eye Institute is a two-year program designed to provide medical and surgical training and clinical- and vision-science research opportunities related to vitreoretinal disease. Major components of the fellowship relate to diabetic retinopathy, diseases of the macula and retina, hereditary retinal degenerations, ocular trauma, ophthalmic oncology, rhegmatogenous retinal disease, vitreoretinal surgery, pediatric retinal disease, and diagnostic imaging. Clinical training includes the prevention, diagnosis, and treatment of retinal, choroidal, vitreous, and related ocular disease. Fellows participate in retinal clinics and surgical procedures at the Stein Eye Institute and four UCLA-affiliated hospitals. Clinical, laboratory, or translational research is also encouraged. Other activities include teaching of vitreoretinal diseases at the Stein Eye Institute and affiliated institutions and case presentations at teaching sessions. The program also includes the participation of several international fellows.

International Fellowship and Exchange Program

To promote and encourage research and education interaction with ophthalmology institutions throughout the world, the Stein Eye Institute offers an International Ophthalmology Fellowship and Exchange Program consisting of one-year to two-year fellowships under the supervision of specific Institute faculty. Candidates for these fellowships are nominated by prestigious institutions outside the United States and often hold academic positions within their own countries. Fellows participate in the clinical and research activities of ophthalmic subspecialties according to their training needs.
Volunteer and consulting faculty—many of whom have contributed to the Department’s educational mission for more than 25 years—teach courses, participate in conferences, and bring hands-on practical experience and common-sense guidance that is invaluable to young ophthalmologists in training.

---

### Volunteer Faculty

#### Clinical Professors of Ophthalmology
- J. Bronwyn Bateman, MD
- Bruce B. Becker, MD, PC
- Michael S. Berlin, MD
- William P. Chen, MD
- Paul Deiter, MD (Senior Status)
- Uday Devgan, MD, FACS, FRCS
- J. Bronwyn Bateman, MD
- Bruce B. Becker, MD, PC
- Michael S. Berlin, MD
- William P. Chen, MD
- Paul Deiter, MD (Senior Status)
- Uday Devgan, MD, FACS, FRCS

#### Chief of Ophthalmology
- Olive View-UCLA Medical Center
- Donald Dickerson, MD (Senior Status)
- Donald S. Fong, MD, MPH
- Leland M. Garrison, MD
- Thomas A. Hanscom, MD
- John D. Hofbauer, MD
- Kenneth J. Hoffer, MD
- C. Richard Hulquist, MD
- Barry M. Kerman, MD
- Roger A. Kohn, MD
- Howard R. Krauss, MD
- Benjamin C. Kwan, MD
- Jeremy Levenson, MD (Senior Status)
- Jonathan I. Macy, MD
- Ezra Maguen, MD
- Robert K. Maloney, MD
- Samuel Maskeat, MD
- Leon G. Partamian, MD
- George Primbs, MD (Senior Status)
- Yaron S. Rabinowitz, MD
- Teresa O. Rosales, MD
- Robert J. Schechter, MD (Senior Status)
- Stephen Seiff, MD (Senior Status)
- Alan L. Shabo, MD
- Norman Shorr, MD
- Roger W. Sorenson, MD (Senior Status)

#### Associate Clinical Professors of Ophthalmology
- Gerald Barron, MD (Senior Status)
- Arnold Barton, MD (Senior Status)
- Kevin J. Belville, MD
- Louis Bernstein, MD (Senior Status)
- W. Benton Boone, MD
- Harvey Brown, MD
- Andrew E. Choy, MD
- Melissa W. Chun, OD
- Peter J. Cornell, MD
- Bernard Davidorf, MD (Senior Status)
- Paul B. Donzis, MD
- Kathryn M. Gardner, MD
- Donald I. Goldstein, MD
- Michael J. Groth, MD
- Andrew Henrick, MD
- Edwin P. Hill, MD
- Jonathan A. Hoenig, MD
- Richard H. Hoft, MD
- David F. Kamin, MD
- Stanley Kopelow, MD (Senior Status)
- Joseph Lambert, MD (Senior Status)
- Brian L. Lee, MD
- Steven Leibowitz, MD
- Gene Matzkin, MD (Senior Status)
- Joan E. McFarland, MD
- James McKinzie, MD (Senior Status)
- Alan Norton, MD (Senior Status)
- John F. Paschal, MD (Senior Status)
- Firas Rahhal, MD
- George M. Rajacich, MD
- Michael Reynard, MD
- David S. Robbin, MD
- David E. Savar, MD
- Timothy V. Scott, MD
- Kayur Shah, MD
- Albert Sheffer, MD
- James D. Shuler, MD
- Yossi Sidikaro, MD, PhD
- Matthew Sloan, MD
- Ronald J. Smith, MD
- Alfred Solish, MD, MS
- Kenneth D. Steinsapir, MD
- Sadiqa Stelzner, MD, MA, FACS
- William C. Stuvelman, MD (Senior Status)
- Hector L. Sulit, MD
- Kamal A. Zakka, MD

#### Assistant Clinical Professors of Ophthalmology
- David H. Aizuss, MD
- Malvin B. Anders, MD
- Richard K. Apt, MD
- Reginald G. Ariyasu, MD, PhD
- Arthur A. Astorino, MD
- Mark A. Baskin, MD
- Arthur Benjamin, MD
- Katherine L. Bergwerk, MD
- Betsy E. Bleichman, MD
- Cynthia A. Boxrud, MD
- Amarpreet S. Brar, MD
- Almira W. Cann, MD, PhD
- Arnett Carraby, MD
- Vicki K. Chan, MD
- Andrew M. Chang, MD
- Candice Chen, MD
- Thomas B-H. Choi, MD
- Milton W. Chu, MD
- Robert A. Clark, MD
- Charles A. Cooper, MD
- Yadavinder P. Dang, MD
- Jonathan M. Davidorf, MD
- John L. Davidson, MD
- Sanford S. Davidson, MD
- Louise Cooley Davis, MD
- Farid Eghbali, OD
- Troy R. Elander, MD
- Naomi L. Ellenhor, MD
- Calvin T. Eng, MD
- Robert E. Engstrom, MD
- Doreen T. Fazio, MD
- Sanford G. Feldman, MD
- Laura E. Fox, MD
- Ronald P. Gallenmore, MD
- George H. Garcia, MD
- Leslie C. Garland, MD (Senior Status)
- W. James Gealy, Jr., MD
- Damien Goldberg, MD
- Lawrence “Tim” Goodwin, MD
- Lawrence H. Green, MD (Senior Status)
- Richard Havunjian, MD
- Man M. Singh Hayreh, MD
- Matthew L. Hecht, MD
- David A. Holland, MD
- Jeffery Hong, MD
- Catherine J. Hwang, MD, MPH
- Morton P. Israel, MD
- Steven J. Jacobson, MD
- Batool Jafri, MD
- Aarchan Joshi, MD
- Véronique H. Jotterand, MD
- J. David Karlin, MD
- David S. Katzin, MD
Assistant Clinical Professors of Ophthalmology continued

James F. Kleckner, MD (Senior Status)
Jerome R. Klein, MD
Craig H. Kliger, MD
Howard E. Lazerson, MD (Senior Status)
Robert T. Lin, MD
Joanne E. Low, MD
Bryant J. Lum, MD
Michael C. Lynch, MD
M. Polly McKinstry, MD
Ashish M. Mehta, MD
Kenneth J. Miller, MD (Senior Status)
David R. Milstein, MD
Ronald L. Morton, MD
Roger L. Novack, MD, PhD
David Paik, MD
Alpa A.S. Patel, MD
James H. Peace, MD
Gilbert Perlman, MD (Senior Status)
Cheryl J. Powell, MD
John R. Privett, MD (Senior Status)
Laurence N. Roer, MD
Gerald Sanders, MD (Senior Status)
Aaron M. Savar, MD
Barry S. Seibel, MD
Meryl Shapiro-Tuchin, MD
David M. Shultz, MD
Eliot B. Siegel, MD
Lance M. Siegel, MD
John D. Slaney, MD
Robert J. Smyth, MD
Kenneth O. Sparks, MD
Mehryar “Ray” Taban, MD, FACS
Homayoun Tabandeh, MD
Robert C. Tarter, MD
Debra G. Tennen, MD
Teddy Y. Tong, MD
Sterling M. Trenberth, MD (Senior Status)
Robert C. Tudor, MD (Senior Status)
Henry E. Ullman, MD
Tay J. Weinman, MD (Senior Status)
Irwin S. Weiss, MD (Senior Status)
Sidney J. Weiss, MD
Scott Whitcup, MD
David L. Williams, MD (Senior Status)
Jeffrey V. Winston, MD
David M. Winters, MD (Senior Status)
David L. Wirta, MD
Barry J. Wolstan, MD
Wilson C. Wu, MD, PhD
Michael C. Yang, MD
Patrick C. Yeh, MD
Richard H. Yook, MD (Senior Status)
Peter D. Zeegen, MD (Senior Status)

Clinical Instructors in Ophthalmology

Eduardo Besser, MD
Maria Braun, MD
Stephen S. Byslma, MD
Andrew Caster, MD
Hajir Dadgostar, MD
John J. Darin, MD (Senior Status)
Paul J. Dougherty, MD
Sean Dumars, MD
Daniel Ebroon, MD
Brad S. Elkins, MD
Satvinder Gujral, MD
Lawrence M. Hopp, MD, MS
Anisha J. Judge, MD
Jason Jun, MD
Rajesh Khanna, MD
Julie A. King, MD
Monica R. Khitri, MD
Mark H. Kramar, MD
Daniel Krivoy, MD
Laura C. McColl, MD
Mitra Nejad, MD
Jayantkumar Patel, MD
Susan S. Ransome, MD
Steven H. Rauchman, MD
Richard H. Roe, MD
Louis M. Savar, MD
Ahmanson Laboratory
of Neurobiology
Peter H. Win, MD
Andrew Young, MD

Consulting Members of the Stein Eye Institute

Robert W. Baloh, MD
Professor of Neurology and Surgery
(Head and Neck)

Ferdinand V. Coroniti, PhD
Professor, Department of Physics and Astronomy

David Eisenberg, DPhil
Investigator, Howard Hughes Medical Institute

Paul D. Boyer Professor of Biochemistry and Molecular Biology
Professor, Departments of Chemistry and Biochemistry, and Biological Chemistry
Molecular Biology Institute

Alan M. Fogelman, MD
Caster Professor and Executive Chair
Department of Medicine

Alan D. Grinnell, PhD
Professor of Physiology and Physiological Science
Director, Jerry Lewis Neuromuscular Research Center
Director, Ahmanson Laboratory

C. Kumar Patel, PhD
Professor, Department of Physics and Astronomy

Leonard H. Rome, PhD
Senior Associate Dean for Research
Professor of Biological Chemistry

Peter C. Whybrow, MD
Judson Braun Professor and Executive Chair
Department of Psychiatry and Biobehavioral Sciences
Director and Physician in Chief
Neuropsychiatric Institute
Residents and Fellows

Residents

Third-Year Residents 2015–2018
Todd H. Driver, MD
Juliet O. Essiflie, MD
Sean F. Garrity, MD
Wei “Wayne” Gui, MD
Shawn Lin, MD
Erika T. Tanaka Friesen, MD
Ye Elaine Wang, MD
David Xu, MD

Second-Year Residents 2016–2019
Christine L. Bokman, MD
Benjamin C. Campbell, MD
Elisha C. Garg, MD
Kirk K. Hou, MD
Patrick J. Lee, MD
Xiongfei Lu, MD
Eric Shieh, MD
Victoria L. Tseng, MD, PhD (EyeSTAR)

First-Year Residents 2017–2020
Judd Cahoon, MD
Tamara L. Lenis, MD, PhD (EyeSTAR)
Cameron Pole, MD
David T. Stark, MD, PhD (EyeSTAR)
William Stoddard, MD
Sandip Suresh, MD
Qing Wang, MD, PhD (EyeSTAR)
Madeline Yung, MD

EyeSTAR Trainees
Adrian Au, MD
Tamara L. Lenis, MD
Anh H. Pham, MD, PhD
David Stark, MD, PhD
Michel Sun, MD, PhD
Victoria Tseng, MD, PhD
Qing Wang, MD, PhD

Clinical Fellows

Cornea/External Ocular Diseases and Refractive Surgery
Pejman Bakhtiary, MD

Glucoma
Thomas Avallone, MD
Janet Lee, MD
Wen-Shin Lee, MD
Christine V. Nguyen, MD
(Doheny Eye Center UCLA)

Medical Retina and Ophthalmic Genetics
Siya Huo, MD
Luca Zatreanu, MD

Neuro-Ophthalmology
None

Orbital and Ophthalmic Plastic Surgery
Christopher Lo, MD
Sathyadeepak Ramesh, MD

Pathology (Eye)
Diana Lee, MD

Pediatric Ophthalmology and Strabismus
Shauna Berry, DO
Azam Qureshi, MD

Uveitis and Inflammatory Eye Disease
None

Vitreoretinal Diseases and Surgery
Nikisha Kothari, MD
Jason “Mingyi” Huang, MD
Christian Sanfilippo, MD
Sanket U. Shah, MD

Medical Retina and Ophthalmic Genetics

M. Zubair Yameen Arain, MD
Pakistan
Giulia Corradietti, MD
Italy
Juan Pablo Davila Gonzalez, MD
Mexico
Marco Nassisi, MD
(Doheny Eye Center UCLA)
Italy

Neuro-Ophthalmology
None

Orbital and Ophthalmic Plastic Surgery
Hamzah Mustak, MD
South Africa
Shoaib Ugradar, MD
United Kingdom

Pediatric Ophthalmology
Narisa Rattanalert, MD
Thailand
Muhammad Ali, MBBS
Pakistan

Uveitis
None

Visual Physiology
None

Vitreoretinal Diseases and Surgery
Amirhossein Hariri, MD
(Doheny Eye Center UCLA)
Iran
Anibal Francone, MD
Argentina
Seong Joo Shin, MD
South Korea
Vidal Soberon Ventura, MD
(Retina Oncology)
Mexico

Predoctoral Research Fellows
Kevin Eden
W. Blake Gilmore
Kristopher Griffis
Roni Hazim
Norianne Ingrom
Margaux Kreitman
Alan Le
Eunicce Ng
Joseph Park
Katie Pohl
Gabriel Pollock
Gabriela Sendek
Tongzhou Xu
Postdoctoral Research Fellows

Zachary Balmuth-Loris, PhD
Edouard Baulier, PhD
Abhishek Chadha, PhD
Doug Chung, PhD
Aurelie Dos Santos, PhD
Matthias Elgeti, PhD
Antonio Escudero Paniagua, PhD
Sheyla Gonzalez-Garrido, PhD
Nermin Kady, PhD
Michael Lerch, PhD
Ala Morshedian, PhD
Jonathan Rodriguez, PhD
Charles Avery Sader, PhD
Kwang Sup “Andrew” Shin, PhD
Kaushali Thakore-Shah, PhD
Soh Youn Suh, MD
Ankita Umapathy, PhD
Stefanie Volland, PhD
Yanjie Wang, PhD
Chi Zhang, PhD
Wenlin Zhang, PhD
### Active Funding  
**July 1, 2017–June 30, 2018**

<table>
<thead>
<tr>
<th>Vision Science Grants</th>
<th>Total Award</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anthony J. Aldave, MD</strong></td>
<td></td>
</tr>
<tr>
<td>Identification and Characterization of the Genetic Basis of PPCD</td>
<td>$250,000</td>
</tr>
<tr>
<td>National Eye Institute</td>
<td></td>
</tr>
<tr>
<td>Duration: 12/1/12–11/30/17</td>
<td></td>
</tr>
<tr>
<td>Vision Restoration with a Collagen Crosslinked Boston Keratoprosthesis Unit</td>
<td>$50,492</td>
</tr>
<tr>
<td>Department of Defense</td>
<td></td>
</tr>
<tr>
<td>Sub-award from Massachusetts Eye and Ear Infirmary</td>
<td></td>
</tr>
<tr>
<td>Duration: 9/1/15–8/31/17</td>
<td></td>
</tr>
<tr>
<td><strong>Suraj P. Bhat, PhD</strong></td>
<td></td>
</tr>
<tr>
<td>Childhood Cataractogenesis: Heterogeneity of Gene Expression</td>
<td>$250,000</td>
</tr>
<tr>
<td>National Eye Institute</td>
<td></td>
</tr>
<tr>
<td>Duration: 1/1/15–12/31/18</td>
<td></td>
</tr>
<tr>
<td><strong>Joseph Caprioli, MD</strong></td>
<td></td>
</tr>
<tr>
<td>Clinical Research Program in Glaucoma</td>
<td>$50,000</td>
</tr>
<tr>
<td>Simms-Mann Family Foundation</td>
<td></td>
</tr>
<tr>
<td>Duration: 7/1/14–6/30/18</td>
<td></td>
</tr>
<tr>
<td>The Efficacy and Safety of Bimatoprost SR in Patients with Open-Angle Glaucoma or Ocular Hypertension</td>
<td>$149,974</td>
</tr>
<tr>
<td>Allergan Pharmaceutical Corp.</td>
<td></td>
</tr>
<tr>
<td>Duration: 4/22/15–1/31/19</td>
<td></td>
</tr>
<tr>
<td><strong>Anne L. Coleman, MD, PhD</strong></td>
<td></td>
</tr>
<tr>
<td>UCLA Mobile Eye Clinic Child Vision Program</td>
<td>$1,082,500</td>
</tr>
<tr>
<td>LA County Children and Families First (First 5 LA)</td>
<td></td>
</tr>
<tr>
<td>Duration: 7/1/13–9/30/17</td>
<td></td>
</tr>
<tr>
<td>Ocular Hypertension Treatment Study 20-Year Follow-Up: Clinical Center Grant</td>
<td>$9,483</td>
</tr>
<tr>
<td>National Eye Institute</td>
<td></td>
</tr>
<tr>
<td>Sub-award from Washington University</td>
<td></td>
</tr>
<tr>
<td>Duration: 7/1/15–6/30/18</td>
<td></td>
</tr>
<tr>
<td><strong>Joseph L. Demer, MD, PhD</strong></td>
<td></td>
</tr>
<tr>
<td>Biomechanical Analysis in Strabismus Surgery</td>
<td>$384,867</td>
</tr>
<tr>
<td>National Eye Institute</td>
<td></td>
</tr>
<tr>
<td>Duration: 5/1/16–4/30/20</td>
<td></td>
</tr>
<tr>
<td><strong>Sophie X. Deng, MD, PhD</strong></td>
<td></td>
</tr>
<tr>
<td>Regeneration of a Normal Corneal Surface by Limbal Stem Cell Therapy</td>
<td>$922,786</td>
</tr>
<tr>
<td>California Institute for Regenerative Medicine (CIRM)</td>
<td></td>
</tr>
<tr>
<td>Duration: 8/1/16–11/30/18</td>
<td></td>
</tr>
<tr>
<td><strong>Gordon L. Fain, PhD</strong></td>
<td></td>
</tr>
<tr>
<td>Physiology of Photoreceptors</td>
<td>$250,000</td>
</tr>
<tr>
<td>National Eye Institute</td>
<td></td>
</tr>
<tr>
<td>Duration: 8/1/17–7/31/21</td>
<td></td>
</tr>
</tbody>
</table>
Debora B. Farber, PhD, DPhhc

Edouard Baulier, PhD

Patient-Derived iPSCs, CRISPR/Cas and RPE-Derived Exosomes for the Treatment of Ocular Albinism

Vision of Children

Duration: 6/1/16–5/31/19

$163,783

Lynn K. Gordon, MD, PhD

Diversity and Inclusion Culture and Climate Self-Assessment Tool and Scorecard

Association of American Medical Colleges

Duration: 9/15/17–9/14/18

$12,000

Michael B. Gorin, MD, PhD

IPS Model for Retinal Hemangioma Pathogenesis

VHL Family Alliance

Duration: 10/1/16–9/30/18

$50,000

Natural History of the Progression of X-Linked Retinitis Pigmentosa

NightstaRx

Duration: 9/28/17–8/31/19

$135,770

Gary N. Holland, MD

Macular Edema Treatment Trials Associated with MUST (META-MUST)

National Eye Institute

Sub-award from Johns Hopkins University

Duration: 9/30/14–1/31/18

$39,180

Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study (SITE)

University of Pittsburgh

Duration: 3/2/16–3/2/21

Non-monetary Contract

Systemic Immunosuppressive Therapy for Eye Disease (Cancer Surveillance and Research Branch/CCR)

University of Pittsburgh

Duration: 3/2/16–3/2/21

Non-monetary Contract

Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus

New York University

Duration: 4/3/17–7/31/21

$339,898

Multicenter Uveitis Steroid Treatment (MUST) Trial

National Eye Institute

Sub-award from Johns Hopkins University

Duration: 6/1/12–4/30/18

$14,354

Joseph Horwitz, PhD

Analysis of Lens Crystallins and Cataractous Mutants at High Hydrostatic Pressure

National Eye Institute

Duration: 4/1/14–3/31/19

$150,000

Alex A. Huang, MD, PhD

Discovery and Characterization of Anterior Sclera Pathology in Glaucoma

National Eye Institute

Duration: 9/30/14–9/29/19

$203,981

Research to Prevent Blindness Career Development Award

Research to Prevent Blindness, Inc.

Duration: 1/1/16–12/31/19

$75,000
Wayne L. Hubbell, PhD  
Molecular Basis of Membrane Excitation  
National Eye Institute  
Duration: 5/1/15–4/30/20  $311,375

Michael Ip, MD  
Studies of Comparative Treatments in Retinal Vein Occlusion 2 (SCORE 2)  
National Eye Institute  
Subaward from Penn State University  
Duration: 6/16/16–3/31/19  $47,631

Bartly J. Mondino, MD  
RPB Unrestricted Grant  
Research to Prevent Blindness, Inc.  
Duration: 1/1/12–12/31/18  $115,000

Stacy L. Pineles, MD  
Integrating Perceptual Learning Approaches into Effective Therapies for Low Vision  
National Eye Institute  
Subaward from University of California Riverside  
Duration: 9/1/13–7/31/18  $28,921

Roxana Radu, MD  
The Role of Complement in Recessive Stargardt Disease  
National Eye Institute  
Distribution: 8/1/15–7/31/20  $250,000

SriniVas R. Sadda, MD  
Non Exudative Age-Related Macular Degeneration Imaged with Swept Source Optical Coherence Tomography  
Boston Image Reading Center  
Duration: 2/1/18–2/28/21  $42,520

AREDS 2 10-Year Follow-up  
Emmes Corporation  
Duration: 11/1/17–2/31/18  $20,790

Alfredo A. Sadun, MD, PhD  
Samuel Asanad  
Fall 2017 RPB Medical Student Eye Research Fellowship  
Research to Prevent Blindness, Inc.  
Duration: 1/1/18–12/31/18  $30,000

Alapakkam P. Sampath, PhD  
Molecular Basis of Photoreceptor Wiring  
National Eye Institute  
(Multi-PI award with Scripps Clinic and Research Foundation)  
Duration: 5/1/17–4/30/22  $91,444

Analyses of Retinal Circuits After Rod Rescue in a Mouse Model of Human Blindness  
National Eye Institute  
(Multi-PI award with University of Southern California)  
Duration: 9/1/16–8/31/21  $95,673

Vision Science Training Program  
National Eye Institute  
Duration: 9/1/17–8/31/18  $215,081
David Sarraf, MD  
Diabetic Retinopathy Clinical Research Network  
JAEB Center for Health Research  
Duration: 6/13/17–12/31/18  
Non-monetary Contract

Gabriel H. Travis, MD  
The Role of Müller Cells in Visual Pigment Regeneration  
National Eye Institute  
Duration: 7/1/13–6/30/18  
Instrumentation Grant for Stein Eye Investigators  
Bruce Ford and Anne Smith Bundy Foundation  
Duration: 8/16/11–8/15/18  
Functional Characterization of RGR-OPSIN in Retinal Müller Cells  
National Eye Institute  
Distribution: 9/1/15–8/31/18

Irena Tsui, MD  
Ophthalmic Manifestations of Congenital Zika Virus Infection  
National Eye Institute  
Duration: 3/1/17–2/28/19  
$25,932

David S. Williams, PhD  
The Photoreceptor Cilium  
National Eye Institute  
Duration: 5/1/13–4/30/19  
Photoreceptor Disk Membrane Morphogenesis  
National Eye Institute  
Sub-award from University of California, Santa Barbara  
Duration: 4/1/15–3/31/19  
Gene Editing of the Usher 1B Gene  
Foundation Fighting Blindness  
Duration: 6/1/17–5/31/18  
Cellular Mechanisms of Disease in Patient-Specific RPE Cells  
Foundation Fighting Blindness  
Sub-award from University of California, San Francisco  
Duration: 6/1/17–5/31/18  
RPE Cell Biology, Aging, and Disease  
National Eye Institute  
Duration: 9/1/17–5/31/22  
$296,846

Xian-Jie Yang, PhD  
Neuroprotection Mechanism for Photoreceptors  
National Eye Institute  
Duration: 5/1/16–4/30/21  
$250,000
Research Contracts and Grants

Professional Research Series

Navid Amini, PhD
EyeSee: Mobile Assistive Technology for Hemianopic Patients
Vodafone-US Foundation
Duration: 7/1/16–6/30/19
$66,675

Sonia Guha, PhD
Role of Doublecortin in Axonal Misrouting in OA1-/- Mice
Vision of Children
Duration: 7/1/14–3/15/20
$152,236

Rustum Karanjia, MD, PhD
Photopic Negative Response (PhNR) as an Objective Outcome Measures in Mitochondrial Disease
United Mitochondrial Disease Foundation
Duration: 12/1/17–11/30/19
$50,000

Anna Matynia, PhD
Targeted Hsp70 as a Therapeutic for Central Retinal Artery Occlusion
Rubicon Biotechnology
Duration: 9/30/17–9/30/18
$40,400

Alejandra Young, PhD
Identification of the OA1 Molecule Partners Critical for Axonal Guidance of RGCs Growth Cones
(Proposal Continuation of Grant #20142326)
Vision of Children
Duration: 11/1/13–7/14/20
$195,525

Residents and Fellows

Abhishek Chadha, PhD (Vision-Science Postdoctoral Fellow)
Functional Characterization of MY07A in Retinal Tissue
National Eye Institute
Duration: 7/1/16–6/30/19
$57,066

Roni Hazim (Vision-Science Predoctoral Fellow)
CFH in RPE Cell Biology and Disease
National Eye Institute
Duration: 3/1/17–8/31/18
$26,810

Wenlin Zhang, MD, PhD
Transcriptome Analysis of the Metabolic Reprogramming in SLC4A11 Associated Congenital Hereditary Endothelial Dystrophy
Knights Templar Eye Foundation, Inc.
Duration: 7/1/17–12/31/18
$65,000

Clinical Trials

Michael B. Gorin, MD, PhD
A Single-Masked, Randomized, Controlled, Parallel Group, Phase 3 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-Associated Viral Vector Encoding Rab Escort Protein 1
NightstaRx
Duration: 6/13/18–6/13/21
$96,333
Jean-Pierre Hubschman, MD
A Ph 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor for Macular Telangiectasia Type 2
Lowy Medical Research Institute
Duration: 8/6/14–6/30/18 $750

Extension Study of NT-501 Ciliary Neurotrophic Factor Implant for Macular Telangiectasia
Lowy Medical Research Institute
Duration: 8/14/17-6/30/22 $29,878

Kenneth L. Lu, MD
Using Pattern ERG to Objectively Measure Contrast Sensitivity Associated with Intraocular Lenses: Study Design
Bausch and Lomb
Duration: 11/1/17–6/30/19 $36,661

Tara A. McCannel, MD
Phase 1B Open-Label, Single Ascending Dose Clinical Trial to Evaluate the Safety of Two Dose Levels of Light-Activated AU-011 for Treatment of Subjects with Small to Medium Primary Choroidal Melanoma
Aura Biosciences, Inc.
Duration: 9/28/17–9/28/19 $72,909

Peter A. Quiros, MD
A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered by Single or Multi-Dose Intravitreal Injection(s) to Subjects with Acute Nonarteritic Anterior Ischemic Optic Neuropathy
Quark Pharmaceuticals, Inc.
Duration: 8/4/16–8/4/19 $1,600

Alfredo A. Sadun, MD, PhD
A Prospective, Randomized, Double-Masked, Vehicle-Controlled, Phase 2 Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of MTP-131 TOPI
Stealth Biotherapeutics Inc.
Distribution: 2/12/16–2/12/18 $13,876

Reality LHON Registry
GenSight Biologics
Duration: 1/16/18–9/1/19 $45,810

Long-term Follow-up of ND4 LHON Subjects Treated with GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials
GenSight Biologics
Duration: 1/3/18–1/3/21 $474,754

Steven D. Schwartz, MD
A Phase 2B Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Zimura (Complement CS Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease
Ophthotech Corporation
Duration: 4/10/18–4/10/21 $305,751

Irena Tsui, MD
RAINBOW Study: A Randomized Controlled Study Evaluating the Efficacy and Safety of RAnibizumab Compared with Laser Therapy for the Treatment of INfants BOrn Prematurely with Retinopathy of Prematurity
Novartis Pharmaceuticals
Duration: 4/3/17–7/31/18 $38,953
Research Contracts and Grants
Active Funding
Administered by Doheny Eye Center UCLA

Vision Science Grants

**Alex A. Huang, MD, PhD**
Structure and Function of Aqueous Humor Outflow
American Glaucoma Society and Allergan
Young Clinician Scientist Award
Duration: 3/17/15–9/30/2018 $20,000/initial year
Glaukos Research (Outflowing Imaging)
Glaukos Corporation
Duration: 10/17/15–9/30/2018 $10,000/two years

**Srinivas R. Sadda, MD**
Multimodal Image Analysis in Age-Related Macular Degeneration
Macula Vision Research Foundation
Duration: 1/1/15–12/31/17 $100,000/year
Advanced Image Analysis Tools for Diabetic Retinopathy
Telemedicine Applications
Eyenuk, Inc.
Sub-award on NEI EY026864
Duration: 8/1/16–7/31/18 $47,771
High Resolution Retinal Imaging by Fourier Ptychography
CalTech
Sub-award on NEI Grant EY026228
Duration: 4/1/16–3/31/19 $25,000
Advanced Image Analysis Tools for Diabetic Retinopathy
Telemedicine Application
Eyenuk, Inc.
Sub-award on NEI Grant SB1EY027241
Duration: 9/30/16–7/31/19 $19,108

**Alfredo A. Sadun, MD, PhD**
Psychological and Environmental Effectors of mtDNA Disease Penetrance
Children’s Hospital of Philadelphia
Duration: 10/1/16–6/30/18 $20,000/initial year

**Deming Sun, MD**
Role of IL-17+ Autoreactive T Cells in Experimental Autoimmune Uveitis (EAU)
National Eye Institute
Duration: 9/1/09–7/31/19 $274,912

**James C. Tan, MD, PhD**
Karl Kirchgeissner Foundation Vision Research Grant
The Karl Kirchgeissner Foundation
Duration: 10/17/09–Open $50,000
Fibrillin-1 and TGFB2 Abnormality Models PAOG
Pathogenesis and Treatment
National Eye Institute
Duration: 9/30/17–5/31/20 $250,000
Contractile Modulation of Distal Aqueous Humor Drainage
National Eye Institute
Duration: 6/1/18–5/31/20 $150,000
Clinical Trials

SriniVas R. Sadda, MD
Genetic Epidemiology of Age-Related Macular Degeneration in the Older Order Amish
University of Pennsylvania
Sub-award on NEI Grant EY023164
Duration: 2/1/13–1/31/18
$60,784

Research Contracts and Grants

Research Contracts and Grants
Totals Reported in Previous Years

Vision Science Grants

Anthony J. Aldave, MD
Effect of Corneal Preservation Time on Long-Term Graft Success
JAEB Center for Health Research
Duration: 3/6/12–8/31/17

Genetic Factors in Keratoconus
National Eye Institute
Sub-award from Cedars-Sinai Medical Center
Duration: 12/1/14–2/28/18

Dean Bok, PhD
Analysis of ARMS2 and HTRA 1 Gene Expression in Retinal Pigment Epithelium
Helen Keller Foundation for Research and Education Inc.
Duration: 6/1/16–6/31/18

Anne L. Coleman, MD, PhD
UCLA Mobile Eye Clinic Child Vision Program
LA County Children and Families First (First 5 LA)
Duration: 7/1/13–9/30/17

Sophie X. Deng, MD, PhD
Ex Vivo Expansion of Human Limbal Stem Cells for Transplantation
National Eye Institute
Duration: 9/1/12–6/31/18

Lynn K. Gordon, MD, PhD
Pd-Ligand, a Paradoxical Role in Experimental Uveitis Pathogenesis and Therapy
National Eye Institute
Duration: 4/1/15–3/31/18

Michael B. Gorin, MD, PhD
Genetics-Based Testing of Functional and Structural Endophenotypes for Pre- and Early-Age-Related Macular Degeneration
Arnold and Mabel Beckman Foundation
Duration: 7/1/14–6/30/18

Natural History of the Progression of Choroideremia Study
NightstaRx
Duration: 6/18/15–4/11/18

Steven Nusinowitz, PhD
Michael B. Gorin, MD, PhD (Co-Principal Investigator)
Scotopic Critical Flicker Fusion in Preclinical AMD
BrightFocus Foundation
Duration: 7/1/15–6/30/18
Research Contracts and Grants

Stacy L. Pineles, MD
RPB Walt and Lilly Disney Award for Amblyopia Research
Research to Prevent Blindness, Inc.
Duration: 7/1/14–6/30/19

Daniel B. Rootman, MD, MS
Hyaluronic Acid Gels for Upper Lid Retraction in Thyroid Eye Disease
Galderma Laboratories L.P.
Duration: 6/8/16–7/11/18

Alapakkam P. Sampath, PhD
Experimental and Clinical Investigations of Retinal Stimulation
National Eye Institute
Sub-award from University of Michigan
Duration: 3/1/17–2/28/18

SriniVas R. Sadda, MD
Sears, Connie: Re-engineering the Screening and Staging of Diabetic Retinopathy
Research to Prevent Blindness, Inc.
Duration: 1/1/17–12/31/18

David Sarraf, MD
DRCR Funding Addendum
JAEB Center for Health Research
Duration: 6/13/17–12/31/18

DRCR Protocol W: Intravenous Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
JAEB Center for Health Research
Duration: 6/13/17–12/31/18

Federico G. Velez, MD
An Observational, Multicenter Study of the Prevalence of Cerebrotendinous Xanthomatosis in Patient Population Diagnosed with Early Onset Idiopathic Bilateral Cataract
Retrophin, Inc.
Duration: 1/6/16–12/6/19

Clinical Trials

Joseph Caprioli, MD
The Efficacy and Safety of Bimatoprost SR in Patients with Open-Angle Glaucoma or Ocular Hypertension
Allergan Pharmaceutical Corp.
Duration: 4/22/15–1/31/19

A Randomized Study Comparing the Safety and Efficacy of the InnFocus MicroShunt® Glaucoma Drainage System to Standard Trabeculectomy in Subjects with Primary Open Angle Glaucoma
Protocol INN-005
Innfocus Inc.
Duration: 2/4/16–2/4/18

Brian A. Francis, MD, MS
Study for Benchmarking the Management of Ophthalmic Diseases Using the Diopsys Visual Evoked Potential/Pattern ERG/ERG Protocol
Diopsys Inc.
Duration: 2/21/16–1/31/19
Robert Alan Goldberg, MD
A Multicenter Double-Masked Placebo-Controlled
Efficacy and Safety Study of RV001
Premier Research International, LLC
Duration: 4/16/13–8/31/17

Michael B. Gorin, MD, PhD
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
Alkeus Pharmaceuticals Inc.
Duration: 5/23/16–8/22/18

Jean-Pierre Hubschman, MD
A Phase 3, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti-PDGF-B Pegylated Aptamer)…ARMD
Ophthotech Corporation
Duration: 12/4/13–9/27/17

Jean-Pierre Hubschman, MD
Steven D. Schwartz, MD (Previous Principal Investigator)
A Natural History of Macular (Parafoveal) Telangiectasia
Lowy Medical Research Institute
Duration: 9/1/05–12/31/18

Colin A. McCannel, MD
A Phase II, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients with Subfoveal Neovascular Age-Related Macular Degeneration
Genentech, Inc.
Duration: 9/22/15–6/12/19

Kevin M. Miller, MD
Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects
Clinical Research Consultants, Inc.
Duration: 6/12/14–1/9/19

SriniVas R. Sadda, MD
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-Related Macular Degeneration
CEDAR Study
Allergan Pharmaceutical Corp.
Duration: 3/8/16–5/31/20

Alfredo A. Sadun, MD, PhD
Emergency Administration of EPI-743 to a Single Patient with Leber’s Hereditary Optic Neuropathy
Edison Pharmaceuticals, Inc.
Duration: 10/17/14–9/26/18

A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single, Intravitreal Injection of GS010 (RAAV2/2-ND4) A
GenSight Biologics
Duration: 1/11/16–11/7/18
Research Contracts and Grants

A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial
to Evaluate the Efficacy of a Single, Intravitreal Injection
of GS010 (RAAV2/2-ND4) B
GenSight Biologics
Duration: 1/12/16–11/7/18

David Sarraf, MD
A Phase III, Multicenter, Randomized Double-Masked Sham-Controlled Study
to Assess the Efficacy and Safety of Lampalizumab Administered
Intravitreally to Patients with Geographic Atrophy Secondary to ARMD
Genentech, Inc.
Duration: 11/21/14–9/27/18
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients
with Neurovascular Age-Related Macular Degeneration
Sequoia Study
Allergan Pharmaceutical
Duration: 4/14/16–5/31/20

The IAI-OCTA Study, or: Microvascular Structure and Morphology
of Neovascular Membranes in Age Related Macular Degeneration
After Intravitreal Afiblercept Injection Therapy Using OCT-Angiography Analysis
Regeneron Pharmaceuticals, Inc.

A Randomized, Double-Masked, Active Controlled, Phase 2 Study of the
Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal
REGN910-3 in Patients with Neovascular Age-Related Macular Degeneration
Regeneron Pharmaceuticals, Inc.
Duration: 9/8/16–9/8/19

A Multicenter, Open-Label Extension Study to Evaluate the Long-Term
Safety and Tolerability of Lampalizumab in Patients with Geographic
Atrophy Secondary to Age-Related Macular Degeneration Who Have
Completed a Roche-Sponsored Study
Genentech, Inc.
Duration: 11/16/16–11/16/19

Intravitreous Anti-VEGF Treatment for Prevention of Vision Threatening
Diabetic Retinopathy in Eyes at High Risk, Protocol W
JAEB Center for Health Research
Duration: 8/1/16–7/31/21

Steven D. Schwartz, MD
A Multicenter, Prospective Epidemiologic Study of the Progression of
Geographic Atrophy Secondary to Age-Related Macular Degeneration:
Protocol Number GX29633
Genentech, Inc.
Duration: 10/18/16–8/1/20

Long Term Follow Up to a Phase II/II, Open-Label, Multi-Center
Prospective Study to Determine the Safety and Tolerability of
Subretinal Transplantation of Human Embryonic Stem Cell
Derived Retinal Pigmented Epithelial Cells in Patients
with Stargardt’s Macular Dystrophy
Astellas Institute for Regenerative Medicine
(formerly Advanced Cell Technology and Ocata Therapeutics)
Duration: 3/23/11–1/09/19

A Multicenter, Open-Label Extension Study to Evaluate the
Long-Term Safety and Tolerability of Lampalizumab in Patients
with Geographic Atrophy Secondary to Age-Related Macular
Degeneration Who Have Completed a Roche-Sponsored Study
Genentech, Inc.
Duration: 10/27/16–10/27/19
Long-Term Follow-Up to a Phase I/II, Open-Label, Multicenter, Prospective Study to Determine the Safety and Tolerability of Subretinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigment Epithelial Cells in Patients with Advanced Dry AMD
Astellas Institute for Regenerative Medicine (formerly Advanced Cell Technology and Ocata Therapeutics)
Duration: 4/5/11–6/12/19

A Multiple-Center, Multiple-Dose, Randomized, Active, Comparator-Controlled, Double-Masked, Parallel Group, 28-Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients with Diabetic Macular Edema
Hoffmann-La Roche (Include Roche Molecular Systems, Inc.)
Duration: 10/18/16–11/21/17

A Phase III, Multicenter, Randomized Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to ARMD
Genentech, Inc./Hoffman-La Roche Inc.
Duration: 11/18/14–9/27/18

A Phase 2, Double-Masked, Randomized, Parallel Group, Sham Surgery Placebo Controlled Multicenter Study to Evaluate Systemic Immunosuppression Regimens as Graft Rejection Prophylaxis Following Subretinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial Cells in Patients with Geographic Atrophy Secondary to ARMD
Astellas Institute for Regenerative Medicine (formerly Advanced Cell Technology and Ocata Therapeutics)
Duration: 10/7/15–10/7/17

**Federico G. Velez, MD**
A Randomized, Double-Masked, Parallel-Group, Phenylephrine Controlled Study of the Effect of OMS302 Added to Standard Irrigation Solution on Intraoperative Pupil Diameter and Acute Postoperative Pain in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction with or Without Lens Replacement
Omeros Inc.
Duration: 8/6/15–8/6/17

A Randomized, Multicenter, Double Masked, Parallel-Group Study Assessing the Safety and Efficacy of Loteprednol Etabonate Ophthalmic Gel, 0.5% Versus Prednisolone Acetate Ophthalmic Suspension, 1% for the Treatment of Intraocular Inflammation Following Surgery for Childhood Cataract
Bausch and Lomb
Duration: 9/17/15–9/17/17
Clinical Research Studies

In the 2017–2018 academic year, UCLA Department of Ophthalmology faculty conducted over 80 clinical research studies to better understand the eye and its ocular disorders, as well as to evaluate new and potentially sight-saving treatments.

**Cornea and External Eye Disease**

**Analysis of the Corneal and Limbal Epithelial Changes in Limbal Stem Cell Deficiency Using In Vivo Confocal Microscopy**

Investigators are working to establish a system for diagnosing limbal stem cell deficiency at a cellular level by correlating the information from impression cytology tests, confocal microscopy pictures, and medical records. Investigators: Anthony J. Aldave, MD, and Sophie X. Deng, MD, PhD

**Effect of Corneal Preservation Time on Long-Term Graft Success**

This study evaluates the effect of preservation time on corneal transplants. It will compare the preservation time up to the FDA limit of 14 days and hopes to determine that longer preservation time does not adversely impact graft success and endothelial cell density. Investigators: Anthony J. Aldave, MD, and Sophie X. Deng, MD, PhD

**Evaluation of Corneal Cross-Linking Keratoprosthesis Carrier Tissue**

This clinical trial evaluates the safety and efficacy of corneal collagen cross-linking the keratoprosthesis carrier tissue in subjects who are candidates for high-risk keratoprosthesis implantation because of a history of corneal melts, sterile corneal ulcers, or autoimmune diseases (eg, Stevens-Johnson syndrome, ocular cicatricial pemphigoid). Investigators: Anthony J. Aldave, MD, and Sophie X. Deng, MD PhD

**Genetic Basis of Posterior Polymorphous Corneal Dystrophy**

This study seeks to identify the gene(s) responsible for posterior polymorphous dystrophy, an inherited corneal endothelial disorder that may result in irreversible corneal swelling and loss of vision. Investigators: Anthony J. Aldave, MD, and Gary N. Holland, MD

**Identifying Novel Genes for Fuchs Corneal Endothelial Dystrophy**

Investigators are working to identify the gene(s) responsible for Fuchs corneal endothelial dystrophy, an inherited disorder that may result in irreversible corneal swelling and loss of vision. Investigators: Anthony J. Aldave, MD, Gary N. Holland, MD, and Bartly J. Mondino, MD

**Keratoprosthesis Implantation in Patients with Corneal Opacification**

This study aims to determine the success rate of keratoprosthesis (artificial corneal) transplantation for visual rehabilitation in patients with corneal opacification. Investigators: Anthony J. Aldave, MD, and Gary N. Holland, MD

**Ocular Surface Microbiome Study**

This study aims to investigate and understand the normal ecosystem of microbes that live on the eye’s surface and how their ecological system changes and responds to routine eye care and treatments. Investigators: Hugo Hsu, MD, Vikas Chopra, MD, and Gad Heilweil, MD

**Eye Infections and Inflammations**

**Corneal Endothelial Cell Changes in Children with Uveitis**

This is a prospective study to evaluate the cornea, specifically endothelial cells, in children with uveitis. Uveitis may lead to a change in the number of endothelial cells and their shape. Specular microscopy, which is a non-invasive corneal-imaging technique, helps to estimate changes in corneal endothelium long before clinical signs of corneal damage. Investigators: Joseph Caprioli, MD, JoAnn A. Giaconi, MD, Gary N. Holland, MD, Simon K. Law, MD, PharmD, and Ralph D. Levinson, MD

**Corticosteroids for Uveitic Macular Edema**

This research study compares three treatments for macular edema in patients who have uveitis. Macular edema is swelling of the retina at the back of the eye, and it can cause vision loss. The standard treatment is to inject corticosteroid drugs next to the eye or directly into the eye. Investigators: Gary N. Holland, MD, and Colin A. McCannel, MD

**Factors Related to the Severity of Ocular Toxoplasmosis**

Toxoplasmosis is a common parasitic disease that can cause a vision-threatening infection of the retina. Individuals with and without ocular toxoplasmosis are being evaluated with a blood test to determine whether (1) people can have a genetic predisposition to severe disease when infected with the parasite, or (2) there is a particular strain of parasite that causes more severe disease than others. Investigators: Gary N. Holland, MD, and Ralph D. Levinson, MD
Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy (MERIT) Trial
The MERIT Trial was designed to determine which intravitreal therapy offers the best balance of effectiveness and tolerability in treating persistent uveitic macular edema in eyes with controlled uveitis but persistent macular edema, specifically by comparing the relative efficacy and safety of intravitreal ranibizumab (Lucentis®) and intravitreal methotrexate to intravitreal dexamethasone implant (Ozurdex®). Investigators: Gary N. Holland, MD, Colin A. McCannel, MD, and Pradeep S. Prasad, MD

Zoster Eye Disease Study (ZEDS)
The purpose of this study is to find out whether one year of a low dose of valacyclovir reduces complications of shingles affecting the eye. The study will involve two groups of participants who have eye problems due to shingles. One group will receive daily valacyclovir medication and the other group will receive a placebo. Investigators: Gary N. Holland, MD, Anthony J. Aldave, MD, Sophie X. Deng, MD, PhD, and John A. Irvine, MD

Glaucma
Analysis of Visual Function in Glaucoma
The purpose of this study is to establish electrophysiological benchmarks using the Visual Evoked Potential/Pattern Electroretinogram protocols of populations with glaucoma before treatment and after treatment. Investigators: Brian A. Francis, MD, MS, Alex A. Huang, MD, PhD, Vikas Chopra, MD, Srinivas R. Sadda, MD, and Gad Heilweil, MD

Clinical Measurements of the Optic Nerve in Glaucoma
The goal of this study is to develop novel structural measures of the optic nerve and nerve fiber layer, which are sensitive and specific for early and progressive glaucomatous optic nerve damage. Investigators: Joseph Caprioli, MD, Anne L. Coleman, MD, PhD, and Simon K. Law, MD, PharmD

Effect of Yoga on Glaucoma
The purpose of this study is to examine the practice of yoga and its ability to improve a patient’s vision by relieving stress and reducing eye pressure. Investigator: Anne L. Coleman, MD, PhD

Evaluating a Microshunt for the Treatment of Glaucoma
This study is to assess the safety and efficacy of a microshunt when used to lower intraocular pressure (IOP) in subjects with primary open angle glaucoma whose IOP is not controlled when using maximum-tolerated glaucoma medications. Investigators: Joseph Caprioli, MD, Anne L. Coleman, MD, PhD, JoAnn A. Giaconi, MD, Simon K. Law, MD, PharmD, and Brian A. Francis, MD, MS

Evaluating the Efficacy and Safety of an Investigational Eye Drop in Patients with Open-Angle Glaucoma or Ocular Hypertension
This study evaluates the intraocular pressure-lowering efficacy and safety of two dose strengths of an investigational eye drop in patients with open-angle glaucoma or ocular hypertension after initial and repeated administrations. Investigators: Joseph Caprioli, MD, Anne L. Coleman, MD, PhD, JoAnn A. Giaconi, MD, Simon K. Law, MD, PharmD, and Kouros Nouri-Mahdavi, MD

Eye Health Imaging Study
The purpose of this study is to expand the normative database for the Heidelberg Spectralis OCT by collecting ophthalmic data from healthy eyes of people of Hispanic/Latino, Asian, and African American descent. Investigators: Joseph Caprioli, MD, and Kouros Nouri-Mahdavi, MD

Glaucma Imaging Study
This study is evaluating different imaging techniques and their use in improving open-angle glaucoma detection. Investigators: Joseph Caprioli, MD, and Kouros Nouri-Mahdavi, MD

Ocular Biometric Measurements in Angle-Closure Glaucoma
The purpose of this study is to determine the potential contributing factors in angle-closure patients of different ethnicities and to determine predictive factors for this type of glaucoma. Investigators: Joseph Caprioli, MD, Anne L. Coleman, MD, PhD, Simon K. Law, MD, PharmD, and Kouros Nouri-Mahdavi, MD

Ocular Hypertension Treatment Study
Since topical hypotensive medications are safe and effective in delaying or preventing primary open angle glaucoma, this study is examining whether other forms of treatment can be deferred with little or no penalty. Investigator: Anne L. Coleman, MD, PhD

Ocular Imaging in Simulated Microgravity
Consideration needs to be given to how microgravity may influence the biology and well-being of astronauts. Astronauts returning from space experience visual disturbance in addition to pathological changes that affect the eye. This study noninvasively estimates intracranial pressure in study participants and obtains intraocular/vascular imaging in simulated microgravity environments. Investigator: Alex A. Huang, MD, PhD

Optic Nerve Appearance in Age-Related Macular Degeneration
In order to evaluate the relationship between macular degeneration and optic nerve change, digital imaging technology and photography are being used to assess the structural appearance of the optic nerve in patients with age-related macular degeneration. Investigator: Simon K. Law, MD, PharmD
Role of Pattern Electroretinogram (PERG) in Glaucoma
This study is researching the electrophysiological test, pattern electroretinogram (PERG) to determine the role of PERG in estimating the risk of future glaucoma progression and the reversibility of glaucomatous damage after treatment. The latter could help clinicians better determine to what extent eye pressure needs to be lowered to prevent disease progression. Investigators: Joseph Caprioli, MD, Anne L. Coleman, MD, PhD, JoAnn A. Giaconi, MD, Simon K. Law, MD, PharmD, and Kourosh Nouri-Mahdavi, MD

Vision-Related Quality of Life and Ocular Dominance
This study is designed to evaluate how quality of life is impacted by glaucoma in relation to eye dominance. It aims to determine whether quality of life is affected more by glaucoma if it primarily affects the dominant eye. Investigators: Joseph Caprioli, MD, Anne L. Coleman, MD, PhD, JoAnn A. Giaconi, MD, and Simon K. Law, MD, PharmD

Lens and Cataract
Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects
This study is being conducted to evaluate the safety and effectiveness of an artificial iris prosthetic for the treatment of full or partial aniridia resulting from congenital aniridia, acquired iris defects (including traumatic iris defects and mydriasis), or conditions associated with full or partial aniridia, such as ocular or oculocutaneous albinism and iridocorneal endothelial (ICE) syndrome, and iris coloboma. Investigators: Anthony J. Aldave, MD, and Kevin M. Miller, MD

Macula, Retina, and Vitreous
Analysis for Visual Function in Age-Related Macular Degeneration
The study establishes electrophysiological benchmarks using the visual evoked potential/pattern electroretinogram (VEP/PERG) protocols of populations with glaucoma before treatment and after treatment. Investigators: Srinivas R. Sadda, MD, Gad Heilweil, MD, Brian A. Francis, MD, MS, Alex A. Huang, MD, PhD, and Vikas Chopra, MD

Arm-Mounted Heidelberg OCT-A for Noninvasive Vascular Zone Imaging in Infants with Retinopathy of Prematurity (ROP)
This study evaluates OCT-A imaging data on preterm infants who are screened and/or treated for ROP, especially evaluating the potentially beneficial effects of anti-VEGF treatment on foveal development and visual outcomes. Investigators: Alex Huang, MD, PhD, and Irena Tsui, MD

Clinical Characterization, Genetic Testing, and Visual Function in Patients with Stargardt Disease
Investigators are doing a comprehensive analysis of visual function in patients diagnosed with Stargardt disease, an early onset form of macular degeneration caused by a number of mutations in the ABCR gene. They are performing molecular genetic testing to confirm the Stargardt diagnosis and better understand the diversity of the condition. Investigators: Debora B. Farber, PhD, DPhhc, Michael B. Gorin, MD, PhD, and Steven Nusinowitz, PhD

Determining the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2
This study is assessing the safety of the NT-501 implant in patients with macular telangiectasia type 2. The implant, a small capsule of cells that is placed inside the eye, allows a controlled, sustained release of CNTF directly to the retina. Investigators: Jean-Pierre Hubschman, MD, Steven D. Schwartz, MD, and Hamid Hosseini, MD

Evaluating the Use of an Implant for Patients with Macular Degeneration
This clinical trial determines the efficacy, safety, and pharmacokinetics of ranibizumab delivered through the implant using three ranibizumab formulation arms compared with the control arm in patients with subfoveal neovascular (wet) age-related macular degeneration. The study also evaluates the safety of the ranibizumab port delivery system combination product. Screening and randomization visits will be followed by a treatment period. Investigators: Colin A. McCannel, MD, Tara A. McCannel, MD, PhD, Pradeep S. Prasad, MD, Michael B. Gorin, MD, PhD, and David Sarraf, MD

Evaluation of a New Drug for Stargardt Disease
The study purpose is to find out whether a new drug for Stargardt disease is safe and effective. There are currently no proven treatments for Stargardt disease, a disease that leads to blindness in almost all cases. Investigators: Michael B. Gorin, MD, PhD, and Steven Nusinowitz, PhD

Extension Study of NT-501 Ciliary Neurotrophic Factor Implant for Macular Telangiectasia
The primary objective of this study is to investigate long-term safety and efficacy of the NT-501 implant in participants previously enrolled in NTMT protocols. Investigators: Jean-Pierre Hubschman, MD, Steven D. Schwartz, MD, and Hamid Hosseini, MD

IAI-OCTA Study
This study is utilizing a new, FDA approved, non-standard of care technology (optical coherence tomography-angioography by Optovue) to image and evaluate the treatment outcomes of using standard of care intravitreal Afibercept injections for their approved use in patients diagnosed with neovascular age-related macular degeneration who are naive to previous Anti-VEGF therapies. Investigator: David Sarraf, MD

Modified Retinal Fundus Camera
This study evaluates a modified retinal fundus camera to see if significant differences can be found in patients with choroidal melanoma, age-related macular degeneration, or diabetic retinopathy. Investigator: Irena Tsui, MD

Natural History of the Progression of Choroideremia
This study characterizes the visual function and retinal structural changes associated with X-linked choroideremia with the intention of determining the best means of measuring disease progression and the rate of natural progression for this condition. Investigators: Michael B. Gorin, MD, PhD, and Steven Nusinowitz, PhD
Natural History of the Progression of X-Linked Retinitis Pigmentosa
This study is to characterize the visual function and retinal structural changes associated with X-linked retinitis pigmentosa to determine the best means of measuring disease progression and the rate of natural progression for this condition. Investigator: Michael B. Gorin, MD, PhD

Natural History Study of Macular Telangiectasia
The primary study objective is to develop a registry of participants with MacTel Type 2 (as confirmed by the Reading Center) who may agree to be contacted for inclusion in future clinical trials. Investigators: Jean-Pierre Hubbschman, MD, Hamid Hosseini, MD, Allan E. Kreiger, MD, Tara A. McCannel, MD, PhD, Pradeep Prasad, MD, Irena Tsui, MD, and Steven D. Schwartz, MD

Optical Coherence Tomography Angiography Images of Pregnant Women
This study aims to identify changes that occur in the retina as a result of gestational associated diseases (eg, gestational diabetes, high blood pressure, increased myopia) and unknown changes that may affect the eyes during gestation and in the 2–3 months following birth. Investigator: Irena Tsui, MD

Optical Coherence Tomography Angiography of Foveal Avascular Zone in Premature Children
This prospective study evaluates blood vessel development in children and adults who are born early and compares them with children and adults who were not born early, by getting optical coherence tomography (OCT), OCT-angiography, color pictures, refraction, and axial length on subjects with retinopathy of prematurity and without retinopathy of prematurity. Investigators: Irena Tsui, MD, Stacy L. Pineles, MD, and Federico G. Velez, MD

Repeated Doses of an Investigational Drug in Patients with Neovascular Age-Related Macular Degeneration
This phase 2, year-long study requires the recruitment of patients with wet or neovascular age-related macular degeneration who are naive to anti-VEGF treatment. Investigators: David Sarraf, MD, Michael B. Gorin, MD, PhD, and Colin A. McCannel, MD

Research with Retinal Cells Derived from Stem Cells for Dry Age-Related Macular Degeneration (AMD)
This study evaluates the long-term safety and tolerability of MA09-hRPE cellular therapy in subjects with advanced dry AMD from one to five years following the surgical procedure to implant the MA09-hRPE cells. Investigators: Steven D. Schwartz, MD, Hamid Hosseini, MD, Jean-Pierre Hubbschman, MD, Pradeep Prasad, MD, Irena Tsui, MD

Research with Retinal Cells Derived from Stem Cells for Stargardt Macular Dystrophy
This study evaluates the long-term safety and tolerability of MA09-hRPE cellular therapy in subjects with advanced Stargardt macular dystrophy from one to five years following the surgical procedure to implant the MA09-hRPE cells. Investigators: Steven D. Schwartz, MD, Hamid Hosseini, MD, Jean-Pierre Hubbschman, MD, Pradeep Prasad, MD, and Irena Tsui, MD

Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease
The objectives of this study are to evaluate the safety and efficacy of Zimura™ intravitreal injection compared to sham in subjects with autosomal recessive Stargardt disease 1. Investigators: Steven D. Schwartz, MD, Hamid Hosseini, MD, Jean-Pierre Hubbschman, MD, Pradeep Prasad, MD, and Irena Tsui, MD

Study for Retinopathy of Prematurity
This study is to determine if intravitreal ranibizumab is superior to laser ablation therapy in the treatment of retinopathy of prematurity (ROP). The study will assess the ability of these treatments to lead to regression of active ROP and prevent the development of ocular complications that are associated with poor visual outcome. Investigator: Irena Tsui, MD

Study of Macular Disease Using Spectral Domain Optical Coherence Tomography Angiography (SD-OCTA)
The RTVue XR 100 Avanti with SSADA will be used to screen patients with macular disease as detected with clinical examination or ancillary testing, such as with standard OCT, color fundus photography, fluorescein angiography, or fundus autofluorescence. Investigators: Michael B. Gorin, MD, PhD, Colin A. McCannel, MD, David Sarraf, MD, and Steven D. Schwartz, MD

Understanding the Genetics of Inherited Eye Disorders
This study searches for the gene(s) responsible for inherited disorders that are either specific to the eye or are part of the medical condition. The study provides for the clinical characterization of affected individuals and at-risk family members, in conjunction with molecular genetic testing, to identify the causative genes and mutations. Investigators: Anthony J. Aldave, MD, and Michael B. Gorin, MD, PhD

Neuro-Ophthalmology
A Protocol to Follow-up with Patients on Emergency Administration of EPI-743 with Leber Hereditary Optic Neuropathy
EPI-743, a form of vitamin E that has been changed to a new compound in the laboratory, is an experimental drug that may improve mitochondrial function. Mitochondrial disease manifestations appeared to improve when the EPI-743 was given to cells from a patient with Leber hereditary optic neuropathy that were grown in the laboratory. Investigator: Alfredo A. Sadun, MD, PhD

A Trial of QPI-1007 Delivered by Single or Multi-Dose Intravitreal Injection(s) to Subjects with Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
This research study tests whether the experimental drug QPI-1007 helps prevent loss of visual acuity. QPI-1007 is being developed to treat vision loss that can occur when there is not enough blood flow to the nerve tissue in the eye, such as after a stroke of the optic nerve or from NAION. Investigators: Peter A. Quiros, MD, Gad Heilweil, MD, Michael S. Ip, MD, Mohammad Khan, MD, Alfredo A. Sadun, MD, PhD
Clinical Research Studies

Evaluating the Efficacy of a Single Intravitreal Injection for Patients with Leber Hereditary Optic Neuropathy

This clinical trial is to assess the effectiveness of a gene therapy in improving the visual outcome in patients with Leber Hereditary Optic Neuropathy (LHON) due to a mitochondrial mutation. Investigator: Alfredo A. Sadun, MD, PhD

Evaluation of a Drug for the Treatment of Leber Hereditary Optic Neuropathy

This study evaluates the safety, tolerability, and efficacy of a topical ophthalmic solution in the treatment of subjects with Leber Hereditary Optic Neuropathy (LHON). The study drug has been shown to enhance or benefit mitochondria function in studies done on cells grown in the laboratory. Investigator: Alfredo A. Sadun, MD, PhD

Natural History Study of Leber Hereditary Optic Neuropathy

Leber hereditary optic neuropathy (LHON) is one of the diseases where the mitochondria of the retina cells are not functioning correctly, which can lead to loss of vision. This study is to obtain electroretinography (ERG) data and optical coherence tomography (OCT) data from patients who carry the Leber hereditary optic neuropathy gene. Investigator: Alfredo A. Sadun, MD, PhD

Noninvasive Methods for Early Detection of Alzheimer Disease

The purpose of this study is to obtain electroretinography data and optical coherence tomography data from patients with Alzheimer disease, with the aim of permitting earlier intervention and improved disease monitoring. Investigator: Alfredo Sadun MD, PhD

Ocular Melanoma

Evaluating the Safety and Efficacy of Light-Activated AU-011 for the Treatment of Subjects with Small to Medium Primary Choroidal Melanoma

Primary objectives are to evaluate the safety of intravitreal administration of one of three dose levels and repeat dose regimens of light-activated AU-011 and one or two laser applications in the treatment of subjects with small to medium primary choroidal melanoma. Secondary objectives include evaluating the immunogenicity and effectiveness of AU-011. Investigators: Tara A. McCannel, MD, PhD, Colin McCannel, MD, and Melissa Chun, OD

Molecular and Cytogenetic Studies of Ocular Melanoma

This research is to study ocular melanoma tumor tissue and to identify key molecular and genetic features that could help predict those patients who may be at high risk for metastasis. Investigators: Lynn K. Gordon, MD, PhD, Tara A. McCannel, MD, PhD, and Bradley R. Straatsma, MD, JD

PET/CT Imaging for Early Detection of Ocular Melanoma

This research involves the use of combined positron emission tomography (PET)/computed tomography (CT) scans in subjects with ocular melanoma to ideally develop better ways of monitoring for tumor spread and allow for early treatment if metastasis is found. Investigators: Tara A. McCannel, MD, PhD, and Bradley R. Straatsma, MD, JD

Orbital and Ophthalmic Plastic Surgery

Characteristics of the Brow–Eyelid Margin Relationship

The study purpose is to determine if changing the effect of gravity has an effect on eyelid position. Investigators: Robert Alan Goldberg, MD, and Daniel B. Rootman, MD, MS

Clinical Presentation and Management of Orbital Plasmacytoma

Orbital plasmacytoma is a rare monoclonal proliferation of plasma cells that can be associated with multiple myeloma. The purpose of this study is to contribute to the largest case series of orbital plasmacytomas to date and review its clinical characteristics. Investigator: Daniel B. Rootman, MD, MS

Effect of External Eyelid Weighting on Lid Position in Normal and Ptosis Patients

This investigation compares the ability of normal and ptotic patients to maintain eyelid position by adapting to acute and dramatic changes in protracting forces by using eyelid weights. This project will help elucidate the physiology of the eyelid position maintenance system, and provide insight into its ability to respond to changes in disease. Investigator: Daniel B. Rootman, MD, MS

Hyaluronic Acid Gels for Upper Lid Retraction in Active State Thyroid Eye Disease

This study is to determine if hyaluronic acid gel (HAG) can be used to correct upper eyelid retraction, improve dry eye related symptoms, aesthetic appearance, and quality of life in active-stage thyroid eye disease (TED). The study also aims to determine the long-term outcome of TED and how long the effects of HAG can last. Investigator: Daniel B. Rootman, MD, MS

Neuroendocrine Tumor Metastases in the Eye and Orbit

The purpose of this study is to understand the diversity in presentation of carcinoid tumors of the orbit, as well as to identify, stage, and grade related factors that may affect prognosis and thus treatment decisions. Also considered will be if there are features of carcinoid tumor presentations in the orbit that can predict outcome and thus guide therapeutic decision-making. Investigator: Daniel B. Rootman, MD, MS
Ocular Protrusion in Sitting and Supine Positions
The aim of this study is to compare the degree of ocular protrusion in normal individuals and patients with thyroid eye disease between sitting and lying (supine) positions. Investigators: Robert Alan Goldberg, MD, and Daniel B. Rootman, MD, MS

Pro-Inflammatory Cytokines, Dry Eye, and Thyroid Eye Disease
This study is to determine whether there are specific inflammatory proteins in tears of patients with active-stage thyroid eye disease (TED). If these inflammatory proteins exist, the study aims to determine whether they can be used to predict dry eye symptoms and TED activity. Investigators: Robert Alan Goldberg, MD, and Daniel B. Rootman, MD, MS

Ptosis Surgery Outcomes Scale
This investigation is to define and validate a universal measure for ptosis outcomes that can be used in defining both value and efficacy in ptosis surgery. Investigator: Daniel B. Rootman, MD, MS

Studies on Tissue in Autoimmune Diseases
This study aims to determine the cause of eye problems in Graves disease and other autoimmune diseases. Examination is being done of material removed from orbits during surgical therapy, or of blood drawn for tissue surrounding the eyes, of thyroid tissue removed during the course of surgical therapy, or of blood drawn for laboratory tests. Investigator: Robert Alan Goldberg, MD

Temporal Fossa in Different Ethnicities
The aim of this study is to investigate differences in anatomy of temporal fossa between different ethnicities using three-dimensional CT scan images. Better knowledge of these differences is important for cosmetic procedures to achieve better results and fewer complications. Investigators: Robert Alan Goldberg, MD, and Catherine J. Hwang, MD

Pediatrics and Strabismus
A Prospective Observation Study of Adult Strabismus
This study is to learn about treatments for strabismus in adults. There are several different treatment options for strabismus; sometimes these conditions are treated with special glasses that help to align the eyes (prism) or with exercises that help the eyes work together, and sometimes these conditions are treated with surgery or Botox injection to straighten the eyes. Investigators: Stacy L. Pineles, MD, and Federico G. Velez, MD

Biomechanical Analysis in Strabismus Surgery
This study aims to develop new diagnostic tests and computer models that will lead to improvements in strabismus surgery. Tests of binocular alignment and eye movements, as well as magnetic resonance imaging of the extraocular muscles, are being performed in the Institute’s Clinical and Basic Science Ocular Motility Laboratory before and after strabismus surgery. To date, this research has fundamentally contributed to the knowledge of the functional anatomy of the extraocular muscles and connective tissues, and allowed discovery of causes of common strabismus and development of new types of surgeries. Investigator: Joseph L. Demer, MD, PhD

Determining the Proportion of Patients with Isolated Third, Fourth, and Sixth Nerve Palsies of Microvascular Versus Nonmicrovascular Etiology
Magnetic resonance imaging scanning is currently only recommended in atypical cases (ie, young age, no vascular risk factors). This study is to determine whether central nervous system abnormalities are detected in patients who otherwise would not have neuroimaging. Investigator: Stacy L. Pineles, MD

Genetic and Anatomic Studies of Eye Movement Disorders
This study is conducting magnetic resonance imaging of the extraocular muscles. This procedure clarifies the phenotypes and mechanisms of congenital cranial dysinnervation syndromes whose hereditary properties have been characterized using modern molecular genetics. Patients with these syndromes have severe forms of strabismus. Investigator: Joseph L. Demer, MD, PhD

Observational Study of Patients Diagnosed with Idiopathic Bilateral Cataracts
The purpose of this study is to understand better how many people who have been diagnosed with early-onset idiopathic bilateral cataracts may have a rare but treatable disease called cerebrotendinous xanthomatosis (CTX). Often one of the first signs of CTX is cataracts from an unknown cause at an early age. Investigators: Federico G. Velez, MD, Stacy L. Pineles, MD, and Joseph L. Demer, MD, PhD

Optic Nerve in Amblyopia
Amblyopia is a major cause of childhood visual loss. This study uses high resolution, surface-coil magnetic resonance imaging to study optic nerve size in amblyopia. It tests the theory that the optic nerve is smaller than normal in amblyopia and that optic nerve size may be a limiting factor in restoration of vision by amblyopia treatment. Investigator: Joseph L. Demer, MD, PhD

Optical Coherence Tomography in the Newborn Eye
This study is to better characterize the retina and optic nerve in newborns using spectral-domain optical coherence tomography (SD-OCT). SD-OCT has been used for many years to help diagnose and treat adults with eye diseases, but it has never been studied in newborns, where it could potentially help in the diagnoses of glaucoma, optic nerve hypoplasia, foveal hypoplasia, and colobomata, among many other disorders. Investigator: Sherwin J. Isenberg, MD
Pediatric Cataract Surgery Outcomes Registry
The study aim is to collect core clinical data on children and teens undergoing surgery for cataracts in order to conduct analyses and generate hypotheses. Clinical outcomes data will be collected from affected subjects after cataract surgery has been performed. Investigators: Stacy L. Pineles, MD, and Federico G. Velez, MD.

Prevention of Visual Impairment in School-Age Children
To promote the use of eyeglasses in schools, first- and second-grade students with refractive errors receive two pairs of eyeglasses, with one pair staying at home and the other in the classroom. School nurses collaborate with teachers in monitoring the use of eyeglasses in the classroom, and parents receive eye care education. Investigator: Anne L. Coleman, MD, PhD.

Sensory Processing and Learning
This study evaluates amblyopic patients, who are traditionally thought to be beyond the critical period for treatment. These subjects will be enrolled and randomized to one of the two amblyopia therapies using a perceptual learning technique. Investigator: Stacy L. Pineles, MD.

Sweep Visual Evoked Potential for Use in Amblyopia and Pediatric Optic Nerve Disorders
Using a new technique, investigators are measuring vision in preverbal children to diagnose and follow optic nerve diseases. Currently, treatment decisions are based on clinical examinations that are insensitive and reveal vision loss well after permanent damage has taken place. This technique allows more accurate examinations, which leads to provision of treatments at the first signs of vision loss and thereby decreases the risk of permanent damage. Investigators: Joseph L. Demer, MD, PhD, Sherwin J. Isenberg, MD, Stacy L. Pineles, MD, and Federico G. Velez, MD.

Study of Luminopia One Digital Therapeutic as Amblyopia Treatment
The primary objective of this study is to establish safety and efficacy of the Luminopia One therapeutic for the treatment of amblyopia. Investigators: Joseph L. Demer, MD, PhD, Simon Fung, MD, and Stacy L. Pineles, MD.
2017–2018 Publications of the Full-Time Faculty

In the 2017–2018 academic year, UCLA Department of Ophthalmology full-time faculty advanced vision-science research with 275 publications that include peer-reviewed articles, book chapters, and books.

**July 2017**


Publications


August 2017


September 2017 (Fall)


With the Fast Component of Visual Field Decay in Glaucoma Correlates
Caprioli J
138
1098–1099.

Angiography Technology: Progress in Optical Coherence Tomographic
Garrity ST, McCannel TA
58(12):5548–5555.


DNase I and PEFK1 Knockdowns Relax Foveal Vascular Tension Using Angiography
Sarraf D
5477–5484.


Summary of Three Distinct Retinal Capillary Plexuses in Healthy Eyes Using Optical Coherence Tomography Angiography.


March 2018 (Spring)


May 2018


June 2018 (Summer)


Appendices | Stein Eye Institute 145
The UCLA Stein Eye Institute is a vision-science campus dedicated to the preservation and restoration of vision through its global programs in innovative research, quality patient care, and multidisciplinary, integrative education, all with community outreach.

UCLA’s vision scientists are extending the boundaries of current knowledge and approaching the goal for a lifetime of good vision for everyone, due in large part to a strong tradition of philanthropy from private sources.

Contributions from individuals, foundations, and corporations help underwrite exemplary patient-care programs, innovative scientific advances, key community engagement, and the highest-quality training and education. The Institute offers a variety of giving options to those who wish to contribute to this tradition of excellence.

How to Support the UCLA Stein Eye Institute

Direct Gifts
Direct gifts—whether by cash, check, or credit card—are critically important to Stein Eye because the gifts can be put to work immediately, increasing their impact and extending their reach.

Endowments
A gift of an endowment demonstrates a long-term commitment, since the fund is maintained in perpetuity. A portion of the annual investment income is used to support clinical, educational, and scientific initiatives and the remaining investment yield is returned to principal, thus, over the years, the fund can grow and provide continuous support.

An endowment serves as an enduring legacy as it can bear the donor’s name or honor a loved one. Giving opportunities exist for endowed chairs, endowed fellowships, and endowed funds for research, education, and patient care. These funds can be made payable for up to five years.

Pledges
A pledge is a formal statement of intention to make a gift. Donors who seek to defer the bulk of their giving until a future date, or who want to give via installments over time, may use this giving strategy. A pledge may be followed by an immediate gift or may simply confirm your intention to make a gift in the future. Pledges are typically made in concert with a preliminary first installment and provide a source of consistent and dependable funding. This method often allows donors to give more generously than they may have originally considered.

Securities
Gifts of appreciated securities are tax deductible at their full market value. In most cases, appreciation in the value of the security benefits the University and is not taxable to the donor.

Matching Gifts
Many corporations have demonstrated their support by matching or multiplying their employees’ gifts up to a set amount. Before making a gift, you may want to ask whether your employer participates in a matching gift program. Certain restrictions apply to matching gifts. Please consult your company’s personnel office.

Real Estate
Real estate (your primary residence, vacation home, commercial property, or land) is an asset that you can leverage in a variety of ways to support the Institute while reducing taxes and eliminating the burden of maintaining or selling your property. You can also use real estate to fund gifts that provide you with an income stream for life.

Bequests
Making a gift through your will or living trust gives you the immediate satisfaction of creating a lasting and personal legacy that ensures Stein Eye’s future and costs nothing now.

Charitable Gift Annuity
In exchange for a gift of cash or appreciated securities, you can receive fixed income for life and a portion of the annuity payments is tax-free.

Qualified Retirement Plans
Naming The UCLA Foundation as a beneficiary of some or all of your qualified retirement plan may help you minimize taxes and maximize your philanthropic impact, while leaving to your loved ones, assets that are less taxed.

Tribute Gifts
Contributions may be made in memory, honor, or celebration of a loved one, or to commemorate a special occasion. Donations can be used for unrestricted program support or be directed to any area of the Institute.

Your Gift Can Make a Difference
However you choose to support the Institute, you will be embarking on a partnership with one of the world’s preeminent eye research centers. Such an investment will greatly expand our understanding of the causes of eye diseases, expose alternative treatment options, and ultimately prevent blindness.

For information on how to incorporate the UCLA Stein Eye Institute into your estate and retirement planning, or to make a gift of any kind, please contact:

UCLA Stein Eye Institute
Development Office
100 Stein Plaza, Room 1-124
Los Angeles, California 90095-7000
Phone: (310) 206-6035
Fax: (310) 794-1665
giving@sei.ucla.edu
THE ONLY BARRIER TO A CURE IS ACCESS TO CARE.